var title_f24_3_24624="Thoracentesis";
var content_f24_3_24624=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Thoracentesis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/3/24624/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/3/24624/contributors\" id=\"au39\">",
"       Peter Doelken, MD, FCCP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/3/24624/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/3/24624/contributors\" id=\"se5584\">",
"       Steven A Sahn, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/3/24624/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/3/24624/contributors\" id=\"de1810\">",
"       Helen Hollingsworth, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?24/3/24624?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      THORACENTESIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Thoracentesis is a procedure used to obtain a sample of fluid from the space around the lungs. Normally, only a thin layer of fluid is present in the area between the lungs and chest wall. However, some conditions can cause a large amount of fluid to accumulate. This collection of fluid is called a pleural effusion. Thoracentesis is done to collect a sample of the fluid, which can help determine why the pleural effusion developed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      REASONS FOR THORACENTESIS",
"     </span>",
"    </p>",
"    <p>",
"     A thoracentesis is performed to determine the cause of a pleural effusion. In some cases, a physician may perform thoracentesis to relieve symptoms caused by the pleural effusion, including shortness of breath and low blood oxygen levels. A pleural effusion may be detected during a physical examination or on a chest x-ray.",
"    </p>",
"    <p>",
"     Pleural effusions can be caused by many different conditions, including infections, heart failure, cancer, or tuberculosis. In some cases, blood or other fluid may be leaking into the pleural space from another part of the body, causing the effusion. By examining the fluid and the types of cells it contains, the cause of the effusion can usually be determined.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      THORACENTESIS PREPARATION",
"     </span>",
"    </p>",
"    <p>",
"     Before a thoracentesis, a chest x-ray will be taken to identify the location of the pleural effusion. The doctor will explain the procedure and discuss why it is necessary. He or she will examine the chest closely; the edge of the effusion can often be identified by listening to the lungs and tapping on the chest wall.",
"    </p>",
"    <p>",
"     If you have a bleeding disorder or are on medications that affect blood clotting, you may need extra care to minimize the risk of bleeding. Tell your healthcare provider if you have a history of bleeding problems or if you are taking a medicine that decreases blood clotting. In some cases, a blood test will be taken prior to the procedure to exclude any blood clotting abnormalities caused by disease or medications.",
"    </p>",
"    <p>",
"     Ultrasound machines are used routinely in many institutions to increase the safety of the procedure. Ultrasound guidance is recommended when the fluid is trapped in small pockets around the lung.",
"    </p>",
"    <p>",
"     The procedure takes a short time and can be performed at a patient's bedside or in a physician's office.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      THORACENTESIS PROCEDURE",
"     </span>",
"    </p>",
"    <p>",
"     A thoracentesis involves the following steps:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       You will be placed in a position that allows the doctor to easily access the effusion. Usually, you are asked to sit upright during the procedure. It is important to remain still during the procedure so that the fluid does not shift.",
"      </li>",
"      <li>",
"       A small amount of numbing medicine (a local anesthetic, similar to novocaine) is injected into the area. This medicine helps minimize discomfort during the procedure.",
"      </li>",
"      <li>",
"       A slightly larger needle is inserted in the same location. A syringe is attached to this needle and is used to withdraw fluid from around the lung. If you have symptoms from the effusion (eg, shortness of breath), a large amount of fluid may be removed, which allows the lung to re-expand.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      THORACENTESIS COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     In most cases, a thoracentesis is performed without complications. Most complications are minor and resolve on their own or are easily treated. Potential complications include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Pain &ndash; Some discomfort may occur when the needle is inserted. Using a local anesthetic helps to reduce the pain. Pain generally resolves once the needle is removed.",
"      </li>",
"      <li>",
"       Bleeding &ndash; A blood vessel may be nicked as the needle is inserted through the skin and chest wall, causing bleeding. The bleeding is usually minor and stops on its own, although it may cause bruising around the puncture site. In rare cases, bleeding into or around the lung may occur, requiring drainage or surgery.",
"      </li>",
"      <li>",
"       Infection &ndash; Infection can occur if bacteria are introduced by the needle puncture. Using disinfectant solution to clean the area and using sterile technique during the procedure minimize this risk.",
"      </li>",
"      <li>",
"       Pneumothorax or collapsed lung &ndash; Occasionally, the needle used to obtain a fluid sample can puncture the lung. The hole created by the puncture usually seals quickly on its own. If it does not, air can build up around the lung, causing the lung to collapse. This is called a pneumothorax. When a pneumothorax occurs, a chest tube may be used to drain the air and allow the lung to re-expand. &nbsp;A pneumothorax occurs in less than 12 percent of thoracentesis procedures. Those that do occur are usually small and resolve on their own. A chest tube to help re-expand the lung is necessary only if the pneumothorax is large, continues to expand, or causes symptoms.",
"      </li>",
"      <li>",
"       Drainage-related pneumothorax &ndash; A pneumothorax may also occur if the lung fails to expand when fluid is withdrawn. This is considered to be a drainage-related pneumothorax, and is the most common type of pneumothorax to occur when ultrasound is used for needle placement. Drainage-related pneumothorax is most commonly caused by disorders of the surface lining of the lung and not by the puncture needle. Treatment is rarely needed.",
"      </li>",
"      <li>",
"       Liver or spleen puncture &ndash; In very rare cases, the liver or spleen may be punctured during thoracentesis. Sitting upright and remaining still during the procedure helps to keep the liver and spleen away from the insertion area and minimizes the risk of this complication.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      FOLLOWING THE THORACENTESIS PROCEDURE",
"     </span>",
"    </p>",
"    <p>",
"     After the procedure, the doctor will observe the insertion site for signs of bleeding and assess breathing for signs of lung collapse (pneumothorax). If a pneumothorax is suspected, a chest x-ray will be obtained. The doctor will examine the fluid, particularly its color and consistency, and will also send the fluid for laboratory tests.",
"    </p>",
"    <p>",
"     In general, sedating medicines are not used during thoracentesis. If sedating medicines are used, the patient will need assistance getting home. Patients should discuss these issues with their physician prior to the procedure.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5395698\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5395705\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/45/4819?source=see_link\">",
"      Patient information: Pleuritic chest pain (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/50/10018?source=see_link\">",
"      Patient information: Pleural effusion (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5395722\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Beyond the Basics content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H865792410\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41414?source=see_link\">",
"      An overview of medical thoracoscopy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=see_link\">",
"      Diagnostic thoracentesis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=see_link\">",
"      Imaging of pleural effusions in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=see_link\">",
"      Management of malignant pleural effusions",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Thoracic Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.thoracic.org/\">",
"      www.thoracic.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Lung Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://lungusa.org/\">",
"      lungusa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart Lung &amp; Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/index.htm\">",
"      www.nhlbi.nih.gov/index.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?24/3/24624/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?24/3/24624?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24624/abstract/1\">",
"      Heidecker J, Huggins JT, Sahn SA, Doelken P. Pathophysiology of pneumothorax following ultrasound-guided thoracentesis. Chest 2006; 130:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24624/abstract/2\">",
"      McVay PA, Toy PT. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991; 31:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24624/abstract/3\">",
"      Godwin JE, Sahn SA. Thoracentesis: a safe procedure in mechanically ventilated patients. Ann Intern Med 1990; 113:800.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f24_3_24624=[""].join("\n");
var outline_f24_3_24624=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           THORACENTESIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           REASONS FOR THORACENTESIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           THORACENTESIS PREPARATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           THORACENTESIS PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           THORACENTESIS COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           FOLLOWING THE THORACENTESIS PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f24_3_24625="Dermatomal innervation";
var content_f24_3_24625=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous dermatomal innervation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The shaded areas indicate the dermatomes supplied by the brachial plexus, which may be involved by superior sulcus tumors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_3_24625=[""].join("\n");
var outline_f24_3_24625=null;
var title_f24_3_24626="CT pneumomediastinum";
var content_f24_3_24626=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    CT scan of pneumomediastinum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 407px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This axial CT of the chest with lung windows demonstrates extensive pneuomediastinum (arrow) in the patient whose plain radiographs appear in the accompanying graphic.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Pierre J Sasson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_3_24626=[""].join("\n");
var outline_f24_3_24626=null;
var title_f24_3_24627="Iodipamide meglumine: Drug information";
var content_f24_3_24627=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Iodipamide meglumine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/25/41363?source=see_link\">",
"    see \"Iodipamide meglumine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5946083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cholografin&reg; Meglumine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F183710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iodinated Contrast Media;",
"     </li>",
"     <li>",
"      Radiological/Contrast Media (Ionic, High Osmolality)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5946111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Do not repeat for 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholangiography and cholecystography: I.V.: 20 mL",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5946127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Do not repeat for 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholangiography and cholecystography: I.V.: Infants and Children: 0.3-0.6 mL/kg (maximum: 20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15962256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in patients with concomitant severe renal and hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15962257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in patients with concomitant severe hepatic and renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F183701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cholografin&reg; Meglumine: Iodipamide meglumine 520 mg/mL (20 mL) [provides organically-bound iodine 257 mg/mL; contains edetate disodium, sodium 0.91 mg (0.39 mEq)/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F183698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5946112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For intravenous use only; solution should be at body temperature for administration. Administer slowly over 10 minutes. Slow infusion if nausea or flushing occurs.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F5946094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Incompatible:",
"     </b>",
"     Gentamicin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Dimenhydrinate, diphenhydramine, promethazine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Hyaluronidase.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F183702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contrast medium for intravenous cholangiography and cholecystography",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5946088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Cardiac reactions (rare), cyanosis (rare), hypotension (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Edema of eyelids (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Renal failure, renal function tests altered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Laryngospasm (rare), respiratory difficulties (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Anaphylactoid reaction (rare); hypersensitivity reactions; infusion reactions (generally mild and transient; associated with rapid infusion rates; includes restlessness, sensations of warmth, sneezing, perspiration, salivation, flushing, pressure in the upper abdomen, dizziness, nausea, vomiting, chills, fever, headache, pallor, tremors)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F183704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iodipamide salts or any component of the formulation; use in intrathecal procedures; concomitant severe renal and hepatic dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5946084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Allergic reactions: Use extreme caution with history of previous reaction to contrast dye or iodine-based contrast media or asthma. Severe, potentially life-threatening, reactions and delayed reactions may occur. Pretreatment with corticosteroids (eg, prednisone) and antihistamines (eg, diphenhydramine) may be beneficial to decrease the frequency/severity of allergic reactions in &ldquo;at risk&rdquo; patients. Equipment for resuscitation and trained personnel experienced in handling emergencies should be immediately available. Monitor closely after injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild-to-moderate liver disease; visualization may not be achieved. Contraindicated in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypertension: Use with caution in patients with hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pheochromocytoma: Use with extreme caution in patients with pheochromocytoma; monitor blood pressure closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Nephrotoxicity has been associated with iodinated contrast agents; therefore, use caution in patients with severe renal impairment or in patients predisposed to contrast-induced nephrotoxicity (eg, diabetes, elderly, concomitant medications such as metformin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sickle cell disease: Contrast agents may exacerbate sickling in sickle cell disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate adminstation:",
"     <b>",
"      [U.S. Boxed Warning]: Injectable solution should never be used intrathecally; serious adverse reactions have occurred,",
"     </b>",
"     including acute renal failure, cardiac arrest, cerebral hemorrhage, coma, death, paralysis, and seizures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5946091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F183706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. In general, iodinated contrast media agents are avoided during pregnancy unless essential for diagnosis.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9732412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cholografin Meglumine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     52% (20 mL): $47.19",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Obstetric Practice, &ldquo;ACOG Committee Opinion. Guidelines for Diagnostic Imaging During Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2004, 104(3):647-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/3/24627/abstract-text/15339791/pubmed\" id=\"15339791\" target=\"_blank\">",
"        15339791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8914 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-118.195.65.248-F33F7FC12B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_3_24627=[""].join("\n");
var outline_f24_3_24627=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5946083\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183708\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183710\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5946111\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5946127\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962256\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962257\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183701\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183698\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5946112\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5946094\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183702\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174547\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5946088\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183704\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5946084\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299527\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5946091\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183706\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9732412\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323200\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8914\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8914|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/25/41363?source=related_link\">",
"      Iodipamide meglumine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_3_24628="IMRT plan pelvic inguinalLN";
var content_f24_3_24628=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Intensity-modulated radiation therapy (IMRT) for vulvar cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 443px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAG7AcUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACtfwlodx4l8T6Xotn/r7+5S3U4zt3HBY+wGSfYVkVYsby50+6jurC4mtrmPJSWFyjrkYOCORwTQB9DftK+FdI/wCEYsNa8M2Om20Gk3j6TcCxljkLx4Bikk2E4bKuDu+bLDNfONWkv7xLW4tUu7hba4YNNCJGCSkHILDOCQemaq0AFFFFABRRRQAUUUUAFFFFABRRRQAUVdstMvb11W1tppCxwCqEivQNF+DPibUFSWRLeGE8nfJhsfSgDzKivonTfgTpaxqdS1C4Eg6iLGK3b3wT4d8LaT9ogsI9QnMixRR3Cg72JxV06cqk1CO70FKSirs+XI43kbailj6CtC20HVLnH2exnkz/AHVzX0vFDDDk/wBj+HYGB4CWZfj/AHsj+VXItRu4OII9Ij/3LIj/ANmrr/s+r3X9fIy9vE+a4/BPiWXHl6Letn0jq5b/AA68VTNg6LdoPVkr6QOu6uowLnT1A9LVv/i6YfEmtdruy/8AAZv/AIuj+z6vdfj/AJD9tE8DPwu12G3ae9i+ywr955eAKIPh15pUf23YKzHGGLD+le56tf3+p2yQX93btbeYsjJDAUZipyBkseM+lQPd/aN6MAynqCowa6aWXQ5f3jd/L/goylXd/d2/rzPHp/hd9nIE3iDTFJ6AOW/kDU1h8I7rUjINO1eyuTGMsI92QPxFetQNBbZWCKKLPUIgGa0PDs2zxMzCT5prJlZeMja4wfx3H8qK2ApQpylBu6V9bflb9QhWk5JOx41J8FddQcSxN9M1Tm+EHiKP7sDP9BX0z5wIPzvmq1xeXEcjiF/lUDOea8DFYmGFh7Sd7eX9dgxmMp4On7Wpdry1ff8AJNnzBN8LfFEZ+XTZ2+i1XPw18Vf9Ae6P/AK+s0u22htzENyOad9rcDKsxPvXR6HVvsfIr/DrxWv/ADBbs/8AAKiPgHxUOuhX3/fFfX/2qYDknP1pFvJO+eaAPj0+BvE466Hff9+6jfwb4ijUl9HvFAGSSnSvp3UfFeq22vXFnHDE6RzRxxw+Q5aVWAyQ/QYyfyqTxLrdwdTvdLhuLS2iEajdImZJN2c7MkDtjoetdscBVbje1mr/AC0/zX9JmTqx18v6/Q+Ul0DVHyUspmA64Gaik0fUIs+ZaSrj1FfTsRS2JlspPIk8lYCDEkisF6Ehgefpip/t80q/PFoznGMtYn/4qtquXPm/dPTzvf8ABWIjXVve3Pk+SJ4mxIpU+9Mr6oaxt5QHkisJJAQSJNPhKH1GAobH41RvPDlhdht0WnxOzZAjskEYHpj73/j1Z/2dU/mX4/5Fe3j2f9fM+ZaK98vfhjpt6xzexxe0cBH/ALNWRefCFFA+x3Ym9dx2Y/nSWX1H1X9fIPbx7HjVFest8JbgdDn/ALaD/Co5fhLebf3ZGex80H9MU/7Oqd194vrEezPKqK7e7+HGrxNKIXt5GjbaYjIBJnGeF6ke4rlb3TL2ykdLm1mjKHB3IRXJVpSpScJrU1jJSV0UqKKKzKCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKdGjSOFjUsx6AV6x8OvhLda3El/rWbaxJ/1ZO2Q/hQB534f8Pan4guhBpVq875529q9v8AB/wStrYpceIp1nyMm2AwR+NeoaLpNhotlHbaXbRxIgx5m0Bj9TV5g7sM7qAK2mabp2h2wg0u0jt4h2xmrRn3k9OakWLI5wR70jwKTnoPagCIHe4TfnmuM1fVZdZmWFbZYLaxvW3SNJuaRozjAGOASa7aKDbKpB715zakb9RB6/2hcc/8Cr1Mspxk5Ta1VrfO5zYiTVkupaUjacnNJvAIIPNKUXHLCmsi44YYr1LHMIxDn5utKGAGBUZXB4bilKt6GmFxWwQcnIpRtUEAcUgRieRTvKJPWgCM/L9qZLbzRbWzXUh80JhAQOODk8+1aHhZ4ZfE14YnjkAsEwUYN/y0PpVnwhZhtb1WY42LaxwMpGd25ic/+OkfjXR2ml2Nlu+x2lvbFvveUgXd9cV5+LxMIKdG2rS/Gz1/4BvSpt2kKCo6L+NVBaGQu8kjAseApB/OtQRqKUIoJPFfPYjC0sTb2qul06DxWCo4vlVdcyV9Omun/DFK1Ro4VRwMjPQ1M2GGKtBUPcfSjYMjitacFTgoLZKxtSpqlCNOOySX3FPI4I60rOSAMGrJC+lIVX8Ks0IPN6Z/A1y/iy+D3Y0uOzSSTEVy9wz42KJBwBjnp611phVj9K4jxTtg8TXku0sItMD7QcZ/edK7supxnW1W2vzMa8mo6FeKwutQvRb6fPDA3lSTs0se/IUqNvt97rVWyZbqyguFUJ5qBtoPSrt1Bqmi3FzHc2SNeXtg8VuLa5yIBkbmbIHOSvT0qBIRbW8MS4CxoqcdMgc/rmvai7xvdNdLW877fJa9nY5JKztb+v6/MenyggtkelAVQOv0FRh1P8Q/On7kxnPNOwiWLh87qsROUyAc5qojo3Y0pZUcZJ/ClYLltpNwI71CQRjL4pFYYJXnNPUgjBpWHciuxFNZ3BnijkCxM2XUHBA4NdW+m6frOgWFvqlok8bWkOcjB/1a1yepoZNOkjjRnkmZYVUd2ZgAP1r0W4VVmfaPkBwoHQCvOzF+7Feb/T/P8Dow61bPEfHHwUhlSW68NSBCoyLXGSfoa8L1jSrzR71rXUYGgnXqrV9vKCTlTzXP+MPCGl+LLF7e/hSO4/gmQANn3PpXknSfGdFdl8QPAWpeELwi4TzLVidsqAlce5rjaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACrWn2NxqF1Hb2kTSSudqgDvWp4Q8L6h4o1OO00+IlScPKR8qD1NfUHgPwNpvhW1UQxCW6K/PK3PPfFAHJ/DH4U2+kxRX+uxrNenkQMOIz9e9etFAcBgMKOB6U8EAEd6axx0oARwuMAVVjuGSQpIMHsasE569aryxlipJBxQBOGwDzSswwOaz2uTFP5ZUnjNT+crYKtkUAWQec5xXHeIdIh0+/imtJpwl9JM8tuSPLDCMtuXjIJIB612UNvPLAZo4XeIfxAcCub8XH95pOQQN0//olq68FOUatls0/ybM6qTjdnJm425Vl57UwGaYNt+VR3BqaRVZgWxgdqQskcbAEYbtmvoDzzPE0iXAVpCBmtWKcog83hT0NZ62pmIC/OB020+6VwqJKjqAQeabVxXS0NUOG5BGDRu9wKxnYhiYSQPekDXBboeO4qeUq523gnaDrLhQHa5UFh1IEa4H4ZP510mT+NcT4IuZEbVFIJJuAf/HFreOtWI1BbGe8ijumOFjJwT7V8/jf48vl+SPQp/CjWLAHBNYuteKdK0eZIrqcCZ+iAZrTuoDJC6ROFdgQD6GvDtf8AB2uab4lXU53W5iD7gFBNcpZ7RY38VyVm3hVYZA9q0TOjEANweleSahq0un7GtbW4ku3QZVei/hXbaJdtLo9tcamfJZly27jFAHTBlPQ0hIHU8VnxLC8QeCTcD0YHrUV/I1tb75JkRPU0AawOTwaqX2labf3CT31nBPKq7Q0iAkDPSsu0umniE0FwkqeqGl1LUWttPurkuP3ELSA4zyB6VdNzUlyOz8hO1tSj4zuUHiKxj3FpEs5GYY6BnXb+e0/lWFIzzIxb5UHT3rNk1O7ubtb3UJ2nu2iRGyiqFAyduBx1JpxvTPcKjkBCa+lo0XSpxp9l/wAH9Tz6k+aTYwrIzlY+AO9LEk+W2sa1lWNBlRketQTXipwExnjpV3IKCS3AyMng9au2gkkG93IFTK6SKCq4Pel4C4GOOlDYydCFHAzS7ucd6gZjgYpks7R+WIlSS4llSGJGBIZmYDsR2yevapsBueFrG21DU9SuLxZJXsJYPs67yEQlWJO0cE5A5Ndi0gAJY1iaNYQ6JHdRyXKz3M8vmzSgbQccKAMnAA96teYbliFPyV4GMrKtVbi7x0t9yv8Ae7s76UHCNnuWYXZ3bb9ztU5HHIqOMbBgDtUofHWuU0Kep2Npq9k9jqcCT20gwVevmf4qfDa58LXTXVgGn0yQ5VwPuE9q+onj3DIFQ3EMN5aS2l3EskEoKsrDPFAHw1SV6d8W/h1L4aunvtPUyaZIc5HPl+xNeY0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWx4X0G78Q6tDY2SFmY/MfRe5rIVSzAAZJr6b+DXhNfD+hC9uUU310AyNjohHSgDrfBvhmz8MaSlhYqpkx+9nxhnPvXSKuxcKTkUkEYjTkjJ605mA6mgBO3IANMz0oY5GR0qMnvjmgAZsHFRl+RilY56cGo85Y/MM0AQXiBkd2OCFPIrZ+HPh/+1DJPcuwjTlRjhhWHqEiR2j73AOK9P8G/uPA1rJCo8wpkkd+aANh4bSHRp0tkVYlU5Arwvxyw+2ads+7vnx/35avXNFm8+4ntp8pHKpAyepNeSfE2E2V/YiMDal61vg+joy5/CurBfxkvX8mRU+FnI7gc1XuY8ocHnrT26+9Abgg8ivozziG0hN1dwWfmvHEY2kk2HBYen6U7WbFLER3NpvEIYCSMuWGPXmq8kp0+8t7xTuU5idc9j/k1r3JW5haKVSY2GDXnSoKpOo/tp6PtorfLv8z6GOOlhaeHW9GUbSj3d2p3X82qcX00tYowx5nGDx1/CtPhQMAVjP59lJAJ5Fltidvm45T2NaykDoOMDpXVTqqpfSzW6f8AW3meTicJLDWfMpRltJbP70rNdU1dejRteCY993rSMVIEkUox1G5SCP8AxwfnVXxN4Bt9T8RW+sR3s0M0bBiqjg4qx4LCt4lvduNx07Jx3xKv/wBeuu2jPXNeLj1+/b8l+SNKL9xEMHEagksVGMnvVDUIftsTxO+3PTFXLpZCmFHeqIjk3ng5FcZqY6aFcxXRYBWG3G8nmtqS0il0oQ3Kg4XB4pTNIvDjNSxyrIhU9T2oAwoLELpdxFDcyqkYLK3QisbQtTl1sTWNwjOkJ2b2HXFdnd2zTW7QQyLGzDGcVk2ul3GmW8quwnLNnKrjigBdNt4LCGWKPCKByOgFcv4g1W4up76wtrqBbFQsTmJA7Sbhkjf0Hpx61teLLqKLwfftHHiR0ERyem4hc/rXHJHHABEqIqp8uEGASBjP44r2Msw8ZJ1pd7L5Wd/69TlxFRp8iEYEsWPU8mn2caDM1w4jjB+8asQyQWyCS4zhj8qDkmrdlZi4lW5vuADujtv4VH+1713Va7i/Z0leX4L1/wAt2a4bBRlD6xiXy0/xk+0f1ey662Q60vbW4YRxTnf2Vhjd9KJUVpD7U3xHMs6wRIEa6Mg8srwV9T9KduBPJy3c+tTQnNylCdna2q03+/X/ADRWMoUY0qdeimlO+jab0aV00lo/TdMeCEAxxTg42g1Fux7UiEFgAc5rosecaul2sl7PFBbpHJczzRwQRybtrMzYJO3nAGWP0rr7v4XXumrZ6realLcXFvL9oMEACwxsPugZG4j3zR8KtLl/tS28QXFk9vp1nDOkU07KfPkZtmVA5GNrDJ9a9g03U49TtpSoHQ8V5WNxUqb9nTe+/wCVv611OulSTV5I8IRJJrtxJ34ragjWFAABWdI3l6zOn3SXPH41olfxPtXkHSTB8DHrTxyKiVuOcKfenK2elAE6ZHU8U2VNyEg0itnO7ingbunpQBQvrW31PTpdPv4UkglGCG5r5O+JHhKbwn4gmtTl7dvmjfHXPavre6UqNy1xXxa8Nx+JfCE0oXN3ZK0yYHLcdKAPlCinyRtFIySKVdTgg9qZQAUUUUAFFFFABRRRQAUUUUAFFFFABRRSqCzAKMk9BQB3Xwg8OHXvFUDyIHtLZhJMD3XNfUVtsa4CRACKMbVA6ADpXnvwa0JNE8GLeTReXe3mVbPXaDxXfadkSYHcZNAGsTx2xUbHPGKUkjHFMc0AMbIGDj8KjYtnjbTiSMnNQscNnqT+lAAx55qNj3yPwp0jfL1yKrSyKASANw7UAZ+sQPcuNh4xjBr2nwdbE+C7OEn5hHXj2k79Q1qKID5CQDXv2nWiWNhHAn3UWgDiVcRamp3EBGyc0z4ieH7bXbKKd7fzLXKuwRir7geCCORTtVurZrqQtFgD+daWhaxGgW2uAPJcYBPYU4ycXzRdmgtfc+c7tHjnuIpA4aC4lhJd95YBtynP+6yjn0qD7j7ckjrXYfE7w5f6R4l1rVItLnGizvDILqMqyJ8pViwzuHOOcVyBVlJWQEsD3r6mlJSgpLqvxtd/czzaitJkd9B9otmQNh1O9T2yKs2spmtYJh/y0XJGc89DVbzNvzHoOtJpJIkuLVcHDeYg6Eg+nrWM/crRl0lp81qv1PQpfv8AA1KfWm1Jf4X7svx5X5a+ZpMgljeJuVkUqRWZp87rp0YY52syA+wx/jWox8iJ5ZzsVQT83Gfp6msayDCxjzxudnwfQ45/Sh2+sR72f5oVJv8As+o38PPG3raV7fK1/kWL5g1oJwAJopYtkg4ZcyLnmvVznOf5V5HIGuY/sllHNcXLyRtsijLYAdSSx7D3NepSXLK20pg1xZrtBev6f8Eww3X5fqWLi5jhhd3/AIRnHrXDSeMxBqAS5hZY5DhSFrqp4vtB+cVVutBs7sRmWFSU+77V5B1F6NBPGkvZgCM+lMmgKtuT8KnCiOJYzwBwM1KuCg5+hoAqwI7kt3q3Km+LaxOaI1J6HI705mwcAZoA828W3vmXz6XHasRaXEbzSu4CnjdtC9T1HNULeFZPmbOAck1c8ThG8WavsyeIvNJ6eZt/+JxUUWIIvYg/yr6ihCNOjFQVtE/m0m/67HnVG5TafcNJjL776RcGUkQ5/hQccVckZtjY61Bpjg6TZAHOEI+nzGpJ5kgiMszARr39fascLaNCMm91dv11bPQzPnq46pTivhk4RS7RfLFL5L5vUzlCrrMTDl/KYv8AlxVh3PAA5qtYhtstzIMTTtkD+6vb/PtVnr1arwyfK5tW5nf/AC++1/mTmkkqkKMXf2cVFvu023byTfKvJIf/AAgnrV/Q9PvdT1WOx03T3vbhomlKrKIgijjcSQe5ApbPR724srmaL5pEiZ4RgHcwHAxXo3wyl8O21i2oaRqt1qGsm0jhuTO7H7OThmQAgY+YfpV16qpU3Ute3rv522XzOGnHmkonSCwOjeFdH0TbGDb26CXyzkGTq5z7sSfxroPC9n5Fs79FI71zCXTT3fzS7uc8132mAHT4uMAivmZyc5OT3Z6CVlY8M8XKttr++P7jN+tSpJuQEHrWt8SLGJNYlCLgBQRXP2J/cKPTtUjLwI55zxUiEY7+tVwTt/1e2pUkO8DZxjrQBYVuOMfjUgJzk4/CoM56LUoIHUYNAErHehyBiqUewymN/utwR2Iq2SCKzrolJgRxQB8wfGLw23h/xZOVB8m6JmT0AJ6VwdfUvxo8OjXvCD3UMe68tiNpHXaOtfLbAqxB6g4oASiiigAooooAKKKKACiiigAooooAK6X4e6E/iHxPaWSdzvJ9hya5qvfPgBoQtdMvNauIts4YJCx7qRzQB6xcxwrIkMPywxqFAHsMVLpqjzic9B3qn5inqOWq7p5HnHA4xQBoluORUTkZ6Gnkj0HNMJxxQAwkEc5H1qsGJlZcjAqdzg9c+1VJMAsV4NADmODVe7DiFyjLmpEYsoOc0jAH7yjmgDZ+E9qk2tsZkJIUnnpXoOv+IGsrkQQqD2auN+G8sUOuEFgoKEfjXTeJdEMly80bsXc524oAxL8C4lXj5mOeKiugyMkRB46Y7Vektmt7ZZpCfMztUVXNlczxs7Egk5yKANJlGveGtR0W9maGO5gaIS4BKZHXmvGdZ0e8jv8AWYbmSCe4sLhYmlgi8tZA0YfO3Jx1r1nVnTTPD15qXmeYbeIyFH4BwO9edeGbuXU7e/1C9dDd6jIk8qxAiNB5YCqoPoOvrXr5a5KEu366foc2ISbRwgO4lWBFZlxgzbWVm2jhlOCPat7WI47TV7mCM5PYVj4eJyWXcWPftXruEKkbTV15nPRr1cPNVKMnGS6p2JrO1gba8iu3cK7ZFaIPy8BeOABUKEALuUEU7dgccD2rOFGnTvyRSv2NcRjMRimnXm5W2u7mp4WvbbTteuJbqX7PFPaeSshQlS5kU7SQOPxrtpgGO3cu4V5VfFhp0w5wZYv/AEYtem22C7ZXc4ryczpqMozW7uvut/maYeV1y9v+CRzmSPhT706zuGdlDA81ZlwwxtA/pVXBgGR8zH9K8s6Dz34661qOlWNiLEsiGTLMo9uldN8L9eOveF7d5si4jG1ie9W9c0+DWrYQ6hAs0WeA3arGgaPaaZbJFYRCFQPur3oA3V9FqSKMF+aZbgMoBYlh7VZiTafmOTQB5Z4ijP8Awl+vHPAuIs/9+lqndSFQhC5xWrryeZ4p8SDHP2iL/wBFLWUqszAYyBX1lP4If4Y/+ko8uW79X+bIreOaHmznjVHJJimHCn2pJ45pXX7bOjKpBWKIfKT6mr72yOyNmql5CIPnZjisFhae2tu13b7v02PRea4htzdue1ublXN23720vv5ihdgAY5Y+ldb4e0dBGlzdrjHKhv61xlnMtzexZbCAivSdYuha2kYIBVwFJ9K2qNrQ86KRn+I9Ue00m9ksTseOJ2VgOhAODW9oGkQadBbXKy3U099awSTSSylyTsDd+gyxrldaa2l8M6iF7W0hzjvtNek6XatPpWj7Sflsbc49f3S152YNxopLq9fwOih8b9CS3gP2hZB0xgAd67PTdQeOKOOQbQOOlc7p8bLMBsGR0zWhfSSRMplUDPPXOa8U7Ct8Q9OWW3S6iUl2+8e2K80UhXZAQCTXs2syhvDM7TAKTGQoNeKxQYn8wnOKALisOhOPTmlZjkMp6cVGdrEcA/h0p4wB97AoAtKxKk8VIuMdTVeIjb97INTrtIGG5oAkVuDkH61TvgfNHI5q4D2PGKpagBnOc0AJFsmikt5RlZFKEH3FfKfxP8NHwz4qurWMH7OWzGx755r6ihf96pyfeuF+PXhwat4aTVYfv2QLPgckHigD5oooooAKKKKACiiigAooooAKKKKAL2h2D6nq1pZR/enkCD8TX13p2npo+iWGmx4BgiCPjua8T+AHhwX2sT6ndRZhtU3xsf74Ne5TSvLK8mBkmgBBu3ZbHFWtMJ3tmqhYmL3NX7OJhCGHWgC41RlvUc05ueVPFNx6jNAEDhy2VdRjtWbqCS742DYUHn6VqOD6AVXuEV42BJ6UAU1zb43SBlfkYqzjpWSbK580Et8gPAz0Fake4pmgCWynkttQglUEKrgkjuM17fZTxajYxTqPlYZFeFZdlYAYPSvT/hxqjXGnmzkEamAYHPLUAR+IJJZLpLYrhEO4UnnyRQ7EU4OMmrvifNq5lVQ7vxk9qxbR5ZUwSMHk80AYnxOLL4O1UBWZZY1gRF7u7BR+GTXKaABHYXpjAADEjHbiqni66udS8Z6lFLeXX2K0lt/KtA+Ii20tlh3OQDWjOyadpDyAD5xz9SK9/C0vZUlG976/ekcdWXNL0PPUU3WoXFxJkknrUt/GDGCq9KlsiMycCi/kxFgAZ9K776nN0M+Gd4xyMrVqGVZB8vb1qssTOmTke1aVnCiQg7ctTdgRS1JHk0242Y+TbJz3CsGP8q9ZS1SGMMDgsoP6V5pfqBpl6QoH7h/5V6bcHfGo7iNcfkK8fNH7sPn/AO2nZhlv/XcqTRMWDK2QOoFRS7JCAzA47CrWxo4+eQarsig7lHWvIOkasaH7qmpIpfIf5hn6Uq5UcgY9acFB+bg/WgCzFMHYbRip9zFxwfrWaiuJBg4HtWlGRtB3dPWgDzrWXA8XeIgCMm4i/wDRS1ROI3bPUjtVnVFDeMfELkncJolA7AeWD+dU7lMuD6elfVQ+CH+GP/pKPMlu/V/mxYnkyPQHio9VZmiCtUscoYbSAMVUunaRtqgt6Va3JZm2rf6fEig4DDJH1r0jxQFNrZhwSuRwPpXn0IVblMKQ6nnjvXpAZL/RBNKPujjj0pVd0xwMme2/4p7VSg/d/Y5T/wCOmvWNEkeDRdFlBAX7Db/+ilryu5vVPhnVYmUqPskoBA5+6a9b02JF8LaI24MzWEGFJ6fu1rzsy/gx/wAT/JHRh/4j9B/m+dPuUYXuameOW8uooY0IT+8elU7dm3CJVBJOa6i1K6dYPc3QChRx7V4h2GB8RblYdMgt1kHmAgMoPbFecKuB0OO1aPiTUn1fU5J2OxfuqBWcAQuCSaAFlmSJCWOB71VtpobyU8nAPrUGqOsjxwc4Y4JFW7Kzito/3fOe9AF9DHHwozUquDjAxUSgZFSKBigCUcnpg1WvskLjoKsg4wCM1FegGBiOKAM9T1yOtSRwJqNhcWNyN0My7WBqFeiEE9KlSYxS8KB3oA+RvGekyaN4ivbWRdqrK2zj+HPFYde2/tF6IftltrUahYmRYmx3avEqACiiigAooooAKKKKACnIu51X1OKbXbfCTw//AG/4vtIpY91qrbpD2GKAPoD4e6OfDXgm2syR50pMrH2YDFa2cqQeT1qe62mQJ/CihQB6Cq7YB4oAe+1VHFa9uwMC9uKxZBnHNaGnyhlKZGaALZOOhFRtk9OcVK6DsR+FRkdelAEZzj7pFRSMc/cJ9amYgDFRsM9entQBXdmz92mK8iHaR9KmK7STk80yRBIDn8xQAoBPatDw/qC6XqsNyVJCn5lB61lxBk4JOKkJI4IGfWgD2a/jTVdOWaDDErnH9K44LJFO3loV8sEMPSsrwx4muNMnWGU7oGOOecV6faizvoPOhVGD8kj+tAHzbPFNc+PtZwMos0Bf6bGrV8YsqaMyKedwwK3vHNjZ6F4wnurDWLV7i/lt0n0owh5duSu9SPmXAJP4VxHja483UI4Ymyqrzz3r6Wj70INbWX4JJnn1NGzBs5UWYgjDGm3x33CAdOKo3kptmVjjNTWd/DuD3IkC/wB7ZwK0qV6VJ+/JJ+pth8vxWJjzUacpLa6T37ebNZYlKDnFORljG0nFJJKiorxMro3IPYiobwO8IYYyOeKtanM04tp7ok1Fl/sy9CnJMD/yr04QOI42LZGxe3tXj1wZP7Ou+R/qWz+VetQTyuIgwG0IufyFeVmqsofP/wBtOrDPRk0jCOIkEE+lUg5bAI3GrVwDI4xtA9qYyBeg6V5B0jFACnPWgoDjP5U8EYwBz3zSZ7YoAbtA57/WrEamSM7jjBpSQEzgkfSkt5MZVgaAPOdYKr4r8QgthjNEw46jywM/nxTYUG3J6n1rX8a6ZCt9batBPOss88drLCQNjKc8+uRmsqBg0YGCK+moVFUpRceyX3K36HnVIuMnfu/8ymQFneqV/M/2ryYnKRbA0jqOfwq3dHbK23rWdMGe9dVHLRAc/WjELmUY30bSfoduWtQlUq2TcINq6uk7pJ2eml7q/ULdtl2I45vNidSys3UH0Nek+GFMugRqx5JIzXmlonl38SMuCEcHH0r0DwVdiW3kth0iG6oprlU4LaL066WT/UrHy53RqtJSnBN2SV3zSjey0u0lfz1MTULi7ki1WxiBdnikjRFHLHaeles+H54bjw1pU0U4dDYwBMeyBT+oNcHrQttGD3FtKp1e5+S2gI3M7MQuVUdcZr2Ow8HwaZo2mabaMTDaxCJnY8t3J/EkmuXMn+6j66fdr+lvmc2HXvNlXw9YyXVyJC2UXndik+Imsoto2nwDzHf72D92rniTW4NDsvstoF84rjivMp7iWWVpZmLM3JNeMdZEoJXlce1R3EqwxklgOOlSCUMfkDZPqKY8CyOGfn2oAzLAS3F07v8Ad7CtYROjZBx/s0LCqHK8cdqkUbmxk5oAnXdxnvTwcUiDGMmn8A4/HmgBykkjNNuMfZ3yO1OXJPTpUV8W+ztgUAZiMGQEHAFSOeA2M5qAMPJ9KkhckFT+BoAxfiXpKa74Duoivz2588f8BFfJZ4Jr7Sji+0QXVq/SaNk/MV8j+MtM/sfxLf2H/PGQrQBiUUUUAFFFFABRRRQAV9H/AAC0R9L8M3eozcNd7TESOw6189aZb/a9Rtrf/nrIqfma+wdI03+x/D2naYMf6PHtNAErllB9T3qNuTk54FSv6jtUJyxwentQAP8AMDVjTrcNJvzgCoJMAY7Ve0ofu2GDQBcKdxTNuB0qXaMdT+dMZB6n0oAhZcdF5qMBh04FTFQOufzpCOSB0oAgbPQnmootzErnO3vU+BzkGq4iKSZXcQaAJdmQcimHdx8vH1p4yR0I+tJ+8RuMFfTFADGUHlgBWzomtXVgwEFwyxZ5TsazwqsMsRTJYkf5SD/wGgDM1vxUI/FXiWcQgPKbYZz0wj/4159d3cj3slw5OGJOK0dbtm/4SDW9m4qrw5z/ALhrOeH5TuHNfU4dLki/KP8A6Sjzajd38/zIoIv7SvzuwI4lyAecn/P8qvz3At4yjYKY2kEcEVmQk2V2kvzGFhh8DOK0p76zKbYz9qkPARFOf1Fc1OvSoynGrJJ3e/VdLd9LI9rFYLE4uNGeFg5QUIpWWia+K72T57u7to09iLSQDazRk7licbM9cEZ/pWjArPGQRxVDTFMMLiU4mkbcwPb0q/bMVfGcg1rhouNJJq3l2V9F8lY480qRqYuc4u+12tm7JSa9ZXfzKGpxmCyuduCZAIxz/eIXP616y52RLGAD8oXd9BXleufNZy7BkoVkP0Vgx/QV6hgtt/hyARn3FcWafDD1l/7aY4br8v1JIIiuCWyafLjfgNn2psasGGWFOlKnGSOfSvHOohJGTnj2p8ZHIBqPADetPVl3dDmgCfPT5utMdtpz17VKuAuFH51CyH5iMZoA5zx47RaDHdp8wtLqGZl9fmAx+tcpLK1vI6O+dpI6V0nj5mHhG/BIILw/+jFrBvol+1SHbkFjn869/Lv93Xq/yj/mzhxHx/JfqVlw6tITgAFiT2FVrHbcX09wp/dKojVv7x9aZdMZUngiJB28e/tTbi+gNpGqBoZkUJ5G05z6/j1qq9SMasVUkoxWuvV7W+W/d/eengMNUnhKksPBznJ8mn2Y6O7W+trX2Wt9bEVzIINWBD7zsbPHTNXdB1WbTb8yryr8MvqKzbS3YAyzgmZz09BVkwNnjit8OrxcpL4nf5aJfgkcuZSiqkKMHdU4qN+7u5St5Xk0u6VzubbxrLoupNrlrb2spMMdvJBOmflDk5RgRtPzHrntXpet+LrozOlrmPB6g1863kVxHpt2cqysmw56DccZ/WvW44Wgght5HDPDEkRb+8VUAn9K8/NYRioSW+q+635X/Eyw0m7r+uo66uHuZTJO5dz1JqFSpUkHNOkjwRk570AgHJHHpXjnUN2tjIbA9KYVIIIbI9KWRsOG5NPWRF+ZqAGqufpUqqFHDc0wSh8gKfbFSZIxkfnQA8cjg808Enk0wKTyWFPwDQA4cgA8Ulz/AKlsU/HHGDTLhHaJtvUigDG4KYwDTV3KQRxzTmj2fK2c0xXVWw2efWgC7ASkyMT3FfP37QOj/YfFhvgMC9+cH6DFe/q6tjHUV5p+0Tpf2nQ9NvwCfs4YEj3oA+d6KKKACiiigAooooA3/AtqbrxZpiDtOh/UV9fatuN7J7HpXyX8NHVPGOnbjjMqj9RX1pqQ/wBOlyeQaAKZRsdaVQoG7vUrRgpu6VXKlmwDxQA1gMYPJqfTmaObBPBqFiI/c1GJt3P3SO1AG+SMdKa4464FVbe4JhBc8VZV4yuVOfxoAYSMdMimFW7HAqU4P3RijGetAELL0ycmlAPTOKedw46+1NwzHnigBpAzgn86Qg9jke9SBAByDmk2kg8UARCNQepzTwNoPb0xTsY6kdaRjjO2gDl/GGj2X2WTVlgI1ATQIZVdhkFwuCM4PBIrnpEBJyMjNdj4tjM/hbU1KlmEXmKB1ypyCPoRXILLFcgywSxyxk53Ic474r3svqSlR953s7eisrL8zjxEUpaFR4CuWTFWIo3S3aTfluwp+0Z5HSkWMFyeorvuzm5UUrYmSU7xz6VbIOAU4INMmRY7hdtRXryW9lM6MA/CqSM7SSBn9aaXM0l1DYl1BQNNuiPvGFj+leofeWPuQi/yFc/c+BrBImjm1PVp1UgMjPGFfB6HC5wfrW/HlgBtxjgY7V4OOxNOuo+zd7X/ABt/kd9GnKF7kqg4+amOuT8oxTwqhsYIpx64FeebEGCOgpVz170/Y2cDpSoCCcYIoAmRTtz3NI42g5py5XBAJpJMkE4xQByXxBXPg7UCBwHi5/7aLXL3UziSUejkfrXW/EQH/hCb9v8Abi/9GLXGSbZLuYMP4j/OvoMt/wB3X+KX5ROHEfxPkv1IGi2J5ufmqWPdKoJcijyjnGcgVKFwoGRXdcwtcaIyvpj1p2CVLUu0461FcSmGBpMqJD8kalc7nPCjHfmlq9ENI0vD+n2mraqFu7QTRWCEyFmIXzHKlBjvgKTz613TbpXJPBrM0LRzoqXgkuPtVzcyK8sgj8tflGAAvOMc1pk57HNfO42uq1T3XeK239Xv53+VjvpQ5Y6rUb5b5PNN2fNncT7VJuwOuOaDu5PauQ1Ex8oOAfWmEI2QUH5VKu3GdppxzxgfpQAyJQo6bQfSnkE9fmFIDzhgc07ODgCgBwAC529KeCCPlHFNHrjI9BTt3PFAC4HPJ5pJpNkbc4bFODYXJYVm390JMIqk+pFAFV2beWLZNKIw+0sB1pEVQMYIJ7mnLHg/eoAdHsVtuBiub+MUQk+Gept18sLj8xXTx5yQ3zfSsX4jwmb4cayM/KVXIP1oA+RqKc42uw9Dim0AFFFFABRRRQBpeHLkWevWFwW2rHMrE+wNfY5uotRgh1C3IaG4G9SO4r4mr6M+BHjCLUtKXw9eyBbmEbbYE9R1NAHpkhJQDPWq5BUH0qxMHRirDpUMg3AYHPpQBXYcg55FQsDuOMYq042jG3nvUBQnleDQA2ObahVmODTkuDEeGOKhIIB3HJpjEHAC0AaSaowXlAfepk1Rf4h1rEZyDhRSKQeM4oA6AX0TdTUqTK3KNke9cy42kfNTopSPutx6UAdRu9DmhgeTkj6Vgx37gYD9DVqDVfmAkXrQBphSRz1pAMHio47uNh94E+lStlsHbxQAdDkACuE8XGDTfEs008yQwX0Ky5ZTgSJhT0HGRj8q7wBhn5qSQeZDJHIFKupQ7lyORXThcR9XqczV01Z/1r1M6kOdWPO9vAK4ORkc8EU3nnAx9K0E8I6vaWsMdrqNhdrGNgSaFouPXcCTmmpomvZK7NFBHYyy/wCFe99YofZqJr7vzscXJNbxZzc0kj38afMe2AOa29I0iTxBHeRrNFBaQTxxlzGxeQjDMAc4GCMdKhu/DOsTSnzZdOiQqVdoN8jYPscfnXc6THHb2kdvbxrDGn3UUYArlxWPVNWotOXlrb9P69DSlQ5tZLQ1WfzLl3c4ViTjNOKKTlW/I1VljJjJY4qvaXO1sMc84zXhJW0O00sDPOSR60YJ4FKBvGR0qhNd3CXMyR+XiPnkDmufEYqGGSc76u2iv5/ocuLxlPCRUql9XZWV+jf5Iv7CDyc07gcED8BUVtKLiBZduCeCPcVN6DOTW0JxqRU47PU3pVI1YKpB3TV16MBuxxjFMmyQACfzpWBzwaQ4wSR06mqLOX+I7eX4KvUz954v/Ri1xHmH7VIQMjcf511nj5vtXhrUVjI2ool+u1g39K5Oxne6tL+9trRrmC0VZJ5I51UIGBOMEc4wa+gy1/7NftJ/io2+84cQv3ny/wAyzuB5waYzjtinPKqnrx2I71TMsKnfPPEiZ/icV3JX2MGWGnSJDJPKIogeXboK2PDGknVo7bVJrxlgguzJBCkQG4JwCWIzzyaPCelT3Y03W7i4tvsoZ5IrVYtx43ICWJ69+ldoZDxwBmvMx2MVNulT36vtumtVv5r5HVRo396QjbiSaAoIJyT7Gky+ck5psk6RZLvXiHWSArjke1KM7fb0qhJqUaEkfOKpT6u7A7EKn60AbbcchvzNAkOPvL+dcqdQuHYndk0C8m6upFAHVF1z8zDmmGaNTnfXNtdSSd6YJX6s/wCFAHTveRKOWNRHUVHCjP1rDUiZ9pcLnpTpBs+583FAGlPqW4bVAqsztndwD9apo6glfKIJ96sbWcDKEj1oAmi355P51ZCgnJNQohyuDirDKFXLcH1oAeqlV3DqaxfiVcfZvhnrLuP4VA/OthWLjA/CuC/aA1pdO8J2+lAgveglvbBoA+a2O5ifU5pKKKACiiigAooooAKs2F3cWN1HcWcjxzIcqynBqtSqxU5BwaAPonwJ8WrfUbSOz8RxOt0BtEsa4B9M16NDdafcqrwX9uVI7yCvjVbmZcbZCKtRaxfxf6u5dfoaAPsN4kLbkuYmz6Nmo3tZCePmH+zXyjZeL9XtSCt3Ice9dFYfFbxBaYAuXYehNAH0O8Tqh3oR9BVdkLDIzkV5Xo/xmkx/xMolkPfNdlpHxI0PVAPN22xPfrQBuFSTjFIV9etWbe90y+4srxJSe3SnvaTrk7FYf71AFLGeDimkAMOlTSAg4MOD61ESq9RigBpXuMY9KUnBBXGfejKZHNJJgj5QKAFMrADBxz2qzb380bD5sj3qir7eCOPSnblPYLmgDo7bUIpRh/lara7Wxg5U+lcp8ynrxU9tfTW7gBiU9KAOk2gH5W4qKSNSd2earQXscxHIU9xVtV3cgigCq1uEfzBuOeoqRow6Db8pHPFTnIGMcVC6vn5D9aAKV3dXEa+Wwyp7iqOsX7WFvbrZw+fe3b+TAh4G49z7CtSdm4AXf2xWX4q066ig0u/tIvPms5jPJAp+YpjnHvWNatGDUG9Zbfm/wNqEVKa5tv6t+I6Kx8T2qRSQ67BcSggvDNABG3qMjmkuL+bT5IpNe064uGmDEvp4LorA8DGc4Iq/o9/Z6ha/aIr2MIUMihztbA65B9DxU8esaUkqQz6pbxzvIIljU72LHsQOlcOIlhKivOV1B/4lez6a30+4zxGDWMlCOIpc3K27WS6Na6bK9/Ur6d4t0Se4W2kmksJ+FWK9iMW7PTB6fnXQOU2ho5I3U5w6MGU/iKypl0nUbVxezWM0BkEJ3lWBbP3eelczbqmkeMIdK0meNrO9DtJaIwYQuozuUDpn0rphiYOXIpJ27f1Z9Ntjo9jGS9xONlt00+6x2ctzHGCCwyO1ZlzetLlEOF9qfqmnSwTGSY4hHRh3FZ6yrK2IY8jpmt6VWFWCqQd0zmatoyZYDIMMoKHqD3pt7aG4sbm0hVI0kjK4AwORjmrAyhGGP5U8FySQM8d60TtqI4N/DOum3FvjTwghEQlDPuHGM4z1rq9P0LS7WG2C6baCeKNVMoiG4sBgnPvWkCcfNwfrVee+hhyGcA111sdWrLlk7Ly0v6mcaUYu6LO2OMBRhVxwOwqtcX1vbry24jpzWLeaiZG2xvkH9Ky7hmyCSd2a5DQ2LrVppCRHhVNZzyOeWdj+NVTL8uDSxyYUluaALO9gnJFRK7E471Gz7jnGRj8qdHw2NxIoAmXBJJOPoaU79uEIP1qMrufkVNDbzOf3SEkfhQA2Pkdx9anB2jJIzUwsmC7rp1iX1JFQXWo6DYrulv0Yj+HrQBLGWBLEDipYkmkclEbBHpXH6n8UNFtN0dvErkdzmuY1D4x3YVksYVjB6FaAPYltpcDeyKPfrSvbyRrwWYe1fNt58Q9duZ/Ma8lA9N1aWjfEzWLCVZHu5LhR1ic8GgD3+OWQHCgY/wBqnNIXZQ36Vwmj/F3RL2IHVIBZyAchAW5qxqfxb8PWFuZNPjF7N2VlKigD0B5bbS9Pm1C/kWKCJSRvOMn0FfLHxH8UyeKvEM91lhbBv3KH+EVY8d/EDVPFkxWZ2gsx923U/KD61xlABRRSnrQAlFFFABRRRQAUUUUAFFFFABRRRQAU9JHT7rEfQ0yigDUsNcv7H/UTsD7mup0P4l6xpzhpJmkA7Hn+dcFRQB7rpXxqedlS+gjC9yFArrLLx/4av8LI5jkPqwr5epysVIKkgjuKAPr+3l0e8j321/bg+henf2eOsMqy/wC5zXyNHqF3Gf3dzKv0Y1pWnizXrT/j21W6j+j0AfURtLheTC+fXbVaWJkJ3IQfevnRfiF4sXprl3+JB/pT/wDhYvis9dYlP1jQ/wDstAH0MCpXBJBHvTADnrXzy3xA8UMedWkz/wBck/8AiaZ/wnvib/oLS/8AfCf4UAfRi7g2c8+1WoL2WEgBvzr5p/4TzxN/0Fpv++V/wpD468Snrq03/fK/4UAfVsN+jY39asmdGH3xXyUPHniYHjVpv++V/wAKcPiB4oHTWJv++E/woA+s7a6WK4DFQy+uOnuKn1Wbb9lliYZ5IPY18jj4h+Kx01mf/vhP8KcfiJ4sKqp1qcqDkDYnH6VxVMFGWJhiU9V+Ks/8ylLTlPsCDXbS/gktfEdjazWojKjEYUkHgjNbei6Toen6TbReH7VFtlBO1fnfPcsTyTXxI3xG8WMu1tYlI9DGn/xNWLP4oeNbTP2TXbmLPXZGg/8AZadTBxnz625vJdrf15lKrJLlvofZcGiaJ84k0S2jQy+c3mxDBf8AvfWq2oX+haTfefpGiWKaqflN2sKljng8/Svkb/hZ/wAQLsiP+3L6UseFESnP/jtbdlL8U76MTLNdRp1DSiKP+YzRSwVOlN1Fu/8AgX/IbrTatc+jte1ESFopwjSN1HZf/r1iCaNBgAceleGzQfEqR2Z9RLsTyd6Hn8qYLb4kDA+3EZ/20/wowODjg6Spxd31fmROXM7nvAu4zyGGar3eqx268da8Ney+I4Yqbttw64ZP8KQaT8RZjg3JOfV0/wAK7CT1e81mSZjhsDtiqLzGQZYsT9a81bQfiGoyZ/8Ax9P8KcmifEZ1LCZsD1ZP8KAPQizdAQAfXrTmYjHOa87GhfEUjcbgDHrJH/hU8WhfEpyAlwp+rR/4UAd+kbSfdRj7Crv2KRYi0pEEQ6tIMV55/wAI78USM/alA9pIx/Sql74M+I9+pW7uzIvo10MUAeivc6LbqTNrNnkc4D81h3nxA0O0lMaWs9wAeZEcAGuCb4V+MZCd8UB9SZxSD4TeMNpAhgx6faBQB3cvxO0aCLzLWBvM9GYHFc7qfxjvJVaO1iWMdiEFYv8Awp/xbjP2a2/7/ij/AIU/4swT9nteP+m4oAwdT8aavfs3m3DbT2zWDLd3ErFnmck/7Vd4Pg94tIz9mtf+/wCKcPg54uPS2tf/AAIFAHnRJJyTk0lejf8ACm/F3/Pta/8AgQKP+FN+L+f9GteP+ngUAec0oOCCK9EPwc8X/wDPpbf9/wBaP+FOeL/+fO3/AO/60AcBPHsCNn743VDXor/CHxg2A1rBhRgZnHAqN/hF4rUZNtbf9/xQB59RXoUfwh8WSDK21t+M4rmfFvhfU/Cl/FZ6xHHHNLEJlCOGBUkjr+BoAw6KKKACiiigArtfgp/yVzwh/wBhOD/0MVxVFAH1R+0VHdT/AA11H+1X1GGW214yW39tLCZZ42DLttShyIh975hyMc8Yr5XoooAKKKKACiiigAooooAKKKKACiiigAooq3p+nXupSmPT7Se5kHVYYy5H5UAVKKt3OnXltI0dxazxOvDKyEEVo6F4V1rXfM/suxkmCDLHhR+ZoAw6K2T4W17zCg0fUGIODtt2I/PFdj4W+FGpapC0+qzDTUHSORCXb8O1AHmtFe2L8G9PB/eaxcY/2YhViP4N6KwH/E01E+uI1H9KAPC6UAsQACSewr3+z+E/h+2fdP8AbblB2kYKD+VdRo/hfw/pZH2DSbbdnIZ1MjD8TmgD550LwbrutsPsOnzeWesjjao98mvR9E+DdvFh9f1ZcjrDajOf+BGvYkgnmIyGCenQClOmqDk4UA9qAOO03wZ4U05QIdIimIHLXJ8zP51efTNJQr9n0TTVJ4BW3XiupSwhQkY3nuTUwhjQZCqD2460Ac9HFMLcR2sMcS55KR7cfSp4rK5b/WvuHT5jW0CT1470uMkgHj3oAxF0keYX8zoQcKOtWhpsXmBmySORWioVVPy5zTT/AA5JxQBUaxjd94JHrUy2yqeSCPYVM8gUgDn29KqnUIvMEandID92gCdoVC85J9BWRfqfPEcUjOTxsU9K2XjuZI3cIUixknGaqwoigPCQfU45oC5DY6WFQy3I3v2GeBWjAwQ7QoGO2Kc6eZEIskc5JFVJhFbqcMd3TAPJoAuI2SQPpQ3CjB+Y9aLXTbouskkiqjDPJyR+FdDYeGLmZiUt5nBGQ0h2inY4ZZjQT5YNyfaKuYSqNgHr3oCgMoB711Y8JXoGPsy/XzOlTnwNdk5+0w9cj5TSNqGI9tf3Wrd1Y5EjCdeM0ibcEevc10Fz4R1dJGVIkkX+8GxWHc6bqFqzmaznCqeTsOB+NB0DQRwDxUi4yOPzqvGwZA9WOqA96AFI7g0u5h2ppYEEDk0AjuMUAODYPSnA5brTN2Ac06MjA96AJud1IY0f7yggU1W7inhuRnrQBWmtIzyowB6V88ftNADxfpWDn/iXr/6G9fSXUYX6V85/tSRCHxjpIBznTlP/AI+9AHjFFFFABRRRQAUUUUAbek+Fdd1izN3pek3l3bBzH5kMZYbvT9ast4F8VJnd4f1MY/6d2/wr6H/ZnjDfDWVvMAP9oSfKWx/CvNeswWMt3KY4pFyfVuKAPhseDPEpbaNC1Ld6fZ2/wrc0z4TeMNQUFdKaAH/n4YR/zr7gg8KQRKjXmoAeuCAB+OawPFfiHwN4bYx6h4jhjugOI/M8w/iFBoA+aNO+AesyoG1HUrW09QqGTH6iultPgPosMSm81S+uH7mIKi/qDXrkevWWo2EVzpzyTwS52sqEA/nV21kkSeGUR4A5w44oA8vX4CaJJGrQQarIhH3gQf6Vnz/Arw5yBe6pFIONpKdf++a99i8S3Kvh4wRjAETbBVbVdXbUII4vsqptyS5O5j+NAHz3J8A7Eg+Vq9yvpuQGse4+A08bnbr8ITOBm2bP86+gwG2ltpq5pmjXGqH9y8SIp+bcefwFAHzlD8CSCrT6+rL3WO1IP5k10unfBjw/alWlF5dnuJnCg/kK9g1Cz+yyMsT+Yq9Sw21jtczyKxiVdgONxoA42H4WeGVyx0WInPRpXwP1rqtK0Kz0yPy7G3htY8YxCuD+J61DoXiDT767ubUX8Uk8GQyDqDWw1xGkoUsBuHBoAqyaXExYkRnP96MHNJBpkEW7heeyqF/lVszgkZPBoZ+MqM49O1AFU6f2WeVR6A4qWC0jhHA3MepbmnfaFIAH3ielSlSxGeKAIJJIkYrIFBPSiELcyCGFA0jHCjHWoLyRbZwZYHlU/wASjNY9zqE8Wo288FvLEsTBhxjNAHq+leCLWCMT6zKJV258rGFX6+tZPiHwv9gzdabH5lm3OFH3P/rV0On+IrHxBp0SJciO7AGVk4BPerC3N1pvDx+bb9yOQaAPMC7F8Ywvc0gkBzswz5xiu91HRNN1stLpjpFddTE3ANcJrmlXVhd5vI5bcLwCmcN+NAAMnqPrVaKT/SpldyUCkqD25FNhMZYlZXYdTk03yZFkaSNoiDnhjk4znpiuPFyqQdOUE2k9Uu1n5rrY4MdOpTlSnTi5JS1Ud7cr811sWGkUL94DPFMd2XlBmmrgKN+wufvEDjrUckoMm1CPcmutO6ud0XdJ7DnaVzhQF460uwqoZnJIFP3Ajg9Ku2Fkbh1eQfuz0HdqZlXrwoQ55v8A4PkvMz9rS4ADDnGfWnro725LJEM92Bya6+2gtPs7PO8gC8AJgD9alFzpF8YYIVNqw4MgGS31p6HG62NlaUaaS7N6v/IyrditpGW7JzXPTRPGzCIBo89hzXYanpsllMIJZEfzV3Ky+nasNZ0tsALlge4oZhlCl+95lZ823qUWsZJpY2SV1VhjYFrTstNhtSHxul9W5ra0zxUlvD5ctjEwxgsowaqJdaXnMk10oz0CA0KxtmdPE1YKnh9nvrY7TwhawS6THNJDG0qu2GK81m+O/EGo6WmyyhaNB/y1xnP0rCsPED2kyRWl24iViyoy4DD3rfTxgrgi4tYJBnjbIB/PNFrmOFxlPDU4060XFpdnr9x5lL448RNN8t5cKuegT/61alr4x8R+ciwySztnlXWu6Hiiz3bjp0WfXeuf5VZPi/REIOyQN7RClY9GhiqWIv7N3t5P9SXwvqWtX0n/ABNbFLePHBGRXSsodcMAQexrlLnxzpscJaFJnfsCuBWPN8QpiGWCxUPjgl+lB0HV6r4esNQTDxCJh0ZOK811u2XTrx7dZRKq/wASilv/ABbq+ow+TK6RRE5byxgn2qguZM7jnPc0ARxzKXI54707zELEbuaAgHTg+1NCjHTmgCXzFIIHNOVsAY6UxFAI9xTwmcjJNAEqnNPUHBNVmSUfcfin2+R99yT70AWkPr1r53/aoOfGWkcY/wCJav8A6G9fRCYGMcmvnj9qn/kctH4x/wAS1f8A0Y9AHilFFFABRRRQAUUUUAXLTU76zi8u1u54Y87tqOQM+tXYfEGt7wsGq3u7tiZh/WqOn3hsnkdER2ZSvzqCB71HFKwuBICqyE5zjgUAadxrWtak3l3uqXkip/z0mYhf1r1L4G/D+DXbmTW9bjea0hYCFJRxIfU+orziDS7S4vLaP7X50tw4DIg7k19j+HtNh0XQrPT7dQiQxgAetAF9RDDGkMESJHGBgKMACmyyM4DZGM0iyAvjHWoh8xdDjg8UAPUbWGO1OU8nPApg+4cdjims/Kj1oAkLduxpoLK/mQyNFIpyGU4poGNw9KHYCOQ56DJoAxtan1fVVaKa7WI5wJFTkj3p0UZtbYQLgsq8k9z3NOuI5ZHjdJSihwcAdRT7o7p5FDDcVOD+FAHD+HfC1vDreoeIGO0SuY9qEc5711TJ5+xlUqE4DMetcl8P59RN1qdpq9vNFGspEZdCAw9RXcgZj2sPk/h9qAK8Uz7mBICDjFTW0oDsqD5WOScVGtrsYfNuUtnHvSyq8SOEb5hyDQBOUVJRJ0FTK+4M3b1rAtrxbe6MFzPKZ7jkKRwmK0Y4pk/5acenrQBfJwoHrQ3P3hxjvWXqGpjTzArRvI8zbFCjgGrkV1vwJR5bdcE9aAGm3WOQvCNpPXHetDT9cvbRsWtw2F/gfkflVbaQc56+lUL6CU/vrd8Sr2/vUAdbb6/bTkLqFt5T9p7b5Tn1xW5Bf3LwqIXg1W1PBR/9YB7ivM9PvRdK24BZFOCKuwzyW0geGRkkByGU4oA7S60vwzqTFriCSxfpjBQVBJ8P45o2ay1MuMfIuARVK08USSIsGrW8d5EerEYYD2NdJpEtpJbvJoc4E4/5d5G/SgDjLvwHr9tG8iNa3GOiISCfzqvovw61e9v/ADtVcW0AOSM5Negi/wBQedIp0nt3booAIH41zNv8S4NQ1LUNIto3+0WcnlPIePNAJBZR6Agg1ShKScktFuK6TsbqeFdItdJuAq+dKiHLk9DWRo1g0+lTfZUJlDBAeuARmul0CZLmCaCQqWlU9+tZOhaiNCuZ7O7hb5pBufOAo9cUkefjKqpVqUp/Brf1tp+pm3/h64i05JZiyKpwVXqaZYaFcuqPBbFU/vyMBXTX/iq2XMaxb1PGTyDXN63fanOx8lz5B6CM4ApHop3V0WvEO6zuLQmTzGjhznr3rzDXvE9vpsgiCG9v5QxWCJ1BTHdyfujnPTnFdzqcjDR7Hey/aGZkfJzheteG3Vwpv9TeBobhpL2T95Hja4GAoB74HH1zXoYDDRrzbnsjzYKVGVSaa993XpY0E1jWnw1xrE4kIX5beNI0U45GMHP1qZtW1PjOtahz/wBc/wD4msaVZ1K/cA74qZRiQZ59zXtuhT/lX3L/ACF7SXcuvq2q7wP7WvyOmcp/8TUb6tqrDnVL8/Qp/wDE1A5O4jApy8ZHFL2NP+Vfcv8AIftJdy/pfivUbEypfxyapAw/dncsUkZz3ODuFdRpuu2mpW8kkAlieEhZIpQNyEjI6E5HvXC4J78V03gqLzpNWJ2bQ0MYAOScKxyR2HzY/A1w4/DUlTdSMbNdvVLbb7kjehUk5crZvy3sfkDHJPA4qxBE7/OMKAO9QJbQxtgnJzkCrJcsSvTpXhnWRgFu3RqtLgNkelMCbeB3608YHXpjrQA7uOMU4Dk9/So8EIB3NPPykZIFADgnYU8d6ap5zn8afkHvQA5R3odWOSmM+4pR8oPSnj1oAbAH/ik59MV89ftUAjxlpGWLf8S5f/Q3r6MjHTNfO37Vf/I56P8A9g1f/Q3oA8TooooAKKKKACiiigDc8P8AhTW/EPOj6dPcpkqXVflB9M9K37n4UeMLeFpJNLbCjJAYE/kK93/ZmTPwqlIA3HUpBnvjYlemNHmXPJxQB8jfDrR7r/hPdKgv7Vrd0kAZWXBwK+tJG3O3tgCsvU9ItJtRt9QaBftEDZVwMEVcuZRypyGYdRQBGXUSAB1yO2afFy4fOc1nrZorA/ePPJp9sWiLSEnaD06igC6rPjKLkk9KbeSLbRh3IU9SKsJLvUGNspjr6VnX1tHcq6XGSD0INADl1S28svvG0gcio7m6je3Lo2VAySPSqsemW8cHBJReMGgnyYz/ABAnAFAFeyu2lLSFMRNnBLelPhkDSGQsxVT1IoUFmOWTZjO0L0pqupjwEGM4IHagC3NMbu6ViQQibRin5zjnAqCOB2kjaBM8fNk1r29ntILgH2oAo8tJk8ACnrFuQ5HUdqnvU2z4AAGKrmXAIBwKAMfUNFWTULe6gu5YTHndGACHz61rZCkdciq7uVYHJ21IrFkJ6bulADLiMO6HHzA5BqK5jEzKH5YVLcnCZHUVBDceY+WQ5HegBRN5NwsapI57nsKuK67Sc4PvVRzKXLKyoMfWkljMir5jnj04oAxdQulstQMkJVgeq5rQ03VYbxdpIWT+6e9PbTbMj5oFZj3NYWpapYabqhstNsRdXEYzO7MY1iPBC5wckjmtaVGdaXLTV2KUlFXZ1jsI1kmkwkMa7nkbgKvqTVCPxNo0Dq66vbhycL5RZ2z16KCa4G8+0akWOq3U0isS32SOZhAnGMAdT+PrUpZiMAgDGAB2r1IZXFL95K78v83e/wBxzPE9kenL8Xru1jltrXRjqcafLFeSXAiV+B1UruwCcfhXJG+t/D1xFr+rrC0KxXspisi7JucoVi3kHBLFzlvWudAbbg8ntmp47uW2SSGUK9vOpSSGQ4WRe4xXdDDUaceSMdHvq7vpv8+iXyMHVlKW56l8O/HMCyTp4hjstInVFnt2ln+SSF+VAY8bgMZHXnpXX332bxVYHUNBnhuHjYoxicMr47ZFeX6bqFpqe2S3EUF0AA0RAAAHYD0qoml3Nrd3d3Y3+qae0rF5Rp1wV8w44yOnbtXFVwFOcm4+7+X+f5mvtbx5ZLmR2s15LYZiu4JocjlWj3D8KWFmkQi0jmnXGSIlJxXnlpqt5Izfb/EvieMjoDdZP8qTUPFeuxad/Z+n67fPaLcecLjJF4y7QPLL5xtzz0qP7Lf86+5/5HD9WpW5U5KPbm09Da8Va5DZp5d9cLZKdxRmGGGBgkZHOM+leSWKtGkZ3btpb5+f3nJ+cZ55611Gv6ZNNYW2oahcXdxqc/DSXUpdgnYegFZ8cQ8sKQM4r0MJh44aLSle/wCl/wDP/gGzUElGEeVdhsUytEORk9c08FWHXODULW0UbSDd8yYDqP4SRkfpUtrtKYXkd66XYRIWBJOB1pMktuRSR39qbOzRwSyRxGR1XKoM8n8K0/DmlaRrN9epPffbZ4IoyhtfMhWLOdzLk/MQcDJ/Ks6lSNODqSvZdlft/n1fpcqMXJ2Rn7TjNdJ4MkCXGprkeYY4WVe5AL5P4ZH51l6po99pUcDSOdQtizK8kUTtMnUqzDJBGOCeO1X/AASnnX13fxBxaiAW0btEVEpLZJUnqBtH51y4uUauGlOLuu/zRrSThUSZ1ZXc6nFTrgt0xTR6e3WpFB/u54r507hdvyEk+9RmQ7wFXKjvVC6vnyyIhGDg1PDLLtGISe2aALrYGGxQVBIJNQMzhcybE9yc1Cb2JW5lOfyFAGmBxThgYrNF+uflyT781ILqTghcfhQBoggYyc0ofHRDiqHnvjqQe/GacJ3GCJvw20AaUbZIypFfO37VRz4z0j/sGr/6G9e/w3eXVSwLehGK+fv2pm3eMtIPH/IOX/0N6APFqKKKACiiigAooooA+tv2ZP8Akk8vp/aUvP8AwBK9OyACQa81/Zi/5JHN/wBhOX/0BK9EuGOAPWgCO4IKZJGCazwPNkdicgDAFXJGAjOe1UIpFG5xypGRQBA8zGbYoIHTpUsbBQydKoyM6zBgckmknuMSpyNx6igC6szWsnAyhOcVNdMshV16VVQ5jQnnNPbJDdhQAb9p24yKr3yK6Ru25VU5+U4qZxgAZ5NPMeYirc4GaAM+IO4IhwxPUn0qaGz+UPuAAPNTWbpG7KAABS3M4t7Vi/duMUAW7F0hypq19rjRD83I61hLKZJHcjap5FMklbOI0Zz9OKAL11exHLGQDPc1USeMZJlTA4zmq0mmpNGTdSHOc7RVR7OIgoseEAxQBq4BUkt9OaBK2OBkYqpaW/kRAMxb0B7VZHtQAMSx+Yk+1K34AU3JxS0ALgbWLZ2qCxwOwGa4r/hJNUulSaIWNnbsu6NDEZXYZOC2TwSMHj1q542vpJHi0aESRxyx/aLqYDHyAgKinPc8HFc5K5t7YvFFvEYCqnJwBwPevYwmGhCi61VXvrteyX6v0/Mx9+tVjRpbtpb21fmbbeJNZcKoh0q2zjdKm92A74U8ZrLjhAMrIZHaV98ksr7ncgYySetZo1O6fKxWaBzwCFYkfgaLmz1KcmW+Rooo0OXCjA/AURx1KN1habfoml82z2v9W60Gvr9eFNf4lKT/AMMY766aO5LLq9uhZYYWkbGAxOBn6VGLu/nwtvabcnIIQ4/M0aSupTQFNOPkwhstJ93cfc9T9Kll0++uJj9tvOVGAdxauCOIxmIV4uTT/lSiv/And/O2p9BPA5Pl03Coqaa/nlKcvK9OKSXdq+gG11eZirSpGcdPMAyPoKim0OeK3aR508xSMKeB/wB9GlOjMPu3fz/7p/xqB9Pu2OyeXKj0JanLC1JpqpRlJvZud/8AhvuYUs1oUWnhsZShBbqNFxb8ktb316rcluZJo1VZJVEgHzOp6n61f024vFVXtdReNj1UMcGq8Wn70jjlYbAMAHrWisKwKVSIBVHYZzX0adoJPc/OqjUqknHZt20t17dPTpsaEXiK5ikSPVbCC4TOBL0IqvqfiN4pQulWNuuf4lUE1mPLHOssEcV1dELuYW0RmCZzjdt6Hg8V3uj/AA3gOi20p1aS21K7iDwK8Y2qSucFTySM15maZvgsphGpjJcvM7LRvzb0vZJasqlSqVW1A4i5kuLyMyTyTtcEZK7GkIHuFB2/jioVjn8mN3stRRGbYJGtW2/Xj5scdcV6JBo1v4Xj+wQ2628pUeZLnLTkfxFjyecnHbNWEdi+yRmYsPlGcE1jHOadRKdD3oPZ33Xlv+bNlhv5tzzOQRjzHkWRDIV3O8EiAnoCWKge3NR+TLFDLJbxibapYKvO4jtkV02r6r4ltxJbXnhVJLeXKpE8LXAcZ/iKtj0OSBV4eF9HvLO3nvtIitbxox50FrMyIjemFOD9a73i1RipVlo+zjL8mjJ0eZ2h+N1+hy+h28usXCRwatpdtIY9/lpDJI5PXBD4HHOcE12mi6Pb6QmUZ7i9eIRzXUjElwDnABJ2j2HpUlhpWmWBSSy020t5Y12rIsQDgYx97r0q4CW+YkCvMxmOdd8tO6h20/Nbr1Z0UqPItdWSR7l+ZWwTQxZvvnhentRuyB3x0proPm85vwrzzYYZOWWNSz9vSiKKViWmk2gjoKgnv4rZcRgGs6fU5WlLb1aIDGwCgDUaa0tuOGkPPrUFxfTFQI1255wKyWuI8KUXBz0PNR+bM8m8EgfoKAL4eVsmRlHruNT24jl27nQk9OOlZnlGWbGeo606JJYpCq547gUAawljjbaxY49BU0epRFgoVhj1HWs5XnKqChZvZc1NHaXEwYiCUH/doA0lv4icFSPwqYTRNklvl9hVEadcbUJt5twGDlTTxZT4wInGevymgDQikibkMue2a+e/2nhjxjpXIP8AxL15H++9e7JbSouNjD8K8E/aV/5GzSsjB/s9f/Q2oA8hooooAKKKKACiiigD63/Zk/5JJMSf+YlLx/wBK9LkAODnmvM/2Zj/AMWinx1Gpy/+gJXo8kmYuOtAFO9k8mIlhkdKzYlEQIz8nYGrN2WuH27T+FUo5d83lHgqe9AEZ3tKVwdpPXFQpZP9s3E7kJ59q0vMLfLgAZ602Ml52RCTnrQA+OHy7hSzKItvA96Wd40ZtmCe9QzWEk8iiaUhQOAKc+mQsF+d8+uaAGNLyDs6io5J2XDEFR3p0ljLESY5WcY6ZrNvYp5l2JIVx1z3oA0rRI55GmRgUbg49ak1KDfp0i55HIJrno/7RsmxCY9noT1pZpr+bY0iMyg4wtAD9BkEzyPcuzhei9q1p7rcAsabVFMTTrmCGOWe3aBHGVyOtamk+H5dTt55oriOFYePnHUmgDGy564z70i8EZPzd810S+DtVmMapPaKD95w+SPoK1Lvw1ZQeG5p4C0k9ucvK/8AF9KAOLZuAMjNPH3R+tdR4X0+wvNLv7i5tlnaNlAB4Kg9cVXXw9onnM8bamoJyFEowP0oAwUSSWFpYlZoVbYzgcA+lVr+S4t7czR25kiXALjov1r1ZLOyt/CN2lvAI4CuTnlmPqfeo9Ms9Pl8HC3uAFScFd2MnPrQB4D4ldrrWdNzJ+8FrK84QEAISNmT3+aqiW/JwST9a6fX/Cl1Z+K721tLhbmC2s4k3Odpy7lh9eENZOsaXdWWkzTIollPyGIc4B6mvoqM1Sw8W+i9fP8AU5I0XXrqmtOZpa6Lt1MS/vL0SiLT7lCqAFvLYZB9z3qnc2eoXZkuLuVVY9QW7fQcVLawJbRjbCwmZRu3t09quwW93qdytjYBQwCvcTnaywqT3B6txwK5vqSrR9ripPXVrmfKvyf/AAT3v7ceXz9hlkY2jopuEed99btWbX3W9SO3umCQWMazySlSUht0BYhRknGRitXT9E1K+i86a5h0tTwkDw+e+MdWIIAOe1aGk6XBpMQSLDXL58y6IHmSk9iew4HA9K2LSykeQPIxCj+Ed6itmXL7uHVkurV/uT0t6q/oeKqLm3Oq7t6mVbeEndS11rcrHjaLe2SMD1zu3Zplx4SXzUEWrX5J65SPj/x2usQELtxt/rUm0biOp6VyPH4hu/N+C/yLVGC6HOJ4NgVCRrGofIP7kXX/AL5pkfgi0kuIZ728vLyGNt/kTBAjnHfaBxzWne61Yw3o0wX1r9vfkwb/AJquR3YSIRl8k9fal9exH834L/IfsodirHa2WmROmm2kNrE4+ZYl25+uOvWtvxBKt1oWlzWhZxAArOAflOMdazJLmJ0EYTkdTTRqM8dlJZKR9mdtxAH9a8XH4WeIrUa8XeUJXd3umrPvrbY1g1FNGpb3Gl6rZwjVpZYr+H5fMOSX+lN0zOj6xaXGoRsEJ3J5gGWX+hrBikltr2GeLBZGDjcMit7UYbLXLNr28v5Yb5Q2xEPyr7Ad685wnlNdOnzSoSeq1lyt3sopLRX1bd10SLv7Ra7na6rKl3O0VyV+xXQDQTpxtOMcke9cLrmlXWjz+UdrKx3Kw6MK0PCN8i6a2mavMWhzmKU9Yz6U7xZeW93qMaW0u9Io1QP2JAr6G1jI5Br6P7U6ySeUynoRUsV75oIVQc8UXmlJcziRySe+O9cl8R/F8/gSG2NrpUVz5w/10p+VT6YoA665uJLZF3nGenvWXcXk7sc5XI615Bo/xs1KGeb+2tPt76BzlEX92U+hrSb422LKR/wjf/kz/wDWoA7+OOR5MTHKdjnFOSF95SJHfn+EZrzK5+NJHNloNujdvNcuPy4rnda+LPifUlKQ3MenxHgpaLsz9e9AHul7Fa6civq2o2tgCMqJnCk/QVzmo/EHwhp/mJHqVzeOvVYosKT9TXzrdXdxdyF7qeSZyc5diagoA9uuvjZawJ/xKtBBcfxXUu4fkMVj3fxv8Qy5+zWmn2uf+ecZP8ya8pooA724+LXjKYt/xNmQHskajH6Vj3njnxLeE+frF4c+khFc1RQBrf8ACSa1/wBBW9/7/N/jVqDxj4hgGI9XvB/21Jrn6KAOuh+I3iyIjZrV1x6tmsnxJ4j1TxLdRXOtXTXM0UflIzAZC5Jx+prHooAKKKKACiiigAooooA+uP2Yjj4Sz/8AYSl/9ASvQbuREcjBBI4Arzn9meYR/CebJ/5iMv8A6AlegMRNIxbjHQetAESSkK4Uc4zk1jrEWeWUH5s4NadzJHbwZb5QTms8SMZCEChT6d6AB2WFchsliAB3qeB1hYsx59aabaURgFFz2z2qM2ryLtbPqTQBqRzwyY+cZI7mnkqF+8ME8c1zs9tk5BORVURzEqhLbOucmgDp5nVE+dgPxqhOBcPujX92OrVmJDJPEySElWOAzHpXpVlolva+Aphwz7S+fQ0AZumaBpk3hyO7vhKXd+AjYJwadapp1g5+x2Z3E8NO28ip7CTf4PhAJzE5GR7mqcbF1AkX5x3JoAs+KLpn8NxLKSz+d8p9Bis3wtOzW13b5bDYIAq/r8e/wwhAyyzjOOwxWX4PY/2k4zwY2/lQBsQ/MrNJKwkXhcdqm1u5kt/CcojcESyiNjjqMVBEGkMigqB9BS61C/8AwiRwCQk4Y+wwaAM3wOzHUZoQ7CNoWJ9CQK04FIcgMGB61j+Cn8vVnLZIMLgfiK2bFpIPPSQA7jwxHSgC5fXD2vhK4CHJkfYfbiq2lkv4fsyDu2kgjPTmpryIzeFbsFlzE3mAD0xVbwu6/wBg3IIP316UAefalJdf8JJr8l1cCSQ3CQjYu1VjSNWQfX94cmmSnzNJuCRkgE5qTX9yeJtbhYEu06TjB42vEoH45jb9KLW3eSzuV2tgxnPFfSU/gi/JfkjgqaSdzi7qNGhOec9x2q34MikDa2kQLr58I9P+WZqjfuUBjC5YHmtr4d7Wn12J2QP5sD7M842EZx6Uscn9Wn6L/wBKiKi/3kbf1ozZitQtzGs20Kpzit0gFBjFRbIymWQH3qmuooiqJUcDnDY4r5w9AvNkqKrOGlSZd7IxUhWHb3qpLqTGQ7FOwdBjrSSzTuR5YOO49KAPNLfwJ/whoufFGoXMmuX8JLxxKCBn1Y55rvdKvpNT0u0vpLY2rXC7zGTnFWL61mn017MqTHcqUdx1XPemQWaafZW1pHIXSAYDYxmgDT0mzkv7lLe3ZfMbJ+Y4GBSXVvJaSyQToVZWwff3HtWt4dtUttPOs3VwYghxGsZ5J7g/WjxhJbXhtb63nBMqAGPIyoHr+deDDNpzzL6tBXpaxvZ6TWrV/T8V9+vs7Qu9/wBDnncDKM2cfdqzArGFyFZyBk7QTgepq34dsLe8vHnvg/2WBdzMBxn0Nbeu6hDpFoItKto2e85Bj5wMdxV4rOfZYtYGhTc6j+UV1d33UdbWCNO8eZvQ5mMsJAoViXPYVbhIJK7fmUnOe1dV4fs/7CtIbvV4Ekv52HlQjkop7/yrP8YRpb67M0UYjWSNWI6YJ617Zkczf3UsMkbJnaTgkUmoWum6vCsWp2UV2vpKu4Csy8u/Lu2Vcyc5A7Cr9vMlxAFZNrOMMy8YoA8N8Z/DW/vfGU0OhwCLTSAVkkO1E9RWjY/CHS7ZQ2p6pNcMf4LdAmD9TmvWZoXVynmMygADJzVWexPmBt3OegHWgDgh8LfCRIHmaoM/9NF4/Sq958HtDmDGy1W6tsd5kD/yxXfS2dwiqqKWLdx2pogkjfa6lgByBQB5PqHwW1AJu0nVbO7HpKDEf61yWpfDrxTYSMsmkTyqP44RvU/lX0JbRvNcbRlBnjPHFaC3UqzGKPd8q9QetAHyZc6RqNq5W4sbmNh2aM1X+y3H/PCX/vg19epeTIwRySx6nA4qT7XOc7CpUdMqKAPj8WtwekEv/fBq9Z+HtYvcfZdNu5f92I19bC6kUAkrnHZRSG4Z+BOeecYoA+XYvAHiuTGzQr0/8AxWla/CrxbORu04QZ7yuBX0qS5UBHce5PWkV3wVwWx360AeC2/wQ8SOR59zpsSnr++LEfhiuY+I3g2TwVqlpZTXaXTz24nLIuAuSRj9K+qVVyisynn0FeDftKZ/4SzSsqV/4l69f996APIqKKKACiiigAooooA+tP2Zo1PwnlYjJ/tOT/0BK9LnRHGCuD6ivOf2Yoi/wllwCf8AiZy9P9xK9LmhMeSQ2ccUAZMluoO/buGf4uae8MfLKF347CppCfJx3qJxiL5T8x9O1AFd5SYzlDuHAqKFzty4+Y9qVg+8dl9akjQKS7jI6UAV5SmAcHk+lVJrhhAYgPvZxx0q8RlyBj1xSFF2n1680AYaw3KbczhiDnHoK7bTPEiL4fu9Nu1cuV2xt2PtWAyK+SUHA61AsKKW2Eg5oA67ws6SaLe2zSxq+9WVW9O9TBLIsV/tKyeX+4r8iuCuorheUYsDxwcViy6nb2kwUWpjnPG7rQB7CLRjo2oCXa0fllkYNkZrm/Btu8urOFPSJun0rlLPUbuzdop7txHMPuN0IrQtr26s5BLaS+XLz8yelAHfW+nPEc3MsFuZOV8xgCfwrSs7B3trzT7yQbJIicgcfUV5XPc3FwztLO8rk5yxq/Y6zqNnbSQQ3DtHIu0h+SPpQBp+E7UnV51DkLEj8+uK2YLe8uW3RWzMucgjoa5LTdWudNuRc2uzzeVO4ZBz1outSv724Ms13KCegQ7VUfQUAen2Fk40u5juII/tDqf3bHgisDwdarc6XeW8kiRTrLlsHoAT0rltH8QanpSyxpdGdJB0m5K+4NUZLifEnkyFJHzlgcZzQByvj3V7weOdXs9FIhDeSPPXIbain5s9gS5z9BXO3Q12+Kw3uoySw9dxlJX/ABq34ta60zxC1w7LcCe3BK4PyoCBgnt83NUE1q1cklJo/TkNn+Vb0VhqmmJqSUuzdlbpa2lvnc+ti8ypUKdXLMPTlDlXvRSlJS6t31Uk+lmvUls9PuLPeZpkljxhQpJwc1lWcOvwavJePrRhgAKIsDFW2k9OnTgflVq7niu7iOa2vTCVAXbICPxGM1PfpqNtK8gtlktQRyFBDD3xyK9Kji6VGm0k3GLtdPm0d/Nuy8zxsZlOLxmIjOpKMKtRNuMk6eqsrK6Scne+nmWIdX1YA7NVkOeo8qP/AAp8Ov6wk8ZlnW7iyQ0MyKikEeqrkc4rIbUTIojtbNUlPBPLEH2H+NL5uqRSeX5YDnn7i/zqXjcHLSFLmXdQ/Wydxf6tZhD+PUhTfaVRJ279dDqI/EFwhcS6G0p6BoLtQhH0YZqaHxdJbLI39gXWNuW/0qMnH0xXJ/bdRhDebbbgOS3l8AfUUJqsDSqRDIpPBO8ED9KzVfLr2nHlfnzr9RT4bzXl56KVSPeEoNfoz0ay8RaLehWg1W1BZBI0crGMpkDglgASM44qK7vtLVsLqlic85+0If61xN6yqSrRh8HuM81nzwxkbhGgB6jaOK6nlVJvSTX3P/I8BYp21R6LNqVpb6al1PeoliZPLEw3PGXx0G0Hmuh0rw7czyWdzdBX0+VfNJRipC4yM5xiuL8EeN7bRbNdJ1qxS50sNvjKIGZGznoevNVtZ8S6rqus3F+Jpbe1AMUSodmIs8Aj3HWvmK+X5tXxFTC0oqlBc37x6qSekbJWan1lrpZaW36ViKaipPV9v66Ho1/q1jHpsVnoWBBNkhw4Pndcgf3v/rVD4cu7W01mGTUB5MSN95hkGvHZZrW0to54xcstqD5Mcd067AT823ngcnNdDp+k+K2uLOS41mI2WVlaHzGcbDzt5HPHrXpUMho5bSap1N223L4pPzavd2t2RP1p1Ht93Q9g1DxNpVlqLGC+tdQ1iQ4UNIo8oHoAhOc4xXL6nfHUb5jPdxvdsMtFvG/Hrt64rmLfw7b/APCV3ut3D+ZueOW1iVivlOoA3N69OPrWvHptk2stq32Yi/8AKMQm3N90gjGOnQmlONGNrSb07fa7b7eZonJ7rr+A9oleTouR1wO1PWDHyryPUUmfJjnnETy+XGXEafefA6D3NcHeeJLu4uPMur260RiAI7NCUIXJwzbl5J9sDirw2DqYm/Jsv66ak1Kqp7noSQRM53Lz71DcadHI24O4Oexrg72/1GCxuJW1vVNyRllBdSCew+7XfWqOLe0aYt5hhjaRTwQ5QFs/jmnicHLDpSbTv69P+HFTqqd0in9nFq7BpJGz0bPSqZdvNIBdR6nvXQMqtn5eakSOPZgop+orkNTIhmtVTDksfYZqKR7YNmInB9q1mtLaQLmNc+3FRtp0OPlyv0oAxzhnJTaM92p5aPAA3MR2XgVovpETr98496cumqg+RVY0AUfJVgDuKg9R3qaOCE/wlQvr1NTtBJGOYQfcNQnHBjH40AKhiU5PQd2NX4BCI928YPYCqiqo5IVfwqRAN2Wc/lQBcMka/wAe0e/evnr9pxw/i/SiDkf2ev8A6G9e/wAMaTyBQv1Y14J+1JEIvGOkBec6cv8A6G9AHjFFFFABRRRQAUUUUAdFoPjTxFoFl9j0bV7uzti5k8uJyBuPBOPwFesfDv46alDPBYeKQLu3kO0XJ++v19a8Osi5cxQwrLJINgBGSM+nvUZidJ/KYESA4x6GgD7oGox3SLLZr5sRAIIPGPWrC84GMCsD4cWksHgzSkuAA5gUkn0xXRouDgMDg5GKAKEy5lJDHGelNlk2qVXgdea0zGCSABk96hvoQ0JaMZYcfWgDPIXfuY8n0pHYBtx5A4HvTm4dPMXg0CMMzfMxHtQBC65AK5GTzihVAIyRn1NWUjjQc549ahuraGZgCCO4INAELGMo+eo7VWsra0mkkLQqW9SKtLZoEwJGxnHJ5qFrJ0nzDNjHQEUAUdaEYmRZIiV6LisN7y6tpCVGEJ+VT0ArqdRYPblWXEq89K56aJrmBw3DoMigCe11JXBLxkuOqoM1djuRLtxG6HOcMK423u74+JrDTrWKVLX791KF6g9ADXbNBbxhJFBSYjChm+bFAD1ljxjfz71IhBJwQSRWHNqX2S5iS5tXkidsGbjbGc8A1rRbRIWI46gj0oAn2ZbJxwKcxzj2quJsMe6+3Wpw6HAVxyOlAHOeM7C4LW+p2ayTtChgmt4gS0iMRggDqVPOK5iRILmYxT28qzqM+XPE0cm31+nPrXpo4IYHnHaq9/YWWpGP+0rWC5MedhlUErnrj8hXo0Mco01Sqxul/Wz3/rsZKE4T9pSk4vyuvxR5u2n2pYHyCuOwY1Hc2M8lwZYLnaW7MSMV3h8N6GWJFlKmedsNxJGo+ig4FY8nhbVInItrrT7qEklTcq6Mgzwvyn5uO5rbmwVdcluXr/Lr6p/mdlHNMxw01UVRzsmve99Wdm9JX6pbGAz64vzC+MpHOzzM5/OoH1PUgd09sGXocxYB/KugudA1q2gaY29hcBcZitXfzSM87d3HHWs2OTzY9yeYoBKlZEKsrDGQQeh5FVTwUWr4etJfNP8AM6f7eUtMVhKU/wDt3lf3oof2zdjpaoB6Yb/Gq1zqN3dtH8gXyzuGFxz9TWzvOQDkcVC6lkd5GCxIMs7dB/j9BzWqwNWTSnWk12SS/FC/tzCU7yw+ChGXduUrX8noUwbkREnBBOfmNWLPSLrVFIiSZsdewH412FhpNjZ2m+S0v7i7Ck4bT7grn2GytLRrLxRrrGG20iG0tlhEnm6iGhyc/dARsjjnmu6dXlV3p66fmfOxpOxz1toOm6ZbgatcGSUnmOLnbVe8h0OZHj+0XNpEBkyOCyAdyRXUp4OhtWdtZuP7Xnk2jbaPJbxQYJyPlb5+o5PpWo/hvwVaWSPd+HJ7iWKXzd8czSOxxjDEnJX2ORXHPH0Yya5m/Rafjb8hOdOMlCUkm+lzx2/hjtLlbTzVuYHzsZEdA69D95R+ldHp/iLVLWzt4JUsLgQosYLB1Z1AxknJAP4dq2PiRNP4l1TTrqzMdklmjRpHOm/KsRkn3GOlcnqNq2jXEVpc3gvFaHzYbkps34PKHqMjg5zV06tDGRSl8XbW/XrZLb+tDaUZ0XdbGoPE2p5AaHTkLA8BHIHPTO4ZrPu9U1a7lmkTVr20kYjCW8hWNAMAhVJ74Pfqaz5i0sbkRsJEUlFPG49hVhWGFDddoJ9jjkfga2hh6UHeMV9yIlVm9Gy/Y6pqdrcxyxandT7choruRpI2BBHQEcjg1pz+Ir66tZbW4i0yWGdDG4aGTkH/AIHWCDkkLx70E7fu/hRPD05y5nFX9EEasoq1xsipbWNut3m6jt3jLqSR5qhwduc56YH4V6hdbhcSDOW3da8tu5VNtiY7ImdFkcKGKqWGSBnrivU7ohrmZj2Y8DpXm5r9h/4v/bTow2z+X6jI3YEoR+PpU5JxhcVDFjaS2B3Jp6Sb0yuPSvIOkl+XI9u1IxIYEcg8UwZBx7VIxH8XagBwOfpTx14qLeuTigSr0GSaAJ/60ySFH6jH0pPMZuEH4mpEB/iPNAEX2NCpG5qX7DGcAu5FWVOKco496AEgtYogNoOfU18+ftUjHjLR/wDsGr/6G9fREZ6HJr53/aqIPjPR8f8AQNX/ANDegDxSiiigAooooAKKKKAJYWlhImiLoQeHHGD9a0PDkJvfEVhFyWknUHvnJqiLqYWptg37ktu24710nwuh87x1pCf9N1P60AfZaQLbW8NsuQI0CD8Ka+5ASvGOmKuXakysVHQ1XOMkk9eKAHtIDGd2A2MmnW7pKvBGD2qkUIVh2PT1pseUwQwBWgCW9gEa5EWR6+lVzKRGQq4yO1X4ZfMOG+9jp61BNanlo849KAM+SXKjgn1qSNf3Ssx5HODTxG/ccdxTCQWwT+VACHkZAziggFgcc9c05eevGKecHrQAw4YkEDgVFPaRO4ZoxyMcVOFG7j86cQSoHcGgDKl0lI/3lsxVgOOayzbMl0skoZpAcbvSurQds4OajmtxMpwdrEdaAOQvfDlje6lFqF7JP+75KGQhOO5FUL/xt4dYSpZ6jE9xG5jKhTxg81u6oZLWHZckujfKWA4NV7PRNKsrUHTtNs43ly7uYwWJIz1oAsafdR3WnJfWhNwjx5GFxmsAa5bafqSW+tO0H2nmP5fuj61saAs6lSWURdNqjAHtSatoumahqdteXY3z2+VUH7oz7UAXlu0WZYtr+URlZc5BFT3HFq0kci8UoSNrZok4HQD0qnfpHDaiLfygyVHegDOTxE6rhokYg460621u5u5xHFAuD6dqz7S0N5PiNfkzk57V1VlZxWyARoFbuR3oAdbh05kkJb09K5bxPpd1Fqs99Z2c13bXQEk3kgFoXUY4XOW3DnA5yK7a1tZruUR2sbSv1woziut0rQbLTWE2rSiS4GMQKfuntmt8PXlQnzR1InBTVmeF2lpcTuDJpGvCP+8unMf611/hnRrO71r7VdaTcLp9hbYt49Rt/LMt0x5bYeoVRwT0Jr1C5vNZu28qG2MFuG+Qxchh7mpfEmkPJZxXmdjRL86r/Ou6pmjlBxhGzfW/5aIwjhrO7d16FrwzdzXk0zy4MjjljwV/CsW6sdRXUJLBLppTL88rYIAGeprX8JNG4LJIHbac8c1f8Ous0NzcS4MpmaMse4B4FeUtB4nCxxCXM2rdnY5CS1gt4mhEEszH/luDtC/Qf41WfUrWNUh1eMIo+WN4uGA9/WvTfKiY4CRkY6YrlNV0OyuZZJLmOSBgflIG5RTuTHAYeEXFQVmcP4l0y2lgjuLSSOdTkhhwwX0IrzPxnYuz6VIbF7i2gaRn2wedg4G0Feu045r3J9GWXw7cw2qLORJnzF4YL3xXD3NvLartky8R4D/0NbUKzo1FUSva/wCKsY01TpSeEbt1jvt2u99enY8psbeOKyhjtXM6ECTf6lhnt0Ht2qV42SXDqQOvIrq/+Ec0dpC4sIAxOcY4/KuV1p7TTtY1C3Uw2sfmK0cYOAFKLyPbINe/hsZHFTcYp33/AK1/QqpQdON2KRhMg9TSY5z27VFFcW0xCxXCyPgkRxAyO2BnhVBrXsfDur3lq1wGt7EAjybW6TLSL3Z2B+TPpzXRUnGl/EfL6/1/XUyjFy+FXKEMK3U9vZs21LmeOJmABIBcZxnvXpBkDSytgAMTxXKab4dure/t7vUL+3AgmEwtraIkHbyo3tzjPXita5uZZdywJ1PevCzGtCpOKg72/W3+XodtCLjHVGi63D4wgwelTwpMgG4riq+jPNt8q56Y+U+laXyhVDH7xIrzjcjy27hcj1FK3zAbgQucVG07xtxCWX61YinEwyOPYjpQA3aAcYyKkUbccYpoZlPK8+tGXByTuFAD1OM4GfelGSRk/gKaDntUqjvQAq8e9SKACSOppq1HPI+0pEuWPegC1G2TyQD6Zr54/aoGPGWj4H/MNX/0N6+grGLyxl1+Y9e9fP37VWD4z0fH/QNX/wBGPQB4pRRRQAUUUUAFFFFAGrBNDLoj2ghH2lZDKJcZJGPu1u/C64CePdIkkJLeco9Mc1yMEzwSB4zhhWr4TvGs/E2n3R/hnVj270AfdU6/vWyeCc4qqyfJuPQHipxILi2huEbKSoGBHoaY/wAwC/w0AV2wMHP/ANeomAOTUk45QDjFN2LINpBwec0AJIOFOMNjqO1SwXBX5ZMEU0LjHUj3pjBUweeTzQBPNIHI2Ec9arzKNw245pcqMknrSnjgDp0oAiOc4xgUpADdM+1OG3kkU4Lg8CgCEjngH6U/BwcjFShcAeppAhyTjmgBoUDr0NO2gjg4OKULz0zRg5x0HrQBBcW8dxbskihgfWsS+gliQRwxDjgDPSujUHvRKiu4LAZFAHN2UZhkW3bbjqT05+lRSxpH+7wQ7EkAjg1v6lZRO6zrEplTvjkCsG+1P928drtaYHGD6UAS2n7hHYsXY8dOBWbG11d6jcQzLEQPlTC859c+lDwT3kSwQSvE7kZWNvm57V6LovhKDTrSKXVZiHVc+UDlz9TQByVhZC2URxpvcnnAzk10un+G5WCzai/2aFuidXb6Cuh03dLIYtKtIrcdN+Mtj1zUmpX1joPzE/bNSI6Mc7T/AEoAlsLGdbXybKJdPt+8jffaoDf+HdGdnkna6mY/MQN5BFcfqur6hq7A3U7Kg6RxnC/lWaEjTqyg/WgDrb74kbfMjsLDvhHdsD8qyU+IetxSKbqyt7iHPzqgwcViNDEy/eU854o8rYvynkmgD0LRPF+hzQ72iNnNIDuXbwPxrJ0zWDavdQ2knmQsxIDdevDVyMygx9MUiB43WSNiGUdQaZy4nDuraUHacdn+j8md3H4mljs598eZemQOlS2/iO1WA/agVLLk81yttqiqv7wFXxg4GQasNoS61bTXELECEZwhyG/CixFHFSclTqwcZemnyf8AmdBbeJdPiZWivUTn7pqa4h0LV3aS2vkguG+8P4WP0rzybwtFcyI0d4yEHBXFadn4eeK4ERmbb2J6mkb1sPTrx5aiujpE8HTyTTsEtiqn5XIzvH9KyrrwjcC5O6wbPfYAwNX7WWfTMxQ30mRyVBJ4q5L4turZGbeJcAAApj8zTucay1Q/hVJRfr+Gpzx8JXH8NnOnPVAAaY3g2csT5F7k+hqTUfiPqMQKoEUt0+QcViyePdclc7LravbHFGnYr6nV/wCf8vw/yNY+EJ0U5t7s57nmq9z4Q1qwhaU2gmHZY23N+VO0n4h6zkRzGJwDjLDJNeoeHNXbVLbdLC0bgdccGkdFCjOlfmm5X72PFnW6t51iurWW3fPIZea0Y4ZHhyF47V7XPawXCFZ4kkB67hmuE8Y6bDpKfabcgI3HlDr+FB0HGiMg4IOfSjaBwMc1H9uaVifKcY9RSq7OwwMD360APY4HPU0i5UYPNIUfA5FKImPHmjPsKAJVwR8pyfSpEQ56j8TVOSzMjZeVx/u8UsWnpG+7c7fU0AW2zu2qPxNPjAXqMmmIgDDirCoCuD37igCSPjtXzr+1S27xnpHX/kGr1/33r6Mt8l8HqK+df2rP+Rz0f/sGr/6G9AHiVFFFABRRRQAUUUUAPi2GRfNLBM8letT2kcktyBbclCWXPHAqrU5MaxRmFpBNzvyePwoA+yfg94ii8R+B7bDbrq0UQzLnkEf0rr2GAQeor47+GvjiXwVrsN7ab2tZQEu4GPDj1FfX2j6np/iHSYtT0q4We2lXOV6qfQj1oAYSWdlYdeRQBtJI6npVnylZvMwRggCkkTJbHT19KAK4UhcHrRjPUVKy4GDQgBzkZoAr7QTyO1OZTx69qlcEsOBg0u07VI4oAh2kZ3dfSgLnnHIq1DaTXG/yEMhHLEdAKicrH/reP5UARkYPvSgnFRyXNupADMT7DrTluUYcqw+vegB4Ulck0uOfaoGnbB2jANM8yUcA8e9AFmSSNB8x/AU0SI5B6D0qsE3EE5OaHjG4cEUAT3M6hXVSMsMZrAbS7Mb8ht7clua2ViA6jJoeIZLMccUAWvhxplla61JJdyKW2jyd/rXf6ppMlxdrJFtKOfmz2rzBnhUfK+COeKuWfiPU7EFbSV3jPJWTmgDtfEd9Fodj9msgFuJR1Hb3rzuWHznMkzuztyTnrTrrU7i+uWnvlfzD6VClxCrYLuv1GaAJIoliYmPgng5NZUru80wZ4gFP8SDn9K2i6M/Mik59ao/YGeO5Mi4dn3RnP1/+tXmZlHEy5Fh2+t7NrppqvwPGzeGLnyLCt/avZtbLTVee3mLbokkCSCNVJ4OB1qRY8nIz+NSQCTyIxOm114PI59+KUDnrXdQbdOPM7uy3Vn93Q9PDuTowc227K91Z3trddCrMj7Dghs9qhLSRgBkHuaukccdM5oYBhgjj3rU2M92RyFVip7VqeF9R+wtuE4S8LkbSeGX6VSktPmyp+XPSoktmjuVfAYqMjPWhGOIoutDkUnHzR2ur6dJNLBeWcRiEy7zH796v6bpU94YyyspX+M9qz/D/AIiaCJldFkjzzE5wVPqDWzF4qlEu9bSP7KMAhTkj8adjijmVOEVGtdSWj0/HTSxs2+hwwQuE2+a45cqCfwrndU8Gyzb2+1IIup3cYqa68W3Bjk8qCOEfwuxziuT1PxVPd5DtNOPT7i/lRYazKNXTDRc39y+bY6++Hwni8xdStVTru39qoReD9NgObjUHmPZLdev1JpkWpyuufLjHboae91K/G9se3FGhV8bPS0Y+e/3bfibunJoumENa6TGzcbmnk3/l6V1E3jDRrS2UwP5hAx5ca9K8zcfNwNxPekCKRSOihSq07upPmv5Jfkdfqnji5ud0enxCBP77ctXPXF3PdktdSvKe249KqIoGeOalUEcY60HQBjAPHT3pu3kdKkwdx56U4KOvWgCLbzjilVMHjmpdvOBShcGgBoBI9Keg9e1OVMinhQM5IFADQMdec0kkoi2hvun9KZJdQRLjeC3oKz7i6aWVSoGB2NAGql7EGw2QfWvnj9qeVJvGWkGM5A05R/4+9e6zXCz7VEWzHp3r5+/aVAHi3SsZ/wCQevX/AH2oA8hooooAKKKKACiiigD6C+CXwT0T4gfDu41rUNSvLO9W6kt0KFfLAVVIJBH+0e9LP+zsI53RfESsqnGRb9f1o+BfxF0Dwz4Hk0vV717e4a8eYAISNpVR/SvRV+LHgtuutIv1ib/CgDkdD/Zpsb9ik/iV0ccgCEc/rXaeFvgRrnhC/Mvh3xmEt2Pz289ruVvr82KpXPxe8GQA41SSTH/PKI5/pWc/x18IoeJdXce0I/8AiqAPVNQgu9MMUV35Ush+80XAP4dqh85WJBGD9a80tPjf4MuZPLkbUoix+/LCNo/ImtqL4g+DZ3BTxBaKT/fDg/yoA64yqW2qhZm4wKtJp925UFY4Q3AEjYP5VzcHizQARLb63p5I5DecB/Ord98UdHitQs/iPT4tvdXy36ZoA1dTt7rTZlhnEZYrkY5rPHmyEE7iP5Vyl38VfB53zT+IEuJBz8qOSfpkVw3iP4/2UAMfh7TpJ2xxLc/KAf8AdHWgD2yzurq0EiwyFVfhh61XmBmAE3K+lfLl18bfF877luLaEZziOFRUc3xp8YSx7Rdwx+6QqDQB9RrbRcFQQR7GpBGOOT+VfHtz8SfGFw7M/iC/AP8ACspA/KpLH4m+LrPcE1u7kDDGJHLY+maAPr+XZDEWkKoo5LOwUfrUEF3Z3EbPDdW0qoMsY5VIX618T6pruqarcNNqF/cTyMckvITVJLmeNWCTSKG4IDEZoA+tNc+J/hLS5jFNqzzODgrax7wD9cil0L4l+FdViLx6slqVONt2NhP86+RTSUAfYerfELwpp0RafX4ZR/dtR5jVyOo/GvwxbZ+yW1/f5H8ZEf8AjXzVRQB77P8AHyzAItfDRHp5lzn+lZkvx+1XJ8jRdMVewYMT/OvFaKAPc7H49atczxwPoFlNI5CqkIYMxPYda7HXviVZ+H7fTG1vSJY57wOZBDMCIiuOOnJ5r5+8CeIV8Na7Hey20dxEQUfIG5QepU9jXW/GS8tL+x8P3On3CTwSCZgVPIzs4I7GvNrYivHGU6SVoO+vfR6eX6lpLlbPdND17QNe0ptQi1I2sflNNsuMK2xTgseT8ueM1uadardWkVxa3qzJKcIYHDj6n2r5T8A6jZ2mneKY9QuliafSZILdXBO9ywIUYH1rW+G97Do+k3moQ+IrWx1qQGC1jnaQCEH7znapHQnFZ169eCqpt6Nctl3Xo9O78hpLQ+l4FvGujDKdqodrPjP0xUBvXW4aN48gNtyOMjOK8S8JfFm8sr+x0zV737QsM7CTUpJnZGBP3yuMtjtkVcPxvRtckhuNIt5rLztiywuVJG77/Pr1xW1GtWlXlGafLbTRW9fnvbp+aaVtD2q+mS0lCyK3lk4V/wChqJLuF/usDWRqPj7wjPcy6cmr263DdfMBKD23DjNQM/G61kiuIv78Thx+lPLa1avh1OsrP8/O3QJpJ6HQC4jZvvKB9aPOTIwd3biuZBkIyhIJ7U77QVG1gSTXeQdA21mJUrke9PSWSEFoZdr+meDXMuAQ7hwpHOPWozNhtx3Z9qBSSkuWWqOgu7maRj9pZmXI+6eB+FNRomk6sPrXNLI7c+Y2Ce5pxeUKD5pIzyCaAjFRVoqyOsCoFYhgMGnK6jnco9Oa5CWVucMee2eKaG3YG88ds0DOx8yPIPmID35pPOgByJk+ma5FnGzuSKSNnC5U9fSgDsRdW2f9envzSC+tc8TLkenNcnE/JDoPc4oRtp+XGCaAOwOo2gPEmfoKSfULdQNpL+u2uXR23sQopwc5xlvwFAHRHVogchCe3NRtqzknbEo+tYzSwoMzzQw+8sgX+ZrMv/FvhbS1f7ZrUMkqdY4QXb+WP1oA6f8AtG5cEB8f7opoknlPzM7V5hqHxp0K0VhpemXV23YzEIP0zXK6p8cdfn+XTba0so8dow7fmaAPfYrWRyDsYfXiq2o6lo+lDOqatZ2p6bWkG78hXyrq3jbxHqwZb7WLySNv4PMIX8q5+SR5DmR2c+rHNAH1Le/FDwbYybDqM87DvDDuH5kivGPjP4r03xb4gsrvSPO8mG1ELeau05DMf6159RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAu4+p/OgknrSUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSknAGTgdBSUUAFFFFABRRRQAuec1ItxMgwk0ij0DEVFRQBN9quP+e8v/AH2aPtM//PeX/vs1DRQBN9pn/wCe8v8A32aPtM//AD2l/wC+zUNFAE32mf8A57S/99mj7TP/AM9pf++zUNFAE32mf/ntL/30aT7TP/z2k/76NRUUATfaZ/8AntL/AN9mj7TP/wA9pf8Avs1DRQBN9pn/AOe8v/fZo+0z/wDPaX/vs1DRQBN9quP+e8v/AH2aPtVx/wA95f8Avs1DRQBK08z/AHpZG+rE1GST1NJRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial (A) and coronal (B) computed tomography (CT) scan images for an IMRT treatment plan targeting the pelvic and inguinal lymph nodes. The inguinal, external iliac and internal iliac vessels are contoured in red.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin Bradley, MD and Derek McHaffie, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_3_24628=[""].join("\n");
var outline_f24_3_24628=null;
var title_f24_3_24629="Allopurinol: Pediatric drug information";
var content_f24_3_24629=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Allopurinol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"    see \"Allopurinol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/14/2277?source=see_link\">",
"    see \"Allopurinol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F131745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aloprim&reg;;",
"     </li>",
"     <li>",
"      Zyloprim&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F131746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alloprin&reg;;",
"     </li>",
"     <li>",
"      Novo-Purol;",
"     </li>",
"     <li>",
"      Zyloprim&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antigout Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Uric Acid Lowering Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"      see \"Allopurinol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of acute uric acid nephropathy in myeloproliferative neoplastic disorders (beginning 1-2 days before chemotherapy): Daily doses &gt;300 mg should be administered in divided doses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &le;10 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 1-3 divided doses; maximum dose: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 10 mg/kg/day in 2-3 divided doses or 200-300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 2-4 divided doses; maximum dose: 800 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternative:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6 years: 150 mg/day in 3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-10 years: 300 mg/day in 2-3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;10 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 200-400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 1-3 divided doses; maximum: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 600-800 mg/day in 2-3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gout: Children &gt;10 years and Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild: 200-300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe: 400-600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recurrent calcium oxalate stones: Children &gt;10 years and Adults: Oral: 200-300 mg daily in divided or single daily dosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage change",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Reduce dosage to 50% of recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Reduce dosage to 30% of recommended",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F131716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium [strength expressed as base]: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aloprim&reg;: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zyloprim&reg;: 100 mg, 300 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F131701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer after meals with plenty of fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Reconstitute 500 mg vial with 25 mL SWI; prior to administration, further dilute with D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS to a maximum concentration of 6 mg/mL; rate of infusion is dependent upon the volume of infusate (in research studies, 100-300 mg doses were infused over 30 minutes)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F131802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, sterile water for injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, aminophylline, ampicillin, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, cefazolin, cefotetan, ceftazidime, cefuroxime, cisplatin, cyclophosphamide, dactinomycin, dexamethasone sodium phosphate, doxorubicin liposome, enalaprilat, etoposide, famotidine, filgrastim, fluconazole, fludarabine, fluorouracil, furosemide, gallium nitrate, ganciclovir, granisetron, heparin, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydromorphone, ifosfamide, lorazepam, mannitol, melphalan, mesna, methotrexate, metronidazole, mitomycin, mitoxantrone, morphine, oxaliplatin, piperacillin, potassium chloride, ranitidine, sulfamethoxazole and trimethoprim, teniposide, thiotepa, ticarcillin/clavulanate, vancomycin, vinblastine, vincristine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amikacin, amphotericin B, carmustine, cefotaxime, chlorpromazine, cimetidine, clindamycin, cytarabine, dacarbazine, daunorubicin, diphenhydramine, doxorubicin, doxycycline, droperidol, floxuridine, gentamicin, haloperidol, hydroxyzine, idarubicin, imipenem/cilastatin, mechlorethamine, meperidine, methylprednisolone sodium succinate, metoclopramide, minocycline, nalbuphine, ondansetron, prochlorperazine edisylate, promethazine, sodium bicarbonate, streptozocin, tobramycin, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in  syringe: Incompatible:",
"     </b>",
"     Ceftriaxone",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1056396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstituted parenteral solution should be stored at room temperature; do not refrigerate; use within 10 hours of preparation; physically",
"     <b>",
"      incompatible",
"     </b>",
"     when mixed with or infused through the same line with the following: Amikacin, amphotericin B, carmustine, cefotaxime, chlorpromazine, cimetidine, clindamycin, cytarabine, dacarbazine, daunorubicin, diphenhydramine, doxorubicin, doxycycline, droperidol, floxuridine, gentamicin, haloperidol, hydroxyzine, idarubicin, imipenem-cilastatin, mechlorethamine, meperidine, metoclopramide, methylprednisolone sodium succinate, minocycline, nalbuphine, netilmicin, ondansetron, prochlorperazine, promethazine, sodium bicarbonate, streptozocin, tobramycin, vinorelbine",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of attacks of gouty arthritis and nephropathy; also used in treatment of secondary hyperuricemia which may occur during treatment of tumors or leukemia; prevention of recurrent calcium oxalate calculi",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F131804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Allopurinol may be confused with Apresoline",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zyloprim&reg; may be confused with ZORprin&reg;, Zovirax&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F131801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gout (acute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, agranulocytosis, alopecia, angioedema, aplastic anemia, arthralgia, bronchospasm, cataracts, cholestatic jaundice, dermatitis (eczematoid, exfoliative, vascular bullous), dyspepsia, ecchymosis, eosinophilia, epistaxis, fever, gastritis, granuloma annulare, hepatitis, gynecomastia, headache, hepatic necrosis, hepatomegaly, hyperbilirubinemia, hypersensitivity reactions, leukocytosis, leukopenia, lichen planus, loss of taste perception, macular retinitis, myopathy, necrotizing angiitis, nephritis, neuritis, neuropathy, onycholysis, pancreatitis, paresthesia, purpura, pruritus, renal failure, somnolence, Stevens-Johnson syndrome, taste perversion, thrombocytopenia, toxic epidermal necrolysis, toxic pustuloderma, uremia, vasculitis, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to allopurinol or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce dosage in renal impairment; discontinue drug at the first sign of rash; risk of skin rash may be increased in patients receiving amoxicillin or ampicillin; risk of hypersensitivity may be increased in patients receiving thiazides and possibly ACE inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use to treat asymptomatic hyperuricemia; monitor liver function and complete blood counts before initiating therapy and periodically",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F131710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amoxicillin: Allopurinol may enhance the potential for allergic or hypersensitivity reactions to Amoxicillin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ampicillin: Allopurinol may enhance the potential for allergic or hypersensitivity reactions to Ampicillin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Allopurinol.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Allopurinol may increase the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: Allopurinol may decrease the metabolism of AzaTHIOprine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: Allopurinol may enhance the adverse/toxic effect of Bendamustine. Specifically, the risk of severe skin reactions may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Allopurinol may increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ChlorproPAMIDE: Allopurinol may increase the serum concentration of ChlorproPAMIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclophosphamide: Allopurinol may enhance the adverse/toxic effect of Cyclophosphamide. Specifically, bone marrow suppression.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Allopurinol may increase the serum concentration of Didanosine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically, Loop Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: Allopurinol may decrease the metabolism of Mercaptopurine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegloticase: Allopurinol may enhance the adverse/toxic effect of Pegloticase. Specifically, Allopurinol may blunt increases in serum urate that would signal an increased risk of anaphylaxis and infusion reactions.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Allopurinol may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Allopurinol may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F131712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F131728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are few reports describing the use of allopurinol during pregnancy; no adverse fetal outcomes attributable to allopurinol have been reported in humans; use only if potential benefit outweighs the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, liver function tests, renal function, serum uric acid; 24-hour urinary urate (when treating calcium oxalate stones)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1056403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Uric acid: Male: 3.0-7.0 mg/dL; Female: 2.0-6.0 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Urinary urate excretion: Male: &lt;800 mg/day; Female: &lt;750 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases the production of uric acid by inhibiting the action of xanthine oxidase, an enzyme that converts hypoxanthine to xanthine and xanthine to uric acid",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1056408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decrease in serum uric acid occurs in 1-2 days with a nadir achieved in 1-3 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: &sim;80% from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Into breast milk; breast milk to plasma ratio: 0.9-1.4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: &sim;75% of drug metabolized to active metabolites, chiefly oxypurinol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parent: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxypurinol metabolite: 18-30 hours in patients with normal renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Allopurinol and oxypurinol are dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/14/2277?source=see_link\">",
"      see \"Allopurinol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report any skin rash, painful urination, blood in urine, irritation of the eyes, or swelling of lips or mouth; avoid alcohol; drink plenty of fluids; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F131723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 20 mg/mL oral suspension may be made with tablets and either a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg; or a 1:4 mixture of cherry syrup concentrate and simple syrup, NF. Crush eight 300 mg tablets in a mortar and reduce to a fine powder. Add small portions of chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &ldquo;shake well&rdquo;. Stable for 60 days refrigerated or at room temperature (Allen, 1996; Nahata, 2004).",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV Jr and Erickson MA 3rd, \"Stability of Acetazolamide, Allopurinol, Azathioprine, Clonazepam, and Flucytosine in Extemporaneously Compounded Oral Liquids,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1996, 53(16):1944-9.",
"     <span class=\"pubmed-id\">",
"      8862208",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bennett WM, Aronoff GR, Golper TA, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure",
"      </i>",
"      , Philadelphia, PA: American College of Physicians, 1987.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krakoff IH and Murphy ML, &ldquo;Hyperuricemia in Neoplastic Disease in Children: Prevention With Allopurinol, A Xanthine Oxidase Inhibitor&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1968, 41(1):52-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/3/24629/abstract-text/5635486 /pubmed\" id=\"5635486 \" target=\"_blank\">",
"        5635486",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13339 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-813CF6A707-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_3_24629=[""].join("\n");
var outline_f24_3_24629=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131745\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131746\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056400\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056393\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131716\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131701\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056405\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131802\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056396\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056404\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131804\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131801\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056410\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056392\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056391\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298712\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131710\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131712\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131728\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056399\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056403\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056390\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056408\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056409\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056398\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131723\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13339\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13339|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=related_link\">",
"      Allopurinol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/14/2277?source=related_link\">",
"      Allopurinol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_3_24630="Ganciclovir (systemic): Drug information";
var content_f24_3_24630=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ganciclovir (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/18/31012?source=see_link\">",
"    see \"Ganciclovir (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/42/13990?source=see_link\">",
"    see \"Ganciclovir (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8106920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8106925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cytovene&reg;-IV",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8106926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cytovene&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8106930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiviral Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8107009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CMV CNS infection in HIV-exposed/-infected patients (unlabeled use; CDC, 2009)",
"     </b>",
"     :",
"     <i>",
"      I.V.:",
"     </i>",
"     5 mg/kg/dose every 12 hours plus foscarnet until symptoms improve followed by chronic suppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CMV retinitis:",
"     </b>",
"     <i>",
"      I.V. (slow infusion):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Induction therapy: 5 mg/kg/dose every 12 hours for 14-21 days followed by maintenance therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance therapy: 5 mg/kg/day as a single daily dose for 7 days/week or 6 mg/kg/day for 5 days/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention (secondary) of CMV disease in HIV-exposed/-infected patients (unlabeled use; CDC, 2009):",
"     </b>",
"     <i>",
"      I.V.:",
"     </i>",
"     5 mg/kg/dose daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention (secondary) of CMV disease in transplant patients:",
"     </b>",
"     <i>",
"      I.V. (slow infusion):",
"     </i>",
"     5 mg/kg/dose every 12 hours  for  7-14 days, duration of maintenance therapy is dependent on clinical condition and degree of immunosuppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Varicella zoster: Progressive outer retinal necrosis in HIV-exposed/-infected patients (unlabeled use; CDC, 2009):",
"     </b>",
"     <i>",
"      I.V.:",
"     </i>",
"     5 mg/kg/dose every 12 hours plus systemic foscarnet and intravitreal ganciclovir or intravitreal foscarnet",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8107008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/42/13990?source=see_link\">",
"      see \"Ganciclovir (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CMV CNS infection in HIV-exposed/-infected patients (unlabeled use; CDC, 2009):",
"     </b>",
"     Infants and Children:",
"     <i>",
"      I.V.:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      CMV retinitis:",
"     </b>",
"     Children:",
"     <i>",
"      I.V. (slow infusion):",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention (secondary) of CMV disease in HIV-exposed/-infected patients (unlabeled use; CDC, 2009):",
"     </b>",
"     Infants and Children:",
"     <i>",
"      I.V.:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prevention (secondary) of CMV disease in transplant patients:",
"     </b>",
"     Children:",
"     <i>",
"      I.V. (slow infusion):",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Varicella zoster: Progressive outer retinal necrosis in HIV-exposed/-infected patients (unlabeled use; CDC, 2009):",
"     </b>",
"     Infants and Children:",
"     <i>",
"      I.V.:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8107010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. In general, dose selection should be cautious, reflecting greater frequency of organ impairment.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8107011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      I.V. (Induction):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-69 mL/minute: Administer 2.5 mg/kg/dose every 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     25-49 mL/minute: Administer 2.5 mg/kg/dose every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-24 mL/minute: Administer 1.25 mg/kg/dose every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 1.25 mg/kg/dose 3 times/week following hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      I.V. (Maintenance):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-69 mL/minute: Administer 2.5 mg/kg/dose every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     25-49 mL/minute: Administer 1.25 mg/kg/dose every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-24 mL/minute: Administer 0.625 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 0.625 mg/kg/dose 3 times/week following hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (50%): CMV Infection: I.V.: Induction: 1.25 mg/kg every 48-72 hours; Maintenance: 0.625 mg/kg every 48-72 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times/week, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Peritoneal dialysis (PD): Dose as for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005):  Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment: CMV Infection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     CVVH: I.V.: Induction: 2.5 mg/kg every 24 hours; Maintenance: 1.25 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     CVVHD/CVVHDF: I.V.: Induction: 2.5 mg/kg every 12 hours; Maintenance: 2.5 mg/kg every 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8107058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cytovene&reg;-IV: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8106928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8107021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should not be administered by I.M., SubQ, or rapid IVP; administer by slow I.V. infusion over at least 1 hour. Too rapid infusion can cause increased toxicity and excessive plasma levels. Flush line well with NS before and after administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8106989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with paraben preserved bacteriostatic water for injection (may cause precipitation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amphotericin B cholesteryl sulfate complex, anidulafungin, caspofungin, cisplatin, cyclophosphamide, docetaxel, doxorubicin liposome, enalaprilat, etoposide phosphate, filgrastim, fluconazole, granisetron, linezolid, melphalan, methotrexate, paclitaxel, pemetrexed, propofol, remifentanil, teniposide, thiotepa.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amifostine, amsacrine, aztreonam, cefepime, cytarabine, doxorubicin, fludarabine, foscarnet, gemcitabine, ondansetron, piperacillin/tazobactam, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Aldesleukin, cisatracurium, sargramostim, tacrolimus.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8106944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of CMV retinitis in immunocompromised individuals, including patients with acquired immunodeficiency syndrome; prophylaxis of CMV infection in transplant patients",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8106945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CMV retinitis: May be given in combination with foscarnet in patients who relapse after monotherapy with either drug",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8106922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cytovene&reg; may be confused with Cytosar&reg;, Cytosar-U",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ganciclovir may be confused with acyclovir",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8106965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (48%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (44%), anorexia (14%), vomiting (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (57%), leukopenia (41%), anemia (16% to 26%), neutropenia with ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     (12% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Retinal detachment (11%; relationship to ganciclovir not established)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (2% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Sepsis (15%), diaphoresis (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills (10%), neuropathy (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction (including anaphylaxis), alopecia, arrhythmia, bronchospasm, cardiac arrest, cataracts, cholestasis, coma, dyspnea, edema, encephalopathy, exfoliative dermatitis, extrapyramidal symptoms, hepatitis, hepatic failure, pancreatitis, pancytopenia, pulmonary fibrosis, psychosis, rhabdomyolysis, seizure, alopecia, urticaria, eosinophilia, hemorrhage, Stevens-Johnson syndrome, torsade de pointes, renal failure, SIADH, visual loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8106951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ganciclovir, acyclovir, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8106952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias:",
"     <b>",
"      [U.S. Boxed Warning]: Granulocytopenia (neutropenia), anemia, and thrombocytopenia may occur.",
"     </b>",
"     Dosage adjustment or interruption of therapy may be necessary in patients with neutropenia and/or thrombocytopenia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carcinogenic/teratogenic:",
"     <b>",
"      [U.S. Boxed Warning]: Animal studies have demonstrated carcinogenic and teratogenic effects, and inhibition of  spermatogenesis;",
"     </b>",
"     contraceptive precautions for female and male patients need to be followed during and for at least 90 days after therapy with the drug.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment or interruption of therapy may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Take care to administer only into veins with good blood flow.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: Indicated only for treatment of CMV retinitis in the immunocompromised patient and CMV prevention in transplant patients at risk.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8106969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imipenem: Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Imipenem. May increase risk of seizures.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Ganciclovir-Valganciclovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reverse Transcriptase Inhibitors (Nucleoside): Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Stavudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: May increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8106946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8106947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Animal studies have demonstrated carcinogenic and teratogenic effects, and inhibition of spermatogenesis.",
"     </b>",
"     Female patients should use effective contraception during therapy; male patients should use a barrier contraceptive during and for at least 90 days after therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8106949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8106950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the carcinogenic and teratogenic effects observed in animal studies, the possibility of adverse events in a nursing infant is considered likely. Therefore, nursing should be discontinued during therapy. In addition, the CDC recommends",
"     <b>",
"      not",
"     </b>",
"     to breast-feed if diagnosed with HIV to avoid postnatal transmission of the virus.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8107020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cytovene Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $104.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Ganciclovir Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $97.27",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8107025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, serum creatinine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ciganclor (UY);",
"     </li>",
"     <li>",
"      Cymevan (FR);",
"     </li>",
"     <li>",
"      Cymevene (AE, AR, AT, AU, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CN, CO, CY, CZ, DK, EC, EE, EG, ET, FI, GB, GH, GM, GN, GR, HK, HN, ID, IL, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PL, PY, QA, SA, SC, SD, SE, SK, SL, SN, SY, TH, TN, TR, TW, TZ, UG, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Ganguard (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8106992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ganciclovir is phosphorylated to a substrate which competitively inhibits the binding of deoxyguanosine triphosphate to DNA polymerase resulting in inhibition of viral DNA synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8106994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 15.26 L/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ; widely to all tissues including CSF and ocular tissue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 1% to 2%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1.7-5.8 hours; prolonged with renal impairment; End-stage renal disease: 5-28 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (80% to 99% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/3/24630/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/3/24630/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fletcher C, Sawchuk R, Chinnock B, et al, &ldquo;Human Pharmacokinetics of the Antiviral Drug DHPG,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1986, 40(3):281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/3/24630/abstract-text/3017630/pubmed\" id=\"3017630\" target=\"_blank\">",
"        3017630",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gando S, Kameue T, Nanzaki S, et al, &ldquo;Pharmacokinetics and Clearance of Ganciclovir During Continuous Hemodiafiltration,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1998, 26(1):184-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/3/24630/abstract-text/9428565/pubmed\" id=\"9428565\" target=\"_blank\">",
"        9428565",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gudnason T, Belani KK, and Balfour HH Jr, &ldquo;Ganciclovir Treatment of Cytomegalovirus Disease in Immunocompromised Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1989, 8(7):436-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/3/24630/abstract-text/2547191/pubmed\" id=\"2547191\" target=\"_blank\">",
"        2547191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/3/24630/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan JE, Benson C, Holmes KH, et al, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/3/24630/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lake KD, Fletcher CV, Love KR, et al, &ldquo;Ganciclovir Pharmacokinetics During Renal Impairment,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1988, 32(12):1899-900.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/3/24630/abstract-text/2854457/pubmed\" id=\"2854457\" target=\"_blank\">",
"        2854457",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Matthews T and Boehme R, &ldquo;Antiviral Activity and Mechanism of Action of Ganciclovir,&rdquo;",
"      <i>",
"       Rev Infect Dis",
"      </i>",
"      , 1988, 10(Suppl 3):490-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sommadossi JP, Bevan R, Ling T, et al, &ldquo;Clinical Pharmacokinetics of Ganciclovir in Patients With Normal and Impaired Renal Function,&rdquo;",
"      <i>",
"       Rev Infect Dis",
"      </i>",
"      , 1988, 10(Suppl 3):507-14.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/3/24630/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Glaser CA, Bloch KC, et al, &ldquo;The Management of Encephalitis: Clinical Practice Guidelines from the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 47(3):303-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/3/24630/abstract-text/18582201/pubmed\" id=\"18582201\" target=\"_blank\">",
"        18582201",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9140 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-D7E3B57AC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_3_24630=[""].join("\n");
var outline_f24_3_24630=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106920\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106925\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106926\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106930\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107009\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107008\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107010\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107011\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896336\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107058\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106928\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107021\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106989\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106944\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106945\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106922\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106965\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106951\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106952\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299387\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106969\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106946\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106947\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106949\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106950\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107020\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322180\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107025\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390229\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106992\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106994\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9140\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9140|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/5/6228?source=related_link\">",
"      Ganciclovir (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/53/41811?source=related_link\">",
"      Ganciclovir (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/58/6052?source=related_link\">",
"      Ganciclovir (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/18/31012?source=related_link\">",
"      Ganciclovir (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/42/13990?source=related_link\">",
"      Ganciclovir (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_3_24631="Complications of gynecologic surgery";
var content_f24_3_24631=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of gynecologic surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/3/24631/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/3/24631/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/3/24631/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/3/24631/contributors\">",
"     Howard T Sharp, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/3/24631/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/3/24631/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/3/24631/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive gynecologic surgery often entails meticulous dissection near the bladder, rectum, ureters, and great vessels of the pelvis. Complications of gynecologic surgery include hemorrhage, infection, thromboembolism, and visceral damage. The risk of complications depends upon the extent and approach to surgery and patient characteristics. Understandably, the more common complications from this surgery relate to injuries to these viscera and occur during extensive resections for the treatment of cancer or when anatomy is distorted due to infection or endometriosis. Other complications, such as pulmonary embolus, myocardial infarction, pneumonia, or fluid or electrolyte imbalance are common to all surgery. (See individual topic reviews on these subjects).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HEMORRHAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhage in gynecologic surgery is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=see_link\">",
"     \"Management of hemorrhage in gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     UTERINE PERFORATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine perforation is a potential complication of all intrauterine procedures and may be associated with injury to surrounding blood vessels or viscera (bladder, bowel). In addition, uterine perforations and associated complications that are not diagnosed at the time of the procedure can result in hemorrhage or sepsis. The risk of uterine perforation is increased by factors that make access to the endometrial cavity difficult (eg, cervical stenosis) or alter the strength of the myometrial wall (eg, pregnancy, menopause).",
"   </p>",
"   <p>",
"    Uterine perforation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4408?source=see_link\">",
"     \"Uterine perforation during gynecologic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     URINARY TRACT INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rates of ureteric and bladder injury vary with the indication for surgery and the procedure. Risk factors for urinary tract injury include surgery for malignant disease and for urinary incontinence or pelvic organ prolapse.",
"   </p>",
"   <p>",
"    Urinary tract injury in gynecologic surgery is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14056?source=see_link\">",
"     \"Urinary tract injury in gynecologic surgery: Prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=see_link\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BOWEL INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serosal abrasions need not be repaired, but injuries involving the muscularis or muscularis and mucosa should be repaired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Small bowel injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small defects of the serosal or muscularis may be repaired using continuous or interrupted 3-0 silk or synthetic absorbable suture material. Single layer closure of small bowel is adequate in most cases. Suture lines should be perpendicular to the long axis of the bowel to prevent narrowing of the bowel lumen. Large defects can sometimes by closed with a stapling device, or resection with reanastomosis may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Colonic injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repair is similar to that described above for the small bowel. Lack of preoperative bowel prep is not an indication for colostomy. After the bowel is repaired, the abdomen is copiously irrigated. Occasionally, a segment of bowel must be resected, and if reanastomosis is performed, routine care can resume. If bowel reanastomosis cannot be performed due to extensive injury or pathology (ie, dense adhesions or inflammatory changes), a diverting colostomy may be required. Closed-system drains are commonly placed in the pelvis, but are not used by all surgeons.",
"   </p>",
"   <p>",
"    We do not give additional antibiotics to woman who have already received prophylaxis prior to surgery; if no antibiotics were given, we administer broad spectrum antibiotics if the bowel lumen is entered. Postoperatively, enemas and rectal probe temperatures are proscribed in patients with rectal injuries.",
"   </p>",
"   <p>",
"    There are no postoperative dietary restrictions unless the bowel injury and repair involved a large area. We do not use nasogastric tubes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FISTULA FORMATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Urinary tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most fistulas occur after hysterectomy for benign conditions, since these procedures are far more common than surgery for cancer. However, the risk of fistula formation is higher after radical surgery because of the scope of surgery, the presence of tumor, and, in some cases, radiation induced changes.",
"   </p>",
"   <p>",
"    Fistulae of the ureter, bladder, or both occur after radical gynecologic surgery in less than one percent of women. The fistula is localized by cystoscopy, intravenous pyelogram, and retrograde studies of the ureter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29592?source=see_link\">",
"     \"Diagnostic cystourethroscopy for gynecologic conditions\"",
"    </a>",
"    .) Simple vesicovaginal fistulae can be managed by prolonged drainage to allow an opportunity for spontaneous healing. Antibiotic prophylaxis, and, if appropriate, postmenopausal hormone therapy, are given. It is unclear how long drainage should be continued, but usually healing occurs in less than four weeks. Although cautery has been advocated for closing small fistulae, no data exist to support this practice.",
"   </p>",
"   <p>",
"    Surgical correction is necessary when healing fails to occur. An immediate repair may be performed in the absence of infection and excessive granulation tissue, although delayed repairs were recommended in the past. A vaginal approach (eg, Latzko procedure) is the procedure of choice and may be done as an outpatient, with minimal morbidity. If complete closure is not obtained, a second effort may be successful. Otherwise, excision of the fistula, layered closure, and placement of an omental flap to separate bladder and vagina and provide neovascularity can be attempted transabdominally.",
"   </p>",
"   <p>",
"    Simple ureterovaginal fistulae usually heal after being stented, preferably percutaneously. If this fails, surgical repair will be necessary. Complex ureterovesicovaginal fistulae require stenting and drainage until inflammation and infection have resolved. Although spontaneous healing infrequently occurs, the tissue is in more optimal condition for surgical repair. Fistulae are discussed in greater depth elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=see_link\">",
"     \"Urogenital tract fistulas in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal fistulae after gynecologic surgery are rare. They occur 10 to 14 days postoperatively, and may be heralded by spiking temperatures with no clear source, no response to antibiotics, and a tender, but otherwise normal-appearing, incision. The diagnosis and site of the fistula are determined radiographically by injecting dye into the fistula (fistulogram) and subsequently performing a small and large bowel series.",
"   </p>",
"   <p>",
"    Management consists of resting the gastrointestinal tract by eliminating oral intake, and possibly by using inhibitors of pancreatic and gastric secretion (eg, somatostatin). Healing occurs over weeks. However, the fistula will not heal if there is an obstruction distal to it. Parenteral nutrition is indicated in most cases. If healing fails to occur, laparotomy with resection of the anastomosis and primary repair is appropriate. For low rectovaginal fistulae, the Latzko procedure can be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=see_link\">",
"     \"Rectovaginal, anovaginal, and colovesical fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE NAUSEA AND VOMITING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative nausea with or without vomiting (PONV) has been related to a number of patient-, medical-, anesthesia-, and surgery-related factors. Patient factors include female gender, nonsmoking, and history of PONV or motion sickness; surgical factors include intraabdominal surgery and procedures of longer duration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/1\">",
"     1",
"    </a>",
"    ]. Analgesic and anesthetic drugs, especially general anesthesia and opioids, are the most common source of PONV. Postoperative ileus and obstruction are the most common surgery-related causes. Postoperative ileus is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=see_link\">",
"     \"Postoperative ileus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients at moderate to high risk of PONV benefit from preoperative administration of a prophylactic antiemetic agent (eg, serotonin receptor antagonist, dexamethsone, anticholinergic agent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Examples of high quality studies are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A double-blinded randomized controlled trial found that the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (8 mg) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      given intraoperatively reduced the incidence of PONV from 23 percent (with dexamethasone alone) to 17 percent (with 25 mg metoclopramide) or 14.5 percent (with 50 mg metoclopramide) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/4\">",
"       4",
"      </a>",
"      ]. The higher metoclopramide dose had a more prolonged effect than the lower dose (less nausea at 12 to 24 hours) but was associated with more hypotension and tachycardia (18 versus 13 percent).",
"     </li>",
"     <li>",
"      A randomized trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"       scopolamine",
"      </a>",
"      patch (placed the night before surgery, left in place for 72 hours) to placebo in women undergoing gynecologic laparoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/5\">",
"       5",
"      </a>",
"      ]. During the first 24 hours after surgery, use of scopolamine was associated with a significant decrease in postoperative nausea (21 percent in the scopolamine group versus 63 percent in the placebo group) and vomiting (8 versus 38 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with established PONV benefit from treatment with antiemetics. If a prophylactic antiemetic was administered, treatment of PONV within six hours of surgery should be with an antiemetic from a different pharmacologic class (ie, acting at a different receptor) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/1\">",
"     1",
"    </a>",
"    ]. After six hours, PONV can be treated with any antiemetic; sometimes combinations of antiemetics from different classes are needed. Low-dose serotonin receptor antagonists that are effective include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    1.0 mg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=see_link\">",
"     dolasetron",
"    </a>",
"    12.5 mg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    0.1 mg, or tropisetron 0.5 mg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ADHESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;One function of the peritoneal surface of pelvic and abdominal structures is to prevent adherence between these structures when they touch. If the peritoneum is injured as a result of surgery, the damaged areas may stick to each other and a permanent adhesion may form. This typically occurs within the first five days after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postoperative adhesions occur in 60 to 90 percent of women undergoing major gynecologic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/7\">",
"     7",
"    </a>",
"    ]. They are a common cause of small bowel obstruction, although most adhesions do not result in serious sequelae: infertility, chronic pain, intestinal obstruction, or difficult subsequent surgery (possibly resulting in inadvertent enterotomy). The incidence of adhesion-related intestinal obstruction after gynecologic surgery for benign conditions without hysterectomy is approximately 0.3 percent, increasing to 1 to 3 percent among patients who undergo simple hysterectomy, 5 percent after radical hysterectomy, and 20 percent in patients who undergo both radical hysterectomy and pelvic radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Symptoms may occur weeks to years after the procedure. A multihospital series of 135 cases of small bowel obstruction due to intraabdominal adhesions in nononcologic patients reported that 50 percent were related to abdominal hysterectomy (incidence",
"    <span class=\"nowrap\">",
"     49/3597",
"    </span>",
"    abdominal hysterectomies or",
"    <span class=\"nowrap\">",
"     13.6/1000)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=see_link\">",
"     \"Small bowel obstruction: Causes and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=see_link\">",
"     \"Preventing postoperative peritoneal adhesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LYMPHEDEMA AND LYMPHOCYST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unilateral or bilateral lymphedema of the lower extremities is uncommon after radical surgery, even when postoperative radiation is given. It is a chronic problem for which there is little effective intervention. Support hose and leg wraps will minimize edema; elevation of the extremities when sitting and elevating the foot of the bed also help to control the problem. Women with lymphedema should be warned to take care of their skin and pay special attention to the development of erythema or tenderness, which may indicate infection and a need for systemic antibiotics. Diuretics do not improve lymphedema, and may lead to electrolyte abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"     \"Prevention and treatment of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lymphocysts are uncommon after pelvic lymphadenectomy, occurring in 1 to 3 percent of women 11 to 12 days after surgery. They are seldom symptomatic and are detected when radiologic studies are performed surveying the woman for recurrent neoplastic disease. Symptoms consist of vague, colicky, lower abdominal pain. Symptomatic lymphocysts and those causing hydronephrosis can be drained percutaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/11\">",
"     11",
"    </a>",
"    ]. Recurrent lymphocysts should be drained again and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    instilled to sclerose the cavity. There is little, if any, role for laparotomy for drainage or marsupialization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NEUROPATHIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathies associated with gynecological surgery, although relatively rare, are related to malposition of the patient, retraction, hematoma, and operative injury. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=see_link\">",
"     \"Nerve injury associated with pelvic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INFECTIOUS MORBIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one series, approximately 30 percent of women undergoing laparotomy for a gynecological condition developed a fever of 38.0 degrees C (100.4 degrees F) or more [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/12\">",
"     12",
"    </a>",
"    ]. The majority of fever work-ups were of low clinical yield and added moderate cost, except when one or more of the following risk factors were present: surgery for malignancy, bowel resection, several febrile days, higher fever, and moderately increased white blood cell count. Postoperative fever is discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19178?source=see_link\">",
"     \"Postoperative fever\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fever within the first 48 hours of surgery is almost always cytokine related. Fever-associated cytokines are released by tissue trauma and do not necessarily signal infection. Fever due to the trauma of surgery usually resolves within two to three days.",
"   </p>",
"   <p>",
"    Chest radiography, urinalysis, and blood and urine cultures are",
"    <strong>",
"     NOT",
"    </strong>",
"    indicated for all postoperative patients with fever. The need for laboratory testing should be determined by the findings of a careful history and physical examination. The febrile postoperative patient should be evaluated systematically (",
"    <a class=\"graphic graphic_table graphicRef69959 \" href=\"UTD.htm?39/14/40172\">",
"     table 1",
"    </a>",
"    ), taking into account the timing of the onset of fever and the many possible causes (",
"    <a class=\"graphic graphic_table graphicRef79357 \" href=\"UTD.htm?18/48/19213\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A useful initial screen for the more common causes of postoperative fever is represented by the four-part mnemonic \"Wind, Water, Wound, What did we do?\". \"Wind\" refers to pulmonary causes of fever including pneumonia, aspiration, and pulmonary embolism (but not atelectasis). \"Water\" refers to UTI, and \"Wound\" refers to SSI. \"What did we do?\" is a reminder to consider treatments as a cause of fever and includes medications, blood product transfusions, and intravascular, urethral, nasal, and abdominal catheters.",
"   </p>",
"   <p>",
"    Significant febrile morbidity after gynecologic surgery is usually attributable to infection of the urinary tract, wound (including the vaginal cuff and necrotizing fasciitis), or pelvic cellulitis and abscess. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=see_link\">",
"     \"Urinary tract infection associated with urethral catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36406?source=see_link\">",
"     \"Epidemiology and pathogenesis of and risk factors for surgical site infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After the first two postoperative days, a thorough inspection of the wound and good rectovaginal examination are the most important components of the fever work-up. Empiric broad spectrum antibiotics may then be started. It is appropriate to obtain an intravenous pyelogram to look for occult ureteral obstruction in women febrile after 24 hours of antibiotics. Ureteral obstruction should be treated by percutaneous stent placement. Persistent fever despite antibiotics can be a sign of septic pelvic thrombophlebitis, which requires",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6807?source=see_link\">",
"     \"Septic pelvic thrombophlebitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postoperative fever is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19178?source=see_link\">",
"     \"Postoperative fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     HERNIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incisional hernia may occur, as with any abdominal operation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/15\">",
"     15",
"    </a>",
"    ]. One approach to prevention is use of a bulk running closure with a permanent suture and a suture length-to-wound length ratio of at least 4:1 (ie, attempt to close the incision incorporating a length of suture at least four times the length of the incision) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Symptomatic or cosmetically unacceptable hernias are repaired by opening the incision, debriding the edges, and either performing a primary bulk closure or placing a mesh patch. Data suggest that use of a mesh to close incisional hernias, whether large or small, is preferable to simple closure without mesh [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link&amp;anchor=H11#H11\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\", section on 'Fascial dehiscence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=see_link\">",
"     \"Overview of abdominal hernias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE THROMBOEMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     RETAINED FOREIGN OBJECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foreign objects are sometimes inadvertently left in the patient. One study of 54 patients with a total of 61 retained foreign bodies observed that 69 percent were sponges and 31 percent were instruments [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/19\">",
"     19",
"    </a>",
"    ]. Risk factors for retention of a foreign body were emergency surgery, unplanned change in the operation, increasing body-mass index, and absence of a sponge and instrument count.",
"   </p>",
"   <p>",
"    Retained foreign objects, usually lap pads or towels, less commonly clamps, are managed by prompt surgical removal. Symptoms of bowel dysfunction, pain or intra-abdominal abscesses may lead to diagnosis, although asymptomatic retained objects may occasionally show up on radiologic studies ordered for unrelated reasons.",
"   </p>",
"   <p>",
"    If a lap pad count is reported to be incorrect, and the pad cannot be found by the surgeon, x-ray of the abdomen is mandatory (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64696 \" href=\"UTD.htm?26/1/26655\">",
"     image 1",
"    </a>",
"    ). Care must be taken to be sure the entire abdomen, from below the symphysis to above the hemidiaphragms, is included in the film. However, most retained lap pads occur in cases in which the lap pad count, even multiple counts, is reported to be correct. Removal of a retained lap pad may be very difficult, due to extensive adhesions. Towels are infrequently placed within the abdomen, and in many hospitals they are not a counted item, creating potential for their being retained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SEXUAL DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A discussion of sexual function should precede and follow gynecologic surgery. If problems are identified with a woman's sex life, then appropriate counseling is warranted as soon as possible since sexual dysfunction may become worse after surgery or radiation therapy. As an example, vaginal fibrosis may result from radical hysterectomy or vaginal irradiation. However, most gynecologic procedures are not associated with subsequent sexual dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of the physical problems related to sexual dysfunction is multifaceted. Adequate endogenous hormones or exogenous therapy are required. Vaginal lubrication can be augmented with commercial water-soluble lubricants. Use of a vaginal dilator can both enlarge the caliber of the vagina, and increase length over time. Sexual positions in which the female is on the bottom can be made more comfortable by having the woman keep her thighs slightly closer together to create a \"longer\" vagina. This will require her to guide the penis during entry. Female superior or side-by-side positions will allow the female more control over depth of penile penetration. Oral and anal sex may be reasonable considerations in women who find this acceptable. Masturbation by the woman or her sex partner may allow gradual adjustments to altered perceptions of sexual pleasure.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link\">",
"     \"Sexual dysfunction in women: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11767449\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective study of 1.45 million gynecology inpatients in England reported a mortality rate of 0.2 percent within 30 days of admission, and 0.5 percent within 90 days [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24631/abstract/23\">",
"     23",
"    </a>",
"    ]. The 30-day death rate in patients with cancer was higher than for patients without cancer (5.1 percent versus 0.1 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11767377\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complications of gynecologic surgery include hemorrhage, infection, thromboembolism, and visceral damage. The risk of complications depends upon the extent and approach to surgery and patient characteristics. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mortality rate for gynecologic surgery appears to be 0.2 percent within 30 days of admission and 0.5 percent within 90 days. Death rates are higher for women with malignancy. (See",
"      <a class=\"local\" href=\"#H11767449\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For bowel injuries, serosal abrasions need not be repaired, but injuries involving the muscularis or muscularis and mucosa should be repaired.",
"     </li>",
"     <li>",
"      Many women undergoing laparotomy for a gynecological condition develop a postoperative fever of 38.0 degrees C (100.4 degrees F) or more. The majority of fever work-ups are of low clinical yield and added moderate cost, except when one or more of the following risk factors are present: surgery for malignancy, bowel resection, several febrile days, higher fever, and moderately increased white blood cell count. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Infectious morbidity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A discussion of sexual function should precede and follow gynecologic surgery. If problems are identified with a woman's sex life, then appropriate counseling is warranted as soon as possible since sexual dysfunction may become worse after surgery or radiation therapy. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Sexual dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/1\">",
"      Habib AS, Gan TJ. Evidence-based management of postoperative nausea and vomiting: a review. Can J Anaesth 2004; 51:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/2\">",
"      Golembiewski J, Chernin E, Chopra T. Prevention and treatment of postoperative nausea and vomiting. Am J Health Syst Pharm 2005; 62:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/3\">",
"      Rowbotham DJ. Recent advances in the non-pharmacological management of postoperative nausea and vomiting. Br J Anaesth 2005; 95:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/4\">",
"      Wallenborn J, Gelbrich G, Bulst D, et al. Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trial. BMJ 2006; 333:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/5\">",
"      Einarsson JI, Audbergsson BO, Thorsteinsson A. Scopolamine for prevention of postoperative nausea in gynecologic laparoscopy, a randomized trial. J Minim Invasive Gynecol 2008; 15:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/6\">",
"      Liakakos T, Thomakos N, Fine PM, et al. Peritoneal adhesions: etiology, pathophysiology, and clinical significance. Recent advances in prevention and management. Dig Surg 2001; 18:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/7\">",
"      Monk BJ, Berman ML, Montz FJ. Adhesions after extensive gynecologic surgery: clinical significance, etiology, and prevention. Am J Obstet Gynecol 1994; 170:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/8\">",
"      Al-Took S, Platt R, Tulandi T. Adhesion-related small-bowel obstruction after gynecologic operations. Am J Obstet Gynecol 1999; 180:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/9\">",
"      Montz FJ, Holschneider CH, Solh S, et al. Small bowel obstruction following radical hysterectomy: risk factors, incidence, and operative findings. Gynecol Oncol 1994; 53:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/10\">",
"      Al-Sunaidi M, Tulandi T. Adhesion-related bowel obstruction after hysterectomy for benign conditions. Obstet Gynecol 2006; 108:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/11\">",
"      Mann WJ, Vogel F, Patsner B, Chalas E. Management of lymphocysts after radical gynecologic surgery. Gynecol Oncol 1989; 33:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/12\">",
"      de la Torre SH, Mandel L, Goff BA. Evaluation of postoperative fever: usefulness and cost-effectiveness of routine workup. Am J Obstet Gynecol 2003; 188:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/13\">",
"      Badillo AT, Sarani B, Evans SR. Optimizing the use of blood cultures in the febrile postoperative patient. J Am Coll Surg 2002; 194:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/14\">",
"      Schwandt A, Andrews SJ, Fanning J. Prospective analysis of a fever evaluation algorithm after major gynecologic surgery. Am J Obstet Gynecol 2001; 184:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/15\">",
"      Yahchouchy-Chouillard E, Aura T, Picone O, et al. Incisional hernias. I. Related risk factors. Dig Surg 2003; 20:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/16\">",
"      Hodgson NC, Malthaner RA, Ostbye T. The search for an ideal method of abdominal fascial closure: a meta-analysis. Ann Surg 2000; 231:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/17\">",
"      Israelsson LA, Jonsson T. Suture length to wound length ratio and healing of midline laparotomy incisions. Br J Surg 1993; 80:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/18\">",
"      Burger JW, Luijendijk RW, Hop WC, et al. Long-term follow-up of a randomized controlled trial of suture versus mesh repair of incisional hernia. Ann Surg 2004; 240:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/19\">",
"      Gawande AA, Studdert DM, Orav EJ, et al. Risk factors for retained instruments and sponges after surgery. N Engl J Med 2003; 348:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/20\">",
"      Leenhouts GH, Kylstra WA, Everaerd W, et al. Sexual outcomes following treatment for early-stage gynecological cancer: a prospective and cross-sectional multi-center study. J Psychosom Obstet Gynaecol 2002; 23:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/21\">",
"      Thakar R, Ayers S, Clarkson P, et al. Outcomes after total versus subtotal abdominal hysterectomy. N Engl J Med 2002; 347:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/22\">",
"      Galyer KT, Conaglen HM, Hare A, Conaglen JV. The effect of gynecological surgery on sexual desire. J Sex Marital Ther 1999; 25:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24631/abstract/23\">",
"      Mason A, Goldacre M, Meddings D, Woolfson J. Use of case fatality and readmission measures to compare hospital performance in gynaecology. BJOG 2006; 113:695.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3289 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_3_24631=[""].join("\n");
var outline_f24_3_24631=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11767377\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HEMORRHAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      UTERINE PERFORATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      URINARY TRACT INJURIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BOWEL INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Small bowel injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Colonic injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FISTULA FORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Urinary tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      POSTOPERATIVE NAUSEA AND VOMITING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ADHESIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LYMPHEDEMA AND LYMPHOCYST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NEUROPATHIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INFECTIOUS MORBIDITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      HERNIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      POSTOPERATIVE THROMBOEMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      RETAINED FOREIGN OBJECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SEXUAL DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11767449\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11767377\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3289\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3289|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/1/26655\" title=\"diagnostic image 1\">",
"      Plain abdominal film of retained surgical sponge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3289|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/14/40172\" title=\"table 1\">",
"      Causes of postoperative fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/48/19213\" title=\"table 2\">",
"      Evaluation of the patient with postoperative fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29592?source=related_link\">",
"      Diagnostic cystourethroscopy for gynecologic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36406?source=related_link\">",
"      Epidemiology and pathogenesis of and risk factors for surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=related_link\">",
"      Management of hemorrhage in gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=related_link\">",
"      Nerve injury associated with pelvic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19178?source=related_link\">",
"      Postoperative fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=related_link\">",
"      Postoperative ileus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=related_link\">",
"      Preventing postoperative peritoneal adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=related_link\">",
"      Rectovaginal, anovaginal, and colovesical fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6807?source=related_link\">",
"      Septic pelvic thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=related_link\">",
"      Sexual dysfunction in women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=related_link\">",
"      Small bowel obstruction: Causes and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=related_link\">",
"      Urinary tract injury in gynecologic surgery: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14056?source=related_link\">",
"      Urinary tract injury in gynecologic surgery: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=related_link\">",
"      Urogenital tract fistulas in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4408?source=related_link\">",
"      Uterine perforation during gynecologic procedures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_3_24632="Keratoacanthoma: Management and prognosis";
var content_f24_3_24632=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Keratoacanthoma: Management and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/3/24632/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/3/24632/contributors\">",
"     Jerry D Brewer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/3/24632/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/3/24632/contributors\">",
"     June K Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/3/24632/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/3/24632/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/3/24632/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H771357\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Keratoacanthoma (KA) is a cutaneous squamoproliferative tumor that usually presents as a 1 to 2 cm dome-shaped or crateriform nodule with central hyperkeratosis (",
"    <a class=\"graphic graphic_picture graphicRef55042 graphicRef81629 graphicRef59593 graphicRef73408 graphicRef52368 \" href=\"UTD.htm?43/19/44346\">",
"     picture 1A-E",
"    </a>",
"    ). A common and distinctive feature of KA is a clinical course characterized by phases of rapid growth, lesion stability, and spontaneous involution.",
"   </p>",
"   <p>",
"    The approach to the management of KA is debatable since lesions can resolve without treatment. However, the well-accepted difficulty in distinguishing KA from cutaneous squamous cell carcinoma, a common tumor associated with a risk for metastasis, leads many clinicians (including ourselves) to recommend treatment of these lesions.",
"   </p>",
"   <p>",
"    The treatment and prognosis of KA will be discussed here. The epidemiology, risk factors, and diagnosis of KA are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=see_link\">",
"     \"Keratoacanthoma: Epidemiology, risk factors, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H770530\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;A longstanding debate over the classification of KA as a benign, spontaneously resolving tumor versus a variant of cutaneous squamous cell carcinoma with a rare potential for metastasis has contributed to a lack of definitive guidelines on the treatment of these lesions. Although most authors, including ourselves, advocate for treatment of KA [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/1-7\">",
"     1-7",
"    </a>",
"    ], observation until spontaneous resolution has also been used for management of these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=see_link&amp;anchor=H1923197#H1923197\">",
"     \"Keratoacanthoma: Epidemiology, risk factors, and diagnosis\", section on 'Relationship with squamous cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We opt to treat KA based upon the following considerations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No clinical or pathologic features can reliably differentiate KA and cutaneous squamous cell carcinoma",
"     </li>",
"     <li>",
"      Treatment accelerates lesion resolution",
"     </li>",
"     <li>",
"      Treatment is usually straight forward and efficient, with relatively minor risk",
"     </li>",
"     <li>",
"      Early treatment may improve cosmetic outcomes by limiting damage to the skin and underlying structures, such as the nose, eyelids, or lips",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgical excision is the first-line treatment for patients with the most common clinical presentation of KA, a solitary lesion. Other therapeutic options for solitary KA include electrodesiccation and curettage (ED&amp;C), intralesional injections, radiation, and topical therapy.",
"   </p>",
"   <p>",
"    We defer therapeutic intervention and proceed with observation only in patients who refuse to proceed with treatment. (See",
"    <a class=\"local\" href=\"#H770593\">",
"     'Deferring therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The management of patients with numerous KAs or very large KAs is more challenging than the treatment of solitary KA since the methods typically used to treat individual lesions are often impractical in these settings. Systemic pharmacologic therapy is an additional treatment option for patients with large or numerous KAs. Oral retinoids, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , are the systemic agents most commonly prescribed for this indication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=see_link&amp;anchor=H15906018#H15906018\">",
"     \"Keratoacanthoma: Epidemiology, risk factors, and diagnosis\", section on 'Clinical variants'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=see_link&amp;anchor=H2295938#H2295938\">",
"     \"Keratoacanthoma: Epidemiology, risk factors, and diagnosis\", section on 'Multiple keratoacanthomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H770537\">",
"    <span class=\"h1\">",
"     SOLITARY KERATOACANTHOMA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380984\">",
"    <span class=\"h2\">",
"     First-line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional surgical excision is the treatment of choice for solitary KA since it allows for both the assessment of histopathologic features to aid in diagnosis and pathologic confirmation of the removal of the tumor. Mohs surgery, a more complex and more expensive method of surgical excision, is usually reserved for patients in whom a tissue-sparing procedure is desired. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=see_link\">",
"     \"Mohs surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=see_link&amp;anchor=H772735#H772735\">",
"     \"Keratoacanthoma: Epidemiology, risk factors, and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H770544\">",
"    <span class=\"h3\">",
"     Conventional surgical excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the efficacy of conventional surgical excision for the treatment of KA has not been formally studied, this procedure is considered a first-line therapy for KA due to the fact that it is simple, well-tolerated, and as noted above, provides histopathologic confirmation of tumor removal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/2,7,9\">",
"     2,7,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technique utilized to perform surgical excision is important to ensure adequate treatment. The excision should include a periphery of normal skin and should extend into the subcutaneous fat. Due to the well-accepted difficulty in distinguishing KA from cutaneous squamous cell carcinoma, we typically excise these lesions with the recommended surgical margins for squamous cell carcinoma (at least 4 mm) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=see_link&amp;anchor=H1923197#H1923197\">",
"     \"Keratoacanthoma: Epidemiology, risk factors, and diagnosis\", section on 'Relationship with squamous cell carcinoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H770551\">",
"    <span class=\"h3\">",
"     Mohs surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mohs surgery is a tissue-sparing surgical technique that also allows for the intraoperative assessment of 100 percent of the tissue margins, unlike conventional surgical excision, in which only representative sections of the tumor margin are examined [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/10\">",
"     10",
"    </a>",
"    ]. Mohs surgery requires greater time to perform than conventional surgical excision, and is a more costly and less widely available procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=see_link\">",
"     \"Mohs surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cure rates for Mohs surgery for cutaneous squamous cell carcinoma are high, but data on the efficacy of Mohs surgery for KA are limited. In the largest reported series of KA treated with Mohs surgery (n = 43), one lesion (2 percent) recurred after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/11\">",
"     11",
"    </a>",
"    ]. The efficacies of Mohs surgery and conventional surgical excision for KA have not been directly compared.",
"   </p>",
"   <p>",
"    Mohs surgery, when available, is the preferred treatment for KAs in areas such as the central face, ear, nose, and periocular and perioral skin since tissue sparing is desired in these sites. Mohs surgery may also be used for lesions greater than 2 cm in diameter (giant KA) since it allows for confirmation of tumor removal prior to wound closure and may minimize the size of the surgical defect [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/9\">",
"     9",
"    </a>",
"    ]. Intralesional pharmacologic therapy is an additional treatment option for such lesions. (See",
"    <a class=\"local\" href=\"#H770579\">",
"     'Intralesional therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H770565\">",
"    <span class=\"h2\">",
"     Alternative therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of other therapies that have been used for the management of KA include electrodesiccation and curettage (ED&amp;C), intralesional pharmacologic therapy, ionizing radiation, and topical agents. Compared with surgical excision, the major disadvantage of these alternative procedures is the lack of histopathologic confirmation of the removal of the tumor. ED&amp;C is the most commonly used alternative therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380965\">",
"    <span class=\"h3\">",
"     Electrodesiccation and curettage",
"    </span>",
"    &nbsp;&mdash;&nbsp;ED&amp;C is a quick surgical procedure that is often used to treat KA after a shave biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/3\">",
"     3",
"    </a>",
"    ]. The procedure involves three cycles in which curettage is followed by electrodesiccation of the lesion site. Only a few minutes are required to administer this therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H23#H23\">",
"     \"Dermatologic procedures\", section on 'Curettage and electrodesiccation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data on the efficacy of ED&amp;C are limited. In a retrospective study of 111 KAs followed for 3 to 26 months, recurrence was detected in four lesions (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/12\">",
"     12",
"    </a>",
"    ]. An overall recurrence rate of 8 percent was documented in a separate retrospective study in which 75 out of 78 patients received this treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although ED&amp;C is well-tolerated, the round, hypopigmented scar that is typically left after healing makes this a less favorable option for some patients. The potential for this result is of particular concern when a KA is located in a cosmetically sensitive area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H770579\">",
"    <span class=\"h3\">",
"     Intralesional therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional therapy is infrequently utilized for the treatment of KA. Data on the efficacy of these interventions are limited to reports of small numbers of patients, some of whom did not have pretreatment biopsies. Most of the reported cases involve the use of 5-fluorouracil (5-FU) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Compared to 5-FU, intralesional methotrexate is a less expensive therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       5-fluorouracil &ndash;",
"      </strong>",
"      The efficacy of 5-FU is supported by case reports and case series [",
"      <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/16\">",
"       16",
"      </a>",
"      ]. The largest series, which consisted of 41 lesions, found a complete response rate of 98 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/17\">",
"       17",
"      </a>",
"      ]. Intralesional 5-FU is typically administered undiluted in a concentration of 50",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      on a weekly basis for three to eight treatment sessions. The doses used for injection have varied widely; a dose of 40 to 75 mg per lesion was utilized in the largest series.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Resolution of KA after treatment with intralesional methotrexate has been reported in case reports and case series [",
"      <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/14,16\">",
"       14,16",
"      </a>",
"      ]. In a series of nine patients with KA [",
"      <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/15\">",
"       15",
"      </a>",
"      ], all lesions completely resolved, and in another series, complete responses occurred in 15 out of 18 patients (83 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/14\">",
"       14",
"      </a>",
"      ]. In addition, intralesional methotrexate administered prior to surgical excision reduced lesion size in a randomized trial of 25 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/18\">",
"       18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A standard dose for the treatment of KA is the injection of 1 mL of methotrexate in a concentration of 12.5 or 25",
"      <span class=\"nowrap\">",
"       mg/mL.",
"      </span>",
"      Injection is performed every two to three weeks for one to four treatment sessions. One or two treatments are usually sufficient for resolution.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/19-22\">",
"     19-22",
"    </a>",
"    ] and interferon alfa-2a and alfa-2b [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/23,24\">",
"     23,24",
"    </a>",
"    ] are limited to case reports and case series with fewer than 10 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/16\">",
"     16",
"    </a>",
"    ]. These agents also appear to be effective.",
"   </p>",
"   <p>",
"    A common technique used to perform intralesional injection of a KA is the delivery of a total of five injections per lesion: a single injection into the center and one injection into each quadrant. The goal is to blanch the entire rim of the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Due to discomfort associated with the injection of 5-FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , local anesthesia is frequently given prior to these injections. In contrast, anesthesia is not usually necessary for the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and interferon [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/16\">",
"     16",
"    </a>",
"    ]. In all cases, surgical excision with histopathologic evaluation is recommended if lesions fail to respond as expected to intralesional therapy.",
"   </p>",
"   <p>",
"    The potential adverse effects common to these treatments include local pain, erythema, necrosis, ulceration, and crusting. The possibility that side effects associated with the systemic administration of these agents may occur must also be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/16\">",
"     16",
"    </a>",
"    ]. Pancytopenia has occurred in two hemodialysis-dependent patients with renal failure after treatment with 25 mg of intralesional MTX [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Thus, some authors have suggested obtaining a complete blood count before treatment and one week after injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1564847\">",
"    <span class=\"h3\">",
"     Radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the efficacy of radiation therapy for KA is supported by case series and case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/27-31\">",
"     27-31",
"    </a>",
"    ], this treatment is infrequently employed due to the multiple visits required and the potential long term consequences of radiation therapy. Radiation therapy is usually reserved for elderly patients for whom surgical treatment is not an option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link&amp;anchor=H12329859#H12329859\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\", section on 'Long-term complications'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Guidelines for the administration of radiation therapy for KA have not been established. Of note, radiation therapy was associated with the induction of numerous new lesions in a patient with multiple self-healing squamous epithelioma (Ferguson-Smith disease), a genetic disorder characterized by the development of multiple KAs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=see_link&amp;anchor=H2295938#H2295938\">",
"     \"Keratoacanthoma: Epidemiology, risk factors, and diagnosis\", section on 'Multiple keratoacanthomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H210572\">",
"    <span class=\"h3\">",
"     Topical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resolution of KA following topical application of 5-FU has been documented in case reports and case series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/33\">",
"     33",
"    </a>",
"    ]. A 5% formulation of 5-FU is typically applied daily, and resolution usually occurs within eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    5% cream has also been associated with lesion resolution within 4 to 11 weeks in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/36\">",
"     36",
"    </a>",
"    ]. Treatment is usually applied three to four times per week. Significant local inflammation commonly occurs during topical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H770586\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other therapies that have been reported to be effective in small numbers of patients with KA include treatment with curettage alone, cryotherapy, an argon laser [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/37\">",
"     37",
"    </a>",
"    ], an Er:YAG laser in combination with topical 5-FU [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/38\">",
"     38",
"    </a>",
"    ], and photodynamic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/39\">",
"     39",
"    </a>",
"    ]. Of note KA has been reported to occur as a consequence of trauma related to treatment with a fractional laser [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/40\">",
"     40",
"    </a>",
"    ], a CO",
"    <sub>",
"     2",
"    </sub>",
"    laser [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/41\">",
"     41",
"    </a>",
"    ], and cryotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Worsening of a KA lesion has also been documented after photodynamic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H770593\">",
"    <span class=\"h2\">",
"     Deferring therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the possibility for spontaneous resolution of solitary KA, occasional patients elect to defer therapy. When this approach is taken, close patient follow-up is recommended. Several guidelines have been proposed for the management of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Follow-up from presentation through resolution should be performed by a single clinician experienced in the natural history of these lesions",
"     </li>",
"     <li>",
"      The course of the lesion should be documented with photographs every two to three weeks until lesion resolution",
"     </li>",
"     <li>",
"      The patients must be informed that resolution may take six months or longer",
"     </li>",
"     <li>",
"      Patients should be informed of the option for surgical excision and other treatments",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We also inform patients who are considering deferring therapy of the possibility of aggressive lesion behavior and the chance for misdiagnosis of squamous cell carcinoma as KA. If, during the course of observation, the lesion develops an atypical appearance, growth fails to cease, or the tumor fails to regress as expected, surgical excision with histopathologic examination of the lesion is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=see_link&amp;anchor=H2295744#H2295744\">",
"     \"Keratoacanthoma: Epidemiology, risk factors, and diagnosis\", section on 'Solitary keratoacanthoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H770600\">",
"    <span class=\"h1\">",
"     SPECIAL CASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207224\">",
"    <span class=\"h2\">",
"     Multiple and large keratoacanthomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of numerous KAs, such as those seen in the rare multiple KA syndromes, and the extremely large lesions that characterize keratoacanthoma centrifugum marginatum presents unique challenges. Although surgical intervention and the other local therapies described above remain options for treatment, such therapies are usually impractical in patients with hundreds or thousands of lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=see_link&amp;anchor=H2295938#H2295938\">",
"     \"Keratoacanthoma: Epidemiology, risk factors, and diagnosis\", section on 'Multiple keratoacanthomas'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=see_link&amp;anchor=H15906018#H15906018\">",
"     \"Keratoacanthoma: Epidemiology, risk factors, and diagnosis\", section on 'Clinical variants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic agents are an additional option for these patients. Multiple case reports have documented the efficacy of oral retinoids in patients with multiple self-healing squamous epithelioma (MSSE) or generalized eruptive keratoacanthoma of Gryzybowski [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/32,45-57\">",
"     32,45-57",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     Acitretin",
"    </a>",
"    (25 to 60 mg per day) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    (20 mg per day to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) have been used for therapy. Between two and several months of treatment is usually required to achieve a satisfactory response.",
"   </p>",
"   <p>",
"    <br/>",
"    Although long-term maintenance therapy may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/45,50,55,57\">",
"     45,50,55,57",
"    </a>",
"    ], persistent remission after the discontinuation of therapy has been reported in individual patients with MSSE, eruptive keratoacanthomas of Grzybowski, and keratoacanthoma centrifugum marginatum [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Atrophic scars may remain at the sites of healed lesions.",
"   </p>",
"   <p>",
"    Multiple adverse effects are associated with systemic retinoid therapy, including cheilitis, xerosis, visual changes, transaminitis, hyperlipidemia, and teratogenicity. Pregnancy should be avoided for one month after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    therapy and for three years after the discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    . Thus, treatment with acitretin is usually avoided in women of child-bearing age.",
"   </p>",
"   <p>",
"    Other systemic therapies that have been used in a few patients with multiple KAs include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/58\">",
"     58",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/59\">",
"     59",
"    </a>",
"    ], and intravenous 5-FU [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H208437\">",
"    <span class=\"h2\">",
"     Subungual keratoacanthoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although spontaneous resolution of subungual KA has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/61,62\">",
"     61,62",
"    </a>",
"    ], these lesions typically persist [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/5\">",
"     5",
"    </a>",
"    ]. Surgical excision is the preferred therapeutic intervention. Curettage with or without electrodesiccation and systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    have also been utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Digital amputation is reserved for lesions that fail to respond to other therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H208445\">",
"    <span class=\"h2\">",
"     Muir-Torre variant of Lynch syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Muir-Torre variant of Lynch syndrome may present with sebaceous tumors, visceral malignancies, and KA. The management of patients with this syndrome is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1564331\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H287594\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incomplete removal of KA may result in lesion recurrence. As a group, the rate of recurrence after excision or ED&amp;C is estimated to be between 3 and 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1564338\">",
"    <span class=\"h2\">",
"     Involution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is generally well-accepted that solitary KAs usually spontaneously regress, detailed documentation of lesions followed through to regression is limited. In a retrospective review of 19 patients followed with serial photographs by a single clinician, four out of five patients who had the lesions surgically removed during observation did so due to concern about the clinical behavior of the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/8\">",
"     8",
"    </a>",
"    ]. Among the 14 patients followed to lesion involution, the mean time to resolution was 27 weeks. No recurrences were observed during patient follow-up, which ranged from nine months to eight years.",
"   </p>",
"   <p>",
"    The type of KA influences the likelihood for spontaneous resolution. Unlike solitary KA and individual lesions in multiple self-healing squamous epithelioma (Ferguson-Smith disease) and generalized eruptive keratoacanthoma of Grzybowski, involution is unlikely to occur in mucosal KA, subungual KA, and keratoacanthoma centrifugum marginatum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=see_link&amp;anchor=H15906018#H15906018\">",
"     \"Keratoacanthoma: Epidemiology, risk factors, and diagnosis\", section on 'Clinical variants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1564345\">",
"    <span class=\"h2\">",
"     Metastasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cases of metastatic KA have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/64-66\">",
"     64-66",
"    </a>",
"    ], the incidence of this appears to be exceedingly low and there is some question as to whether some or all of the few cases reported as metastatic KA actually represent the misdiagnosis of squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/1,67,68\">",
"     1,67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relevance of the histopathologic detection of perineural invasion in 1 to 4 percent of KAs, a finding associated with an increased risk for local recurrence and metastasis in cutaneous squamous cell carcinoma, is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. Perineural invasion in KA has generally been considered an incidental finding with little impact on prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/70,72\">",
"     70,72",
"    </a>",
"    ]. In the largest series documenting cases of KA with perineural invasion, 1 out of 40 lesions recurred and no metastases were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/69\">",
"     69",
"    </a>",
"    ]. However, aggressive local behavior of a KA with histopathologic evidence for perineural invasion has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24632/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1564574\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be instructed to return for reevaluation if signs of lesion regrowth occur after treatment. The appropriate interval for routine clinical follow-up is not standardized. We typically see patients with small, uncomplicated, solitary KAs six months after treatment for reevaluation of the treatment site and a full skin examination. We then follow these patients once yearly.",
"   </p>",
"   <p>",
"    Certain clinical scenarios may demand more frequent follow-up. Earlier and more frequent follow-up is appropriate for patients with large, aggressive, or multiple lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1564567\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since ultraviolet light exposure likely contributes to the development of KA, daily sun protective measures (application of sunscreen, use of sun-protective clothing, and midday sun avoidance) are recommended as a preventive measure. As noted above, patients with multiple KA syndromes may benefit from long term systemic retinoid therapy to reduce the development of new lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1564616\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Keratoacanthoma (KA) is a cutaneous squamoproliferative tumor with the potential for spontaneous resolution (",
"      <a class=\"graphic graphic_picture graphicRef55042 graphicRef81629 graphicRef59593 graphicRef73408 graphicRef52368 \" href=\"UTD.htm?43/19/44346\">",
"       picture 1A-E",
"      </a>",
"      ). Due to the difficulty in distinguishing KA from cutaneous squamous cell carcinoma, most authors recommend treatment of these lesions. (See",
"      <a class=\"local\" href=\"#H770530\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest surgical excision as the first-line treatment for KA (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Surgical excision provides pathologic confirmation of tumor removal. Conventional surgical excision may be performed on most lesions. Lesions in areas where tissue sparing is desired, such as the central face, can be treated with Mohs surgery. (See",
"      <a class=\"local\" href=\"#H380984\">",
"       'First-line therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other effective options for the treatment of KA include electrodesiccation and curettage (ED&amp;C), intralesional pharmacologic therapy, radiation therapy, and topical therapy. A disadvantage of these interventions compared to surgical excision is the lack of histopathologic confirmation of tumor removal. (See",
"      <a class=\"local\" href=\"#H770565\">",
"       'Alternative therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who elect to defer therapy and prefer to wait for lesion spontaneous resolution, close clinical follow-up should be implemented. Spontaneous resolution may take several months or longer. If lesions deviate from the expected clinical course, surgical excision to confirm the diagnosis is indicated. (See",
"      <a class=\"local\" href=\"#H770593\">",
"       'Deferring therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The local therapies commonly utilized for the management of solitary KA may be impractical for patients with hundreds or thousands of lesions. For patients with numerous KAs, we suggest treatment with oral retinoid therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/1\">",
"      Jackson IT. Diagnostic problem of keratoacanthoma. Lancet 1969; 1:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/2\">",
"      Karaa A, Khachemoune A. Keratoacanthoma: a tumor in search of a classification. Int J Dermatol 2007; 46:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/3\">",
"      Kingman J, Callen JP. Keratoacanthoma. A clinical study. Arch Dermatol 1984; 120:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/4\">",
"      Browne F, O'Connell M, Merchant W, et al. Spontaneous resolution of a giant keratoacanthoma penetrating through the nose. Clin Exp Dermatol 2011; 36:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/5\">",
"      Ko CJ. Keratoacanthoma: facts and controversies. Clin Dermatol 2010; 28:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/6\">",
"      Schwartz RA. Keratoacanthoma: a clinico-pathologic enigma. Dermatol Surg 2004; 30:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/7\">",
"      Schwartz RA. Keratoacanthoma. J Am Acad Dermatol 1994; 30:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/8\">",
"      Griffiths RW. Keratoacanthoma observed. Br J Plast Surg 2004; 57:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/9\">",
"      Garcia-Zuazaga J, Ke M, Lee P. Giant keratoacanthoma of the upper extremity treated with mohs micrographic surgery: a case report and review of current treatment modalities. J Clin Aesthet Dermatol 2009; 2:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/10\">",
"      Shriner DL, McCoy DK, Goldberg DJ, Wagner RF Jr. Mohs micrographic surgery. J Am Acad Dermatol 1998; 39:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/11\">",
"      Larson PO. Keratoacanthomas treated with Mohs' micrographic surgery (chemosurgery). A review of forty-three cases. J Am Acad Dermatol 1987; 16:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/12\">",
"      Nedwich JA. Evaluation of curettage and electrodesiccation in treatment of keratoacanthoma. Australas J Dermatol 1991; 32:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/13\">",
"      Cohen PR, Schulze KE, Teller CF, Nelson BR. Intralesional methotrexate for keratoacanthoma of the nose. Skinmed 2005; 4:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/14\">",
"      Annest NM, VanBeek MJ, Arpey CJ, Whitaker DC. Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature. J Am Acad Dermatol 2007; 56:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/15\">",
"      Melton JL, Nelson BR, Stough DB, et al. Treatment of keratoacanthomas with intralesional methotrexate. J Am Acad Dermatol 1991; 25:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/16\">",
"      Kirby JS, Miller CJ. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. J Am Acad Dermatol 2010; 63:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/17\">",
"      Goette DK, Odom RB. Successful treatment of keratoacanthoma with intralesional fluorouracil. J Am Acad Dermatol 1980; 2:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/18\">",
"      Martorell-Calatayud A, Requena C, Nagore E, et al. [Intralesional infusion of methotrexate as neoadjuvant therapy improves the cosmetic and functional results of surgery to treat keratoacanthoma: results of a randomized trial]. Actas Dermosifiliogr 2011; 102:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/19\">",
"      Andreassi A, Pianigiani E, Taddeucci P, et al. Guess what! Keratoacanthoma treated with intralesional bleomycin. Eur J Dermatol 1999; 9:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/20\">",
"      Sayama S, Tagami H. Treatment of keratoacanthoma with intralesional bleomycin. Br J Dermatol 1983; 109:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/21\">",
"      de la Torre C, Losada A, Cruces MJ. Keratoacanthoma centrifugum marginatum: treatment with intralesional bleomycin. J Am Acad Dermatol 1997; 37:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/22\">",
"      Rapaport J. Giant keratoacanthoma of the nose. Arch Dermatol 1975; 111:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/23\">",
"      Oh CK, Son HS, Lee JB, et al. Intralesional interferon alfa-2b treatment of keratoacanthomas. J Am Acad Dermatol 2004; 51:S177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/24\">",
"      Grob JJ, Suzini F, Richard MA, et al. Large keratoacanthomas treated with intralesional interferon alfa-2a. J Am Acad Dermatol 1993; 29:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/25\">",
"      Goebeler M, Lurz C, Kolve-Goebeler ME, Br&ouml;cker EB. Pancytopenia after treatment of keratoacanthoma by single lesional methotrexate infiltration. Arch Dermatol 2001; 137:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/26\">",
"      Cohen PR, Schulze KE, Nelson BR. Pancytopenia after a single intradermal infiltration of methotrexate. J Drugs Dermatol 2005; 4:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/27\">",
"      Caccialanza M, Sopelana N. Radiation therapy of keratoacanthomas: results in 55 patients. Int J Radiat Oncol Biol Phys 1989; 16:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/28\">",
"      Donahue B, Cooper JS, Rush S. Treatment of aggressive keratoacanthomas by radiotherapy. J Am Acad Dermatol 1990; 23:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/29\">",
"      Shimm DS, Duttenhaver JR, Doucette J, Wang CC. Radiation therapy of keratoacanthoma. Int J Radiat Oncol Biol Phys 1983; 9:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/30\">",
"      Basoglu Y, Metze D, Nashan D, St&auml;nder S. Keratoacanthoma with perineural invasion: an indicator for aggressive behavior? J Dtsch Dermatol Ges 2008; 6:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/31\">",
"      Goldschmidt H, Sherwin WK. Radiation therapy of giant aggressive keratoacanthomas. Arch Dermatol 1993; 129:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/32\">",
"      Robertson SJ, Bashir SJ, Pichert G, et al. Severe exacerbation of multiple self-healing squamous epithelioma (Ferguson-Smith disease) with radiotherapy, which was successfully treated with acitretin. Clin Exp Dermatol 2010; 35:e100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/33\">",
"      Moore AY. Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders. J Dermatolog Treat 2009; 20:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/34\">",
"      Gray RJ, Meland NB. Topical 5-fluorouracil as primary therapy for keratoacanthoma. Ann Plast Surg 2000; 44:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/35\">",
"      Ebner H, Mischer P. [The local treatment of the keratoacanthoma with 5-fluorouracil]. Hautarzt 1975; 26:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/36\">",
"      Jeon HC, Choi M, Paik SH, et al. Treatment of keratoacanthoma with 5% imiquimod cream and review of the previous report. Ann Dermatol 2011; 23:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/37\">",
"      Neumann RA, Knobler RM. Argon laser treatment of small keratoacanthomas in difficult locations. Int J Dermatol 1990; 29:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/38\">",
"      Thiele JJ, Ziemer M, Fuchs S, Elsner P. Combined 5-fluorouracil and Er:YAG laser treatment in a case of recurrent giant keratoacanthoma of the lower leg. Dermatol Surg 2004; 30:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/39\">",
"      Alloo A, Garibyan L, LeBoeuf N, et al. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol 2012; 148:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/40\">",
"      Mamelak AJ, Goldberg LH, Marquez D, et al. Eruptive keratoacanthomas on the legs after fractional photothermolysis: report of two cases. Dermatol Surg 2009; 35:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/41\">",
"      Gewirtzman A, Meirson DH, Rabinovitz H. Eruptive keratoacanthomas following carbon dioxide laser resurfacing. Dermatol Surg 1999; 25:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/42\">",
"      Bunker CB. Keratoacanthoma, trauma, and cryotherapy. Dermatol Surg 2011; 37:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/43\">",
"      Kaptanoglu AF, Kutluay L. Keratoacanthoma developing in previous cryotherapy site for solar keratosis. J Eur Acad Dermatol Venereol 2006; 20:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/44\">",
"      Yeon JH, Jung JY, Choi JW, et al. Keratoacanthoma aggravated after photodynamic therapy. J Dermatol 2010; 37:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/45\">",
"      Feldman RJ, Maize JC. Multiple keratoacanthomas in a young woman: report of a case emphasizing medical management and a review of the spectrum of multiple keratoacanthomas. Int J Dermatol 2007; 46:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/46\">",
"      Vandergriff T, Nakamura K, High WA. Generalized eruptive keratoacanthomas of Grzybowski treated with isotretinoin. J Drugs Dermatol 2008; 7:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/47\">",
"      Aydin F, Senturk N, Sabanciler E, et al. A case of Ferguson-Smith type multiple keratoacanthomas associated with keratoacanthoma centrifugum marginatum: response to oral acitretin. Clin Exp Dermatol 2007; 32:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/48\">",
"      Kato N, Ito K, Kimura K, Shibata M. Ferguson Smith type multiple keratoacanthomas and a keratoacanthoma centrifugum marginatum in a woman from Japan. J Am Acad Dermatol 2003; 49:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/49\">",
"      Benoldi D, Alinovi A. Multiple persistent keratoacanthomas: treatment with oral etretinate. J Am Acad Dermatol 1984; 10:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/50\">",
"      Haydey RP, Reed ML, Dzubow LM, Shupack JL. Treatment of keratoacanthomas with oral 13-cis-retinoic acid. N Engl J Med 1980; 303:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/51\">",
"      Ogasawara Y, Kinoshita E, Ishida T, et al. A case of multiple keratoacanthoma centrifugum marginatum: response to oral etretinate. J Am Acad Dermatol 2003; 48:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/52\">",
"      Blitstein-Willinger E, Haas N, N&uuml;rnberger F, St&uuml;ttgen G. Immunological findings during treatment of multiple keratoacanthoma with etretinate. Br J Dermatol 1986; 114:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/53\">",
"      Barysch MJ, Kamarashev J, Lockwood LL, Dummer R. Successful treatment of multiple keratoacanthoma with topical imiquimod and low-dose acitretin. J Dermatol 2011; 38:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/54\">",
"      Cherif F, Mebazaa A, Kort R, et al. [Multiple keratoacanthoma centrifugum marginatum]. Ann Dermatol Venereol 2002; 129:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/55\">",
"      Schaller M, Korting HC, Wolff H, et al. Multiple keratoacanthomas, giant keratoacanthoma and keratoacanthoma centrifugum marginatum: development in a single patient and treatment with oral isotretinoin. Acta Derm Venereol 1996; 76:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/56\">",
"      Shaw JC, Storrs FJ, Everts E. Multiple keratoacanthomas after megavoltage radiation therapy. J Am Acad Dermatol 1990; 23:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/57\">",
"      Shaw JC, White CR Jr. Treatment of multiple keratoacanthomas with oral isotretinoin. J Am Acad Dermatol 1986; 15:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/58\">",
"      Mangas C, Bielsa I, Ribera M, et al. A case of multiple keratoacanthoma centrifugum marginatum. Dermatol Surg 2004; 30:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/59\">",
"      Oakley A, Ng S. Grzybowski's generalized eruptive keratoacanthoma: remission with cyclophosphamide. Australas J Dermatol 2005; 46:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/60\">",
"      Agarwal M, Chander R, Karmakar S, Walia R. Multiple familial keratoacanthoma of Witten and Zak - A report of three siblings. Dermatology 1999; 198:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/61\">",
"      Sinha A, Marsh R, Langtry J. Spontaneous regression of subungual keratoacanthoma with reossification of underlying distal lytic phalynx. Clin Exp Dermatol 2005; 30:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/62\">",
"      Oliwiecki S, Peachey RD, Bradfield JW, et al. Subungual keratoacanthoma--a report of four cases and review of the literature. Clin Exp Dermatol 1994; 19:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/63\">",
"      Baran R, Goettmann S. Distal digital keratoacanthoma: a report of 12 cases and a review of the literature. Br J Dermatol 1998; 139:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/64\">",
"      Ansai S, Manabe M. Possible spontaneous regression of a metastatic lesion of keratoacanthoma-like squamous cell carcinoma in a regional lymph node. J Dermatol 2005; 32:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/65\">",
"      Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol 1993; 15:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/66\">",
"      Davis BA, Monheit GD, Kline L. Metastatic skin cancer presenting as ptosis and diplopia. Dermatol Surg 2006; 32:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/67\">",
"      Mandrell JC, Santa Cruz D. Keratoacanthoma: hyperplasia, benign neoplasm, or a type of squamous cell carcinoma? Semin Diagn Pathol 2009; 26:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/68\">",
"      Schnur PL, Bozzo P. Metastasizing keratoacanthomas? The difficulties in differentiating keratoacanthomas from squamous cell carcinomas. Plast Reconstr Surg 1978; 62:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/69\">",
"      Godbolt AM, Sullivan JJ, Weedon D. Keratoacanthoma with perineural invasion: a report of 40 cases. Australas J Dermatol 2001; 42:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/70\">",
"      Petrie M, Eliezri Y, Campanelli C. Keratoacanthoma of the head and neck with perineural invasion: incidental finding or cause for concern? Dermatol Surg 2010; 36:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24632/abstract/71\">",
"      Cooper PH, Wolfe JT 3rd. Perioral keratoacanthomas with extensive perineural invasion and intravenous growth. Arch Dermatol 1988; 124:1397.",
"     </a>",
"    </li>",
"    <li>",
"     Weedon D. Tumors of the epidermis. In: Weedon's Skin Pathology, 3rd Ed, Elsevier Limited, 2010. p.667.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17112 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-198.199.123.20-28C064E6EE-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_3_24632=[""].join("\n");
var outline_f24_3_24632=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1564616\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H771357\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H770530\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H770537\">",
"      SOLITARY KERATOACANTHOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H380984\">",
"      First-line therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H770544\">",
"      - Conventional surgical excision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H770551\">",
"      - Mohs surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H770565\">",
"      Alternative therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H380965\">",
"      - Electrodesiccation and curettage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H770579\">",
"      - Intralesional therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1564847\">",
"      - Radiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H210572\">",
"      - Topical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H770586\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H770593\">",
"      Deferring therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H770600\">",
"      SPECIAL CASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H207224\">",
"      Multiple and large keratoacanthomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H208437\">",
"      Subungual keratoacanthoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H208445\">",
"      Muir-Torre variant of Lynch syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1564331\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H287594\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1564338\">",
"      Involution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1564345\">",
"      Metastasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1564574\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1564567\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1564616\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/17112\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/17112|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/33/35347\" title=\"picture 1A\">",
"      Keratoacanthoma - face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/8/19592\" title=\"picture 1B\">",
"      Keratoacanthoma on ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/33/43539\" title=\"picture 1C\">",
"      Keratoacanthoma on hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/32/18949\" title=\"picture 1D\">",
"      Solitary keratoacanthoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/23/38262\" title=\"picture 1E\">",
"      Keratoacanthoma on eyelid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=related_link\">",
"      Keratoacanthoma: Epidemiology, risk factors, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=related_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=related_link\">",
"      Mohs surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=related_link\">",
"      Treatment of basal cell carcinomas at high risk for recurrence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_3_24633="Diagnosis and management of ischemic cardiomyopathy";
var content_f24_3_24633=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and management of ischemic cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/3/24633/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/3/24633/contributors\">",
"     James C Fang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/3/24633/contributors\">",
"     Sary Aranki, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/3/24633/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/3/24633/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/3/24633/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/3/24633/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/3/24633/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/3/24633/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term ischemic cardiomyopathy has been used to describe significantly impaired left ventricular function (left ventricular ejection fraction &le;35 to 40 percent) that results from coronary artery disease. Despite the common clinical use of the term ischemic cardiomyopathy, ventricular dysfunction caused by coronary disease is not a cardiomyopathy as defined by the 2006 American Heart Association and 2008 European Society of Cardiology statements. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link\">",
"     \"Definition and classification of the cardiomyopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two main pathogenetic mechanisms, which are importantly distinguished by the possibility of corrective therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Irreversible loss of myocardium due to prior myocardial infarction with ventricular remodeling. Recovery of myocardial function in such patients cannot be achieved by coronary revascularization since the infarcted tissue is not viable.",
"     </li>",
"     <li>",
"      At least partially reversible loss of contractility due to reduced function of ischemic but still viable myocardium, which can be detected on imaging studies. Hibernating myocardium is typically used interchangeably with viable myocardium. However, by strict definition, the term hibernating myocardium refers to contractile dysfunction in viable myocardium that improves after revascularization or perhaps medical therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/1\">",
"       1",
"      </a>",
"      ]. Stunned myocardium refers to transient postischemic dysfunction and can coexist with hibernating myocardium [",
"      <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8759?source=see_link\">",
"       \"Clinical syndromes of stunned or hibernating myocardium\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will emphasize the definition, incidence, and therapy of reversible ischemic cardiomyopathy. Diagnostic issues related to hibernating viable myocardium are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=see_link\">",
"     \"Evaluation of hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=see_link\">",
"     \"Dobutamine stress echocardiography in the evaluation of hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=see_link\">",
"     \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An effort to provide a standardized definition of ischemic cardiomyopathy was made in a review of 1921 patients with symptomatic heart failure (HF) and a left ventricular ejection fraction (LVEF) &lt;40 percent who underwent coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/3\">",
"     3",
"    </a>",
"    ]. Ischemic cardiomyopathy was considered to be present in patients with HF who have had a myocardial infarction (MI) or have evidence of viable hibernating myocardium or, on angiography, severe coronary disease. Such patients had a worse outcome than those with nonischemic cardiomyopathy. In contrast, patients with single vessel disease who had no history of myocardial infarction or revascularization had a similar prognosis as those with nonischemic cardiomyopathy. It was suggested that such patients should be classified as nonischemic cardiomyopathy, at least for prognostic purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, without evidence of prior infarction or viable myocardium, the presence of asymptomatic angiographic coronary artery disease in patients with dilated cardiomyopathy does not prove causality. The development of severe coronary disease as a secondary event was demonstrated in a study of 55 patients who underwent heart transplantation with a pretransplant diagnosis of idiopathic dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/4\">",
"     4",
"    </a>",
"    ]. All of the patients had had a normal coronary arteriogram within the preceding 10 years and none had a history of ischemic events. Examination of the explanted heart revealed critical lesions in at least one coronary artery segment in 15 patients (27 percent) with no evidence of scars.",
"   </p>",
"   <p>",
"    Similar findings were noted in a report of 291 patients with biventricular dysfunction and no history of myocardial infarction who underwent coronary angiography and endomyocardial biopsy because of progressive HF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/5\">",
"     5",
"    </a>",
"    ]. Seven had severe coronary artery disease, but biopsy specimens in each of these patients showed extensive histologic changes that met criteria for myocarditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic cardiomyopathy is the most common cause of heart failure (HF) in developed countries. In the United States, for example, the population-attributable risk has been estimated to be 68 percent in men and 56 percent in women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology and causes of heart failure\", section on 'Frequency of various causes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of late HF after an acute myocardial infarction (MI) was evaluated in a prospective study of 1044 such patients who were discharged in stable condition [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/7\">",
"     7",
"    </a>",
"    ]. At a median follow-up of 23 months, 112 patients (10.7 percent) were readmitted for the treatment of HF. These patients, compared to those without HF, were significantly more likely to have had a recurrent MI (15.2 versus 6.0 percent).",
"   </p>",
"   <p>",
"    A much higher rate associated with longer follow-up was noted in a review of 1915 patients with an acute MI and no prior history of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/8\">",
"     8",
"    </a>",
"    ]. At a mean follow-up of 6.6 years, new onset HF developed in 791 patients (41 percent); the mean age at diagnosis of HF was 73 years.",
"   </p>",
"   <p>",
"    The development of HF after an MI is related to a variety of factors including the size and location of the infarct, the presence of ischemic mitral regurgitation (MR), and perhaps inflammatory status as assessed by serum C-reactive protein [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. The importance of ischemic mitral regurgitation (MR) was illustrated in one series of 1331 patients with an acute MI in which echocardiography was performed within 30 days in 773 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/9\">",
"     9",
"    </a>",
"    ]. The five-year rate of survival free of heart failure was related to the presence and severity of MR (84, 74, and 35 percent with no, mild, and moderate to severe MR, respectively). The relative risk of HF was 3.44 in patients with moderate to severe MR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with ischemic cardiomyopathy have a clear clinical history of coronary heart disease. However, some patients have no such history. This was illustrated in a review of 1230 patients with an initially unexplained cardiomyopathy; ischemic heart disease was responsible for 7 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of ischemic cardiomyopathy is an independent predictor of mortality; in addition, the extent of coronary artery disease as determined by angiography contributes more prognostic information than the clinical diagnosis of an ischemic cardiomyopathy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/11\">",
"     11",
"    </a>",
"    ]. The diagnostic approach to ischemic cardiomyopathy consists of two steps: the detection of clinically significant coronary artery disease; and the detection of potentially reversible hibernating (ie, viable) myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Detection of coronary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the frequency of ischemic heart disease as a cause of heart failure (HF) and the observation that it also accounts for some cases of initially unexplained HF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/10\">",
"     10",
"    </a>",
"    ], evaluation for coronary artery disease (CAD) is usually part of the evaluation of patients with newly diagnosed HF. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=see_link&amp;anchor=H19#H19\">",
"     \"Evaluation of the patient with heart failure or cardiomyopathy\", section on 'Detection of coronary artery disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, chest pain alone is not sufficient to make the diagnosis since up to one-third of patients with nonischemic cardiomyopathy have chest pain that may resemble angina or be atypical [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/12\">",
"     12",
"    </a>",
"    ]. The evaluation for CAD typically consists of exercise stress testing, often with some form of myocardial imaging, which can detect ischemia and provides prognostic information by assessment of exercise capacity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coronary arteriography (",
"    <a class=\"graphic graphic_algorithm graphicRef66922 \" href=\"UTD.htm?26/47/27390\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The 2009",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on HF concluded that cardiac catheterization with angiography is indicated in virtually all patients with new onset heart failure of uncertain cause. Unless the patient is not eligible for revascularization of any kind, the following recommendations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary arteriography should be performed in patients presenting with HF who have angina or significant ischemia and is reasonable in patients who have chest pain that may or may not be cardiac in origin in whom cardiac anatomy is not known and in patients with known or suspected coronary artery disease who do not have angina.",
"     </li>",
"     <li>",
"      Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients with known coronary artery disease and no angina. In comparison, the evidence was considered less well established, but that noninvasive imaging may be considered to define the likelihood of coronary artery disease in all patients with HF and left ventricular dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is essential that the angiographic findings be considered in the context of the patient's history and other data. As mentioned above, the presence of asymptomatic angiographic coronary artery disease in patients with dilated cardiomyopathy does not prove causality unless there is evidence of prior infarction or hibernating myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although scintigraphic and echocardiographic techniques have traditionally been the noninvasive ischemia tests of choice, noninvasive coronary arteriography, including the use of multidetector row or electron beam computed tomography (CT) and cardiovascular magnetic resonance imaging (CMR) are also being evaluated. The options include CT or CMR angiography and detection of coronary artery calcification by CT or late gadolinium enhancement by CMR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=see_link\">",
"     \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Detection of viable (hibernating) myocardium",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the 2009",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on chronic heart failure (HF) concluded that, unless the patient is not a candidate for revascularization of any kind, noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients with known coronary artery disease and no angina [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/12\">",
"     12",
"    </a>",
"    ]. The guidelines also noted that, although the efficacy is less well established, noninvasive imaging may be considered to define the likelihood of coronary artery disease in other patients with HF and left ventricular dysfunction. The efficacy of the methods used to detect regions of viable myocardium in which function might improve after revascularization is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=see_link\">",
"     \"Evaluation of hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENERAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical management of ischemic cardiomyopathy is similar to that of nonischemic cardiomyopathy and includes both pharmacologic and, in selected patients, device-related strategies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical therapy of heart failure (HF) with systolic dysfunction, as recommended in the 2009",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on chronic heart failure can be summarized as following [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following therapies are appropriate for all patients, unless a contraindication is present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An angiotensin converting enzyme (ACE) inhibitor to slow progression of the HF and improve survival.",
"     </li>",
"     <li>",
"      A beta blocker, also to slow progression of the HF and improve survival; the benefits of ACE inhibitors and beta blockers are additive. There is some evidence that presurgical beta blockers therapy increases the likelihood that surgical revascularization improves outcomes when myocardial viability is present [",
"      <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Improvement in LVEF'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A loop diuretic and dietary salt restriction to correct fluid overload.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, drugs that can adversely affect patients with heart failure due to systolic dysfunction should be avoided or withdrawn. These include nonsteroidal antiinflammatory drugs, most antiarrhythmic drugs, and the non-dihydropyridine calcium channel blockers (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30438?source=see_link\">",
"     \"Calcium channel blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following should be given to selected patients in the absence of a contraindication:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The addition of the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      and a nitrate for patients (particularly blacks) with a reduced left ventricular ejection fraction (LVEF) who have persistent symptoms despite therapy with an ACE inhibitor and beta blocker.",
"     </li>",
"     <li>",
"      The addition of an aldosterone antagonist (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      or, if not tolerated,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      ) to improve survival in patients with NYHA class II, III, or IV symptoms (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ) and a reduced left ventricular ejection fraction who can be monitored for preserved renal function and a normal plasma potassium concentration. Aldosterone antagonists also may be used to assist in the management of diuretic-induced hypokalemia (plasma potassium &le;3.8",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      in patients with mild-to-moderate HF.",
"     </li>",
"     <li>",
"      Angiotensin II receptor blockers (ARBs) as an alternative to ACE inhibitors in patients who cannot tolerate these drugs; the addition of an ARB to an ACE inhibitor may be considered in patients who are persistently symptomatic and have a reduced left ventricular ejection fraction despite being treated with conventional therapy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      to reduce hospitalization for HF or for rate control in patients with concomitant atrial fibrillation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Device therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to these pharmacologic therapies, two types of devices are recommended in selected patients with HF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An implantable cardioverter-defibrillator (ICD) for secondary prevention of sudden cardiac death (SCD) and for primary prevention in selected patients. The criteria for ICD implantation are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link\">",
"       \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link\">",
"       \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac resynchronization therapy with biventricular pacing can improve symptoms and survival in patients who are in sinus rhythm and have an LVEF &le;35 percent, cardiac dyssynchrony, which is currently defined as a prolonged QRS duration (&ge;120 msec), and symptoms (NYHA class II, III or IV HF) despite optimal medical therapy. Most patients who satisfy these criteria are also candidates for an ICD and receive a combined device. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"       \"Cardiac resynchronization therapy in heart failure: Indications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Asymptomatic left ventricular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because echocardiography is commonly performed in patients who have had a myocardial infarction (MI) or have undergone revascularization, asymptomatic left ventricular dysfunction may be detected. Patients at high risk for the development of symptomatic heart failure in these settings should be treated with an ACE inhibitor and beta blocker. Two such groups have been identified: those with an left ventricular ejection fraction (LVEF) &le;40 percent; and those with an acute anterior wall MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=see_link\">",
"     \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Risk factor reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive risk factor reduction for secondary prevention is indicated in many patients with ischemic cardiomyopathy. This includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , control of hypertension and diabetes, and cessation of smoking. Exercise programs are also important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=see_link\">",
"     \"Cardiac rehabilitation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The issue of whether the initiation of statin therapy in patients with ischemic cardiomyopathy improves outcomes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24453?source=see_link&amp;anchor=H4#H4\">",
"     \"Statin therapy in patients with heart failure\", section on 'Statins in systolic HF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     REVASCULARIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An estimated 20 to more than 50 percent of patients with chronic ischemic left ventricular dysfunction have a significant amount of viable myocardium and the potential for clinically important improvement in LV function after revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Most observational studies suggested that revascularization of viable myocardium in patients with ischemic cardiomyopathy improved both survival and left ventricular function compared to medical therapy. The intention-to-treat analysis from a subsequent large randomized trial",
"    <strong>",
"    </strong>",
"    suggests that optimal medical therapy may be as good as surgical revascularization for such patients, although some secondary analyses of the data based on treatment received suggest a benefit from surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2011",
"    <span class=\"nowrap\">",
"     ACCF/AHA",
"    </span>",
"    Guideline for coronary artery bypass graft (CABG) surgery and the 2012 European Society of Cardiology guideline for the diagnosis and treatment of heart failure discuss surgical revascularization in patients with heart failure and reduced left ventricular function and a variety of coronary anatomies (significant left main disease, left main equivalent disease [&ge;70 percent stenosis of the proximal LAD and proximal left circumflex arteries], proximal LAD stenosis with two or three vessel disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that most patients with LVEF of 35 percent or less and coronary artery disease amenable to CABG surgery be treated with an initial course of medical therapy alone rather than medical therapy plus CABG surgery. CABG surgery, however, may be preferred by patients who are willing to accept the increased risk of morbidity related to surgery in exchange for a potentially greater mortality benefit versus medical therapy alone. Revascularization should also be considered for patients with ongoing anginal symptoms despite optimal medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Improvement in survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most but not all observational studies have found that revascularization of viable hibernating myocardium in patients with ischemic cardiomyopathy improves both survival and left ventricular function compared to medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/2,14,16,21-31\">",
"     2,14,16,21-31",
"    </a>",
"    ]. In many of these studies, the presence of angina was also required, which may have served as a clinical indicator of extensive viability. However, as is the case with nonrandomized trials, observational studies have important limitations, including selection bias in patients who undergo coronary artery bypass graft (CABG) surgery, a lesser likelihood of publication of negative studies, and uncertain applicability to current practice due to lack of use of current medical therapies (eg, statins). Data from a large subsequent randomized trial",
"    <strong>",
"    </strong>",
"    have not supported the observational data, showing no significant improvement in mortality between surgical revascularization plus medical therapy and optimal medical therapy alone as an initial management strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/18,32\">",
"     18,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential survival benefit from revascularization was best demonstrated in a 2002 meta-analysis of 24 nonrandomized viability studies involving 3088 patients with coronary artery disease and left ventricular dysfunction who had a mean left ventricular ejection fraction (LVEF) of 32 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with myocardial viability had a significant 80 percent reduction in annual mortality with revascularization (3.2 versus 16 percent with medical therapy), while there was no difference in annual mortality with revascularization in patients without myocardial viability (annual mortality 7.7 versus 6.2 percent with medical therapy). In observational studies, the likelihood of improved survival after revascularization in patients with ischemic cardiomyopathy appeared to be related to the amount of viable myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/2,33\">",
"     2,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2011, the Surgical Treatment for Ischemic Heart Failure (STICH) trial was the first randomized trial to compare surgical revascularization with medical therapy in patients with LVEF of 35 percent or less and coronary artery disease amenable to CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/18\">",
"     18",
"    </a>",
"    ]. The STICH trial randomly assigned 1212 patients to medical therapy plus CABG surgery or medical therapy alone. All patients underwent coronary angiography to define the extent of coronary disease; patients with critical left main coronary disease or unstable coronary syndromes were excluded from the trial. The primary outcome of the study was all cause mortality, with two additional prespecified secondary outcomes (cardiovascular mortality, combination of all-cause mortality and hospitalization for cardiac causes). At a median follow-up of 56 months, medical therapy plus CABG surgery resulted in the following outcomes when compared with medical therapy alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No significant improvement in the primary outcome of all-cause mortality (36 versus 41 percent with medical therapy alone, hazard ratio 0.86, 95% CI 0.72 to 1.04).",
"     </li>",
"     <li>",
"      Significantly lower rates of both secondary endpoints:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cardiovascular mortality (28 versus 33 percent with medical therapy alone; HR 0.81, 95% CI 0.66 to 1.00)",
"     </li>",
"     <li>",
"      All cause mortality plus cardiac hospitalization (58 versus 68 percent with medical therapy alone; HR 0.74, 95% CI 0.64 to 0.85)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the STICH trial, 9 percent of the patients assigned to the medical therapy plus CABG group did not receive CABG, and 17 percent of the patients assigned to the medical therapy alone group underwent CABG during the study period. Crossover between the treatment groups may have led to a diminished treatment benefit, thereby preventing the primary outcome from reaching statistical significance. In an attempt to assess the effects of the treatment received, the investigators reanalyzed the data comparing the 537 patients randomized to medical therapy alone (who did not ultimately cross over and receive CABG) and the 555 patients randomized to medical therapy plus CABG (who actually received CABG). Using this per-protocol analysis, there was a significant reduction in the primary endpoint of all-cause mortality in the medical therapy plus CABG group (HR 0.76, 95% CI 0.62 to 0.92). However, caution should be used in interpreting these results given the introduction of bias due to the exclusion of patients who did not receive their randomly assigned treatment.",
"   </p>",
"   <p>",
"    In a substudy of the STICH trial, 601 of the 1212 patients were evaluated for myocardial viability, then were randomly assigned to receive medical therapy plus CABG surgery or medical therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/32\">",
"     32",
"    </a>",
"    ]. Following adjustment for differences in baseline variables, there was no significant improvement in mortality with medical therapy plus CABG surgery compared to medical therapy alone. In addition, there was no significant improvement in mortality for patients with myocardial viability (compared to those without myocardial viability) regardless of treatment assignment.",
"   </p>",
"   <p>",
"    In a post-hoc analysis of patients in the STICH trial with moderate or severe mitral regurgitation, those who underwent mitral valve surgery at the time of CABG had better survival compared with those undergoing CABG alone (adjusted HR 0.41, 95% CI 0.22-0.77) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/34\">",
"     34",
"    </a>",
"    ]. Unlike the primary component of STICH where patients were randomized to CABG or medical therapy, mitral valve surgery was non-randomized and performed at the surgeon's discretion; therefore, these results should be considered to be hypothesis generating for a future randomized trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For most patients with LVEF of 35 percent or less and coronary artery disease amenable to CABG surgery, we suggest an initial course of optimal medical therapy alone rather than medical therapy plus CABG surgery. This is based on the significant morbidity associated with CABG surgery. Following initiation of medical therapy, patients should be reevaluated on an ongoing basis for any chances in clinical status or symptoms. CABG surgery as initial therapy, however, may be preferred by patients who are willing to accept the increased risk of morbidity related to surgery in exchange for a potential mortality benefit versus optimal medical therapy alone. In addition, revascularization should be considered for patients with ongoing anginal symptoms despite optimal medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Improvement in LVEF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The improvement in survival after revascularization in patients with myocardial viability is typically associated with an increase in left ventricular ejection fraction (LVEF). This was illustrated in a review of 29 studies of 758 patients in which there was a mean increase in LVEF of about 8 percent after revascularization when myocardial viability was present (37 versus 45 percent) compared to no change in the absence of viability (36 versus 37 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recovery of contractile function after restoration of normal flow to areas of viable (ie, hibernating) myocardium can take several days, weeks, or even months after blood flow is restored [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/16\">",
"     16",
"    </a>",
"    ]. The improvement in LVEF is associated with reverse left ventricular remodeling, which is characterized by reductions in the left ventricular end-systolic and end-diastolic dimensions and a less spherical shape of the left ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The degree of improvement is significantly correlated with the number of segments that recover function after revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/36,38\">",
"     36,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may also be a time window during which revascularization will result in improved contractility. Despite evidence of viability by noninvasive means, late revascularization may not result in measurable improvements in contractility.",
"   </p>",
"   <p>",
"    Left ventricular size may be a determinant of outcome after surgical revascularization in patients with ischemic cardiomyopathy. When the left ventricular end diastolic dimension is greater than 7.0 cm (4.0 cm per m2), operative mortality is high and surgery should be carefully reconsidered. The impact of left ventricular enlargement on the improvement in left ventricular function after surgery was illustrated in a review of 61 patients with ischemic heart disease and a mean LVEF of 28 percent, all of whom had evidence of myocardial viability [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/39\">",
"     39",
"    </a>",
"    ]. However, one-third of patients had no increase in LVEF despite the presence of substantial viability. The patients with a significant improvement in LVEF (&ge;5 percent) had a significantly smaller left ventricular end-systolic volume by echocardiography than those without improvement (121 versus 153 mL).",
"   </p>",
"   <p>",
"    There is some evidence that presurgical medical therapy with beta blockers can increase the likelihood that surgical revascularization will improve outcomes when viability is present. In the CHRISTMAS trial of 387 patients with ischemic cardiomyopathy treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    or placebo, there was a significant linear relationship between the number of cardiac segments with viable myocardium at baseline and the improvement in LVEF seen at six months with carvedilol therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/13\">",
"     13",
"    </a>",
"    ]. Beta blockade may improve the function of viable but hibernating myocardium by reducing myocardial oxygen consumption and increasing diastolic perfusion.",
"   </p>",
"   <p>",
"    Improved survival after coronary artery bypass graft (CABG) surgery may not require an improvement in LVEF. This was suggested in a study of 104 consecutive survivors of CABG by a single surgeon with a baseline LVEF &le;30 percent (mean 24 percent); the LVEF was measured again after CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/30\">",
"     30",
"    </a>",
"    ]. The postoperative LVEF increased over the baseline value by more than 5 percent in about two-thirds of patients (24 to 39 percent) and was unchanged in the remaining one-third (24 versus 23 percent). Survival free of cardiac death at a mean of 32 months was similar in the two groups (93 and 94 percent).",
"   </p>",
"   <p>",
"    The authors concluded that effective revascularization of ischemic myocardium protects against future MI and cardiac death even without improvement in the LVEF. Another possible contributor is that, since most repeat LVEF studies were performed soon after CABG (median seven days, mean 16 days), late improvement in left ventricular function noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/16\">",
"     16",
"    </a>",
"    ] would have been missed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     PCI and comparison to CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients in the above studies underwent coronary artery bypass graft (CABG) surgery as the method of revascularization. Among patients who undergo percutaneous coronary intervention (PCI) with stenting, multivariate risk models have identified the presence of heart failure of any cause as an adverse predictor of outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, outcomes after PCI in patients with heart failure continue to improve with enhancements in care (eg, stents, antiplatelet therapy). This was illustrated in a report from the National Heart, Lung and Blood Institute Dynamic Registry of 236 patients with heart failure who underwent PCI from 1997 to 2001; the outcomes were compared to those in 117 patients with heart failure in the 1985 to 1986 PTCA registry [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/40\">",
"     40",
"    </a>",
"    ]. The patients in the later registry had a significantly higher rate of many adverse predictors including older age, diabetes, hypertension, severe noncardiac disease, a lower left ventricular ejection fraction (LVEF), and triple vessel disease. Despite being at increased risk, the patients in the later registry had significantly lower rates of in-hospital mortality (3.8 versus 9.4 percent in the PTCA registry) and, at one year, myocardial infarction (7.4 versus 15.3 percent) or CABG (6.8 versus 18.7 percent).",
"   </p>",
"   <p>",
"    Data are limited on the relative efficacy of PCI. Some information comes from a post hoc analysis from the AWESOME trial of CABG versus PCI in 454 patients who had medically refractory unstable or provocable ischemia after stabilization with medical therapy; 94 of the patients had an LVEF &lt;35 percent (mean 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/41\">",
"     41",
"    </a>",
"    ]. Among these patients as well as patients with an LVEF &lt;35 percent in the nonrandomized AWESOME registry, there was no difference in mortality with CABG or PCI. However, this was a trial of patients with angina and acute coronary syndromes, not heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link&amp;anchor=H23#H23\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\", section on 'PCI versus CABG'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ischemic MR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic mitral regurgitation, which is most often functional, is common in patients with ischemic cardiomyopathy. Issues related to the epidemiology, pathogenesis, and management of ischemic MR are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Potential heart transplant candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been estimated that more than 10 percent of patients referred for consideration of cardiac transplantation have an element of viable myocardium contributing to severe left ventricular contractile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Strong consideration of coronary artery bypass graft (CABG) surgery for these patients as an alternative to heart transplantation is supported by several observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/3/24633/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Given that these studies were performed prior to widespread use of percutaneous coronary intervention (PCI), it might be reasonable to consider PCI as an alternative means of revascularization in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     LEFT VENTRICULAR RECONSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic cardiomyopathy is often associated with both dyskinetic and akinetic segments of the left ventricle due to both infarction and ischemia. Such changes lead to an increase in the sphericity of the ventricle, increasing wall stress. Surgical remodeling of the ventricle involves resection of these segments (usually in the anterior wall) to reestablish the mechanically efficient elliptical structure of the left ventricle; this procedure can be combined with CABG. Despite these theoretical benefits, a randomized trial of 1000 patients with ischemic cardiomyopathy and an anterior akinetic or dyskinetic region of myocardium amenable to ventricular reconstruction found that the addition of left ventricular reconstruction to CABG did not improve outcomes compared to CABG alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35143?source=see_link&amp;anchor=H4#H4\">",
"     \"Surgical management of heart failure\", section on 'Left ventricular reconstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     STEM CELL AND AUTOLOGOUS MYOBLAST TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is suggestive evidence that stem cell and autologous myoblast transplantation may be associated with long-term improvement in left ventricular function in patients with ischemic cardiomyopathy. The data describing the possible efficacy of this still experimental approach are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18617?source=see_link\">",
"     \"Genetic and cellular therapy in heart failure and myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term ischemic cardiomyopathy has been used to describe significantly impaired left ventricular function (left ventricular ejection fraction &le;35 to 40 percent) that results from coronary artery disease. Ischemic cardiomyopathy can result from irreversible loss of myocardium due to prior myocardial infarction or from reversible loss of contractility due to chronically ischemic but still viable myocardium. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ischemic cardiomyopathy is the most common cause of heart failure in developed countries. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two main steps in the evaluation of patients with left ventricular dysfunction in terms of determining the contribution of coronary disease and the possible role of revascularization:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Coronary angiography is performed to determine if coronary disease is present (if not already known) and if the coronary anatomy is suitable for revascularization. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Detection of coronary disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Imaging is used to determine the possible presence and extent of viable myocardium. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Detection of viable (hibernating) myocardium'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=see_link\">",
"       \"Evaluation of hibernating myocardium\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The decision to proceed with medical therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      revascularization in patients with ischemic cardiomyopathy is complex and should be individualized to each patient based on a variety of factors (ie, extent of disease, symptoms, comorbidities, etc). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'General therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Revascularization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical therapy for patients with ischemic cardiomyopathy is similar to that for patients with heart failure and systolic dysfunction of any etiology and includes angiotensin converting enzyme inhibitors, beta blockers, and diuretics with dietary salt restriction in patients with fluid overload. Other therapies to consider in selected patients include the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      and a nitrate, aldosterone antagonists, angiotensin II receptor blockers,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For most patients with LVEF of 35 percent or less and coronary artery disease amenable to CABG surgery, we suggest an initial course of optimal medical therapy alone rather than medical therapy plus CABG surgery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This is based on the significant morbidity associated with CABG surgery. Following initiation of medical therapy, patients should be reevaluated on an ongoing basis for any chances in clinical status or symptoms. CABG surgery as initial therapy, however, may be preferred by patients who are willing to accept the increased risk of morbidity related to surgery in exchange for a potential mortality benefit versus optimal medical therapy alone. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Improvement in survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Revascularization remains an important treatment option for patients with ongoing anginal symptoms despite optimal medical therapy. For such patients, the relative efficacy of percutaneous coronary intervention (PCI) compared with CABG for revascularization is unknown. In one nonrandomized registry, there was no difference in mortality between CABG and PCI. However, the presence of heart failure of any cause may be an adverse predictor of outcomes in patients undergoing PCI. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'PCI and comparison to CABG'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/1\">",
"      Underwood SR, Bax JJ, vom Dahl J, et al. Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardiology. Eur Heart J 2004; 25:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/2\">",
"      Chareonthaitawee P, Gersh BJ, Araoz PA, Gibbons RJ. Revascularization in severe left ventricular dysfunction: the role of viability testing. J Am Coll Cardiol 2005; 46:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/3\">",
"      Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002; 39:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/4\">",
"      Repetto A, Dal Bello B, Pasotti M, et al. Coronary atherosclerosis in end-stage idiopathic dilated cardiomyopathy: an innocent bystander? Eur Heart J 2005; 26:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/5\">",
"      Frustaci A, Chimenti C, Maseri A. Global biventricular dysfunction in patients with asymptomatic coronary artery disease may be caused by myocarditis. Circulation 1999; 99:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/6\">",
"      He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001; 161:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/7\">",
"      Suleiman M, Khatib R, Agmon Y, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 2006; 47:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/8\">",
"      Hellermann JP, Jacobsen SJ, Redfield MM, et al. Heart failure after myocardial infarction: clinical presentation and survival. Eur J Heart Fail 2005; 7:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/9\">",
"      Bursi F, Enriquez-Sarano M, Nkomo VT, et al. Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation. Circulation 2005; 111:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/10\">",
"      Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/11\">",
"      Bart BA, Shaw LK, McCants CB Jr, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 1997; 30:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/12\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/13\">",
"      Cleland JG, Pennell DJ, Ray SG, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 2003; 362:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/14\">",
"      Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/15\">",
"      Bonow RO. The hibernating myocardium: implications for management of congestive heart failure. Am J Cardiol 1995; 75:17A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/16\">",
"      Ragosta M, Beller GA, Watson DD, et al. Quantitative planar rest-redistribution 201Tl imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation 1993; 87:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/17\">",
"      Auerbach MA, Sch&ouml;der H, Hoh C, et al. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation 1999; 99:2921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/18\">",
"      Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011; 364:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/19\">",
"      Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/20\">",
"      McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/21\">",
"      Brundage BH, Massie BM, Botvinick EH. Improved regional ventricular function after successful surgical revascularization. J Am Coll Cardiol 1984; 3:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/22\">",
"      Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/23\">",
"      Lee KS, Marwick TH, Cook SA, et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation 1994; 90:2687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/24\">",
"      Elefteriades JA, Tolis G Jr, Levi E, et al. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol 1993; 22:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/25\">",
"      Pagley PR, Beller GA, Watson DD, et al. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation 1997; 96:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/26\">",
"      Baer FM, Theissen P, Schneider CA, et al. Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularization. J Am Coll Cardiol 1998; 31:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/27\">",
"      Wellnhofer E, Olariu A, Klein C, et al. Magnetic resonance low-dose dobutamine test is superior to SCAR quantification for the prediction of functional recovery. Circulation 2004; 109:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/28\">",
"      Bax JJ, Poldermans D, Elhendy A, et al. Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography. J Am Coll Cardiol 1999; 34:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/29\">",
"      Eitzman D, al-Aouar Z, Kanter HL, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992; 20:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/30\">",
"      Samady H, Elefteriades JA, Abbott BG, et al. Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome. Circulation 1999; 100:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/31\">",
"      Gerber BL, Rousseau MF, Ahn SA, et al. Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy. J Am Coll Cardiol 2012; 59:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/32\">",
"      Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011; 364:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/33\">",
"      Desideri A, Cortigiani L, Christen AI, et al. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 2005; 46:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/34\">",
"      Deja MA, Grayburn PA, Sun B, et al. Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. Circulation 2012; 125:2639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/35\">",
"      Bax JJ, van der Wall EE, Harbinson M. Radionuclide techniques for the assessment of myocardial viability and hibernation. Heart 2004; 90 Suppl 5:v26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/36\">",
"      Carluccio E, Biagioli P, Alunni G, et al. Patients with hibernating myocardium show altered left ventricular volumes and shape, which revert after revascularization: evidence that dyssynergy might directly induce cardiac remodeling. J Am Coll Cardiol 2006; 47:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/37\">",
"      Rahimtoola SH, La Canna G, Ferrari R. Hibernating myocardium: another piece of the puzzle falls into place. J Am Coll Cardiol 2006; 47:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/38\">",
"      Jones RH, Velazquez EJ, Michler RE, et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 2009; 360:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/39\">",
"      Schinkel AF, Poldermans D, Rizzello V, et al. Why do patients with ischemic cardiomyopathy and a substantial amount of viable myocardium not always recover in function after revascularization? J Thorac Cardiovasc Surg 2004; 127:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/40\">",
"      Holper EM, Blair J, Selzer F, et al. The impact of ejection fraction on outcomes after percutaneous coronary intervention in patients with congestive heart failure: an analysis of the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry and Dynamic Registry. Am Heart J 2006; 151:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/41\">",
"      Sedlis SP, Ramanathan KB, Morrison DA, et al. Outcome of percutaneous coronary intervention versus coronary bypass grafting for patients with low left ventricular ejection fractions, unstable angina pectoris, and risk factors for adverse outcomes with bypass (the AWESOME Randomized Trial and Registry). Am J Cardiol 2004; 94:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/42\">",
"      Luu M, Stevenson LW, Brunken RC, et al. Delayed recovery of revascularized myocardium after referral for cardiac transplantation. Am Heart J 1990; 119:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/43\">",
"      Louie HW, Laks H, Milgalter E, et al. Ischemic cardiomyopathy. Criteria for coronary revascularization and cardiac transplantation. Circulation 1991; 84:III290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/44\">",
"      Bortman G, Sellanes M, Odell DS, et al. Discrepancy between pre- and post-transplant diagnosis of end-stage dilated cardiomyopathy. Am J Cardiol 1994; 74:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/45\">",
"      Mickleborough LL, Maruyama H, Takagi Y, et al. Results of revascularization in patients with severe left ventricular dysfunction. Circulation 1995; 92:II73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/3/24633/abstract/46\">",
"      Kron IL, Flanagan TL, Blackbourne LH, et al. Coronary revascularization rather than cardiac transplantation for chronic ischemic cardiomyopathy. Ann Surg 1989; 210:348.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1507 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_3_24633=[""].join("\n");
var outline_f24_3_24633=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Detection of coronary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Detection of viable (hibernating) myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENERAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Device therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Asymptomatic left ventricular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      REVASCULARIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Improvement in survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Improvement in LVEF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PCI and comparison to CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ischemic MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Potential heart transplant candidates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      LEFT VENTRICULAR RECONSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      STEM CELL AND AUTOLOGOUS MYOBLAST TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1507\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1507|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/47/27390\" title=\"algorithm 1\">",
"      Detection Rx ischemic CMP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1507|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=related_link\">",
"      Assessment of myocardial viability by nuclear imaging in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30438?source=related_link\">",
"      Calcium channel blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=related_link\">",
"      Cardiac rehabilitation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8759?source=related_link\">",
"      Clinical syndromes of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=related_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=related_link\">",
"      Dobutamine stress echocardiography in the evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=related_link\">",
"      Epidemiology and causes of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=related_link\">",
"      Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=related_link\">",
"      Evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=related_link\">",
"      Evaluation of the patient with heart failure or cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18617?source=related_link\">",
"      Genetic and cellular therapy in heart failure and myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=related_link\">",
"      Ischemic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=related_link\">",
"      Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24453?source=related_link\">",
"      Statin therapy in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35143?source=related_link\">",
"      Surgical management of heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_3_24634="EEG Benign epilepsy with centrotemporal spikes BCECTS";
var content_f24_3_24634=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    A 10-second EEG segment showing the typical sharp waves of BCECTS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 263px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 10-second segment shows the typical sharp waves of benign childhood epilepsy with centrotemporal spikes (BCECTS).&nbsp;They are markedly more frequent in sleep (stages I and II here) than in wakefulness. The morphology is typical with aduration of almost 200 ms and a high amplitude aftergoing slow wave (as high as the sharp wave). The distribution is centro-temporal, and as in this example they are often bilateral and independent. The dipole with frontal positivity is also typical and would be best shown on a referential montage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Selim R Benbadis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_3_24634=[""].join("\n");
var outline_f24_3_24634=null;
var title_f24_3_24635="Periictal imaging abnormalities";
var content_f24_3_24635=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Periictal imaging abnormalities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Local",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Mass effect, sulcal effacement",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hippocampal swelling",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Focal cortical lesions, increased T2 signal, restricted diffusion",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Migratory lesions",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Blood brain barrier breakdown, contrast enhancement",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Increased vessel caliber/flow",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Increased perfusion",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Remote",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cerebellar diaschesis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Unilateral/bilateral diencephalic lesions",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Splenium abnormalities",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Posterior leukoencephalopathy",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_3_24635=[""].join("\n");
var outline_f24_3_24635=null;
var title_f24_3_24636="Pertussis Rx and prophylaxis";
var content_f24_3_24636=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended antimicrobial treatment and postexposure prophylaxis for pertussis, by age group",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Age group",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Primary",
"agents",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alternate agent*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Azithromycin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Erythromycin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Clarithromycin",
"       </td>",
"       <td class=\"subtitle2\">",
"        TMP-SMZ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;1 month",
"       </td>",
"       <td>",
"        Recommended agent. 10 mg/kg per day in a single dose",
"for 5 days (only limited safety data available)",
"       </td>",
"       <td>",
"        Not preferred. Erythromycin is associated with",
"infantile hypertrophic pyloric stenosis. Use if azithromycin is",
"unavailable; 40-50 mg/kg per day in 4 divided doses for 14 days",
"       </td>",
"       <td>",
"        Not recommended (safety data unavailable)",
"       </td>",
"       <td>",
"        Contraindicated for infants aged &lt;2 months (risk",
"for kernicterus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-5 months",
"       </td>",
"       <td>",
"        10 mg/kg per day in a single dose for 5 days",
"       </td>",
"       <td>",
"        40-50 mg/kg per day in 4 divided doses for 14 days",
"       </td>",
"       <td>",
"        15 mg/kg per day in 2 divided doses for 7 days",
"       </td>",
"       <td>",
"        Contraindicated at age &lt;2 months. For infants",
"aged &ge;2 months, TMP",
"8 mg/kg per day, SMZ 40 mg/kg per day in 2 divided doses for 14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infants (aged &ge;6",
"months) and children",
"       </td>",
"       <td>",
"        10 mg/kg in a single dose on day 1 then 5 mg/kg per day",
"(maximum: 500 mg) on days 2-5",
"       </td>",
"       <td>",
"        40-50 mg/kg per day (maximum: 2 g per day) in 4 divided",
"doses for 14 days",
"       </td>",
"       <td>",
"        15 mg/kg per day in 2 divided doses (maximum: 1 g per",
"day) for 7 days",
"       </td>",
"       <td>",
"        TMP 8 mg/kg per day, SMZ 40 mg/kg per day in 2 divided",
"doses for 14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adults",
"       </td>",
"       <td>",
"        500 mg in a single dose on day 1 then 250 mg per day on",
"days 2-5",
"       </td>",
"       <td>",
"        2 g per day in 4 divided doses for 14 days",
"       </td>",
"       <td>",
"        1 g per day in 2 divided doses for 7 days",
"       </td>",
"       <td>",
"        TMP 320 mg per day, SMZ 1600 mg per day in 2 divided",
"doses for 14 days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Trimethoprim sulfamethoxazole (TMP-SMZ) can be used as an alternative agent to macrolides in patients aged &gt;2 months who are allergic to macrolides, who cannot tolerate macrolides, or who are infected with a rare macrolide-resistant strain of Bordetella pertussis.",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis. 2005 CDC guidelines. MMWR 2005; 54:10.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_3_24636=[""].join("\n");
var outline_f24_3_24636=null;
var title_f24_3_24637="Drug and toxin related anion gap changes";
var content_f24_3_24637=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug- and toxin-induced alterations in the anion gap",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Increased anion gap with metabolic acidosis",
"            <br/>",
"            (&gt;13 meq/L)*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethylene glycol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethanol (alcoholic ketoacidosis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salicylates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Isoniazid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Iron",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Glycol ethers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            NSAID",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ketoprofen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Naproxen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phenylbutazone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sympathomimetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Theophylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Caffeine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cathinones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Albuterol",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Increased anion gap with metabolic acidosis",
"            <br/>",
"            (&gt;13 meq/L) (cont)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salicylates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dinitrophenol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inorganic acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metformin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenformin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paraldehyde",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Formaldehyde",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toluene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfur (elemental)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Colchicine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fluroacetate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Cellular asphyxiants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carbon monoxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cyanide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hydrogen sulfide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Methemoglobinemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Propylene glycol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Benzyl alcohol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Strychnine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vacor",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Decreased anion gap",
"            <br/>",
"            (&lt;6 meq/L)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypermagnesemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypercalcemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bromide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nitrates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lithium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Iodide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spironolactone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ammonium chloride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acetazolamide",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Any poison causing seizure, hypoxemia, shock (hypotension), cellular anoxia, or rhabdomyolysis will result in a high anion gap metabolic acidosis from increased serum lactic acid concentrations.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_3_24637=[""].join("\n");
var outline_f24_3_24637=null;
var title_f24_3_24638="Algorithm I VT versus SVT";
var content_f24_3_24638=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnosis of wide QRS tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 562px; background-image: url(data:image/gif;base64,R0lGODlhVAEyAsQAAP///4CAgH9/fwAAAIiIiBERETMzM8zMzFVVVe7u7iIiIqqqqnd3d0RERJmZmbu7u93d3WZmZsDAwEBAQD8/P6CgoLCwsDAwMCAgINDQ0HBwcODg4GBgYFBQUBAQEJCQkCH5BAAAAAAALAAAAABUATICAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJFPEgGVlpeYmZqbnJ2en6ChoqOklxKSYwEUAqytrq+wsbKztLW2t7i5urusFAGoYgECwEcCv8RfwshFxsteys5CzdFb0NQ/09dY1to82d1V3CcGAwdPDgMDBGUI5TLf4FPi5AUj5OZOBQo2B+npBQ5EREingEECIe3wwYAXLwq3fukCArjnJMEAA/wuAuhXj4E6ABAaKPyR8N2xhvKG/43wSA7jxAHtBgR0UODfxgbpGkCwWABnAXMOFKTDGDQdghI0jQKome6gCAL+FCx4GXPdiH4YH2hs18CgiaIak8IEsOAiuQZQP7ZMN7Vk2o84CWg14FQEQ5ROuAk9sPflgQQFCvCEMEKBYHQReAKAigCrU6wABkrcqBEqA8gnoDZ4+UBrvav+Lh7k688AYRGOUVcewKDsZpwOIAzYdw9CYAAJLQMQSpiegtMj7uJlYg1daAZ+lw5IMNAoxNKKyyLQ/TQ06xG6yxrAPGIBzqF+FYPePqAA8AQM4mK/Xh25dum4ByxQTLFmgoQx/U0t+7GE8OFKWKMeR35ptY8IgA0Agf9h55VHFkypUeZSCZBZxp0INT0A2T3iqYYRVBhNJ5BM4z22WmtjtTOfg/cYGN8BUEVAQgIG6GOefycBmJdKHDlFjgPkEHTAcwWsc8B3MEU3FlhECZWOVSKIJeOFiw2lEYcOjicCOREQEFORSDlJFFMywqcifeXNZo5boR0pk4F1AfCfjkeIQw1FOMxJZxF2RoPnDXruOUSfgrIQaKFAEIpoCocu2oOiOUC1zm1LUJdCSSNQCoOKOzTq6A6QdjdWDJIu9ZkSlnVYAqYYnvoCpyUsmBNwhub4KRGh3lCqpklYigKrpsoAKwkLrBPjC57eikOulB1FTlUkPPfRrq5qV9P/ZtoZ8KE/RiKZwAFB6sQTTgkYVxNyt70l1Ysk3HYfQVMxNWpzNc2HJJQeIedCssrawGw/zg7QWZYUOkgtsWMNRAB/F+nGm2EKGZbAXBb5088+uvGqGbuZ1qOibAeKINQDjMW3gEcyjpAATkcha2u/iaq0AsDhEQxSfssdLOpRlsEXX2ggalmxePBlXI93pXHcqnKhoRfayR+pSFp55tC80Msw+/DvWFi62s6kOX/EK3xx+XxsYT+hPbFoWc5VJbr1ZAgZsLe1M9nGKuqG01QioFwDv1nLsHXAf9l8QE01hj1ptWkOUOaoVVrsZlPgztqhRxddl66VIbrTMQDv/kNj/3nkTOVT6fnp9GDLLgcuBLM/+KwI4K6/ALsPsidCe+0t3O7o7ryv4PuiwAefwvCIFm/8CcgXqvzyJajCy/TUV2/99djL4gv0O1BSyvfgfz/BBOGXb/4np3B/SCXqt58D++7HTwP88tdvO9b2528C/foL6v35mxgfADeRvv4ZIgDkG6ACQUE+A64Pf9WAoAP7wL9kSHCCe6jgMy6IwTxosAsf7CAfQhhBEQqChFpAoQnvoMJtcHCFdGjhFWQIQznQMBwvrOEY/tcJAYKigEXgoSZ8yAkg6jAZq8ieALZXpyRSj4lHBEPzUPA8GEzRLjmMYko6lcX3yWwGVdRinb4IqP8uLouMMQijGPmExr+Z8QZXlNMb10icNtJAjb2z477mSMcAodEA+iKAAuKkAjyyQBzpAMoAVmDIPv7ATv04gG341oJGqgCRCtgHOhjJR0eOMTMGQMBRHuCkgGDOc1hEAiIJUKRNQiBI+gpOJz3JRhRIbCkBWUA95HMCSx6PjDKR1CJFuZECPIAEvqSlF1FAgM3IJjQQEKTj4pRM5gHTAQlw0m4k0oDJyFGZ27BjMzHkzUx5s5r7uyYAjIObo/TjmLIE5wzFuRkAkJIgCRINMmcpOHXuZpGvTEcsUynPcOjRJKo8aK0KalAuJtQG6GRoDOKIo4e6UaJb1EFESRDHjWL/NI8O/eRFPwoF6SkRinxy4vRQSlImCDGACUQfEl6KCSISsKUg5CdxdIrTkvI0QD/taRNuSAWiCtUKRpVCUo8qj6Cq0qlMNQIGQuOBMCw1qk7gQGg6YFWoYnUIFQjNB7r61S9sIDQZIGtZvXCBdGAgGF5dKxA0kA4OwFWuXbBAOipwV7xyIR0b6KtftTCBC6QiroPlQQA0cNjEaiEDFmisY7tx1ckmorKWfWBmr4HZzNJ0gaA1xSMRW1aTKvG0tWCpDjprWYouwZKsnaxrlQBb0n51tkmo7WZrgFsk6Ha3M+htMeIaW8cK1wi/Be5EFVoEsUymLFQkrm2xetwZMCAg/6wUwXeiO1rl9tMElRtLWhRgjsyR6JQjaY4/ymkCXY5AK9zV2nSjaicCTOhw5mDAUaa1D17eYEGUhG8vpevd5ZoAAu0wgAOMQxAACGydGBNKYkig3oik4HDeFLAJkltgkDKTvGkbwYOD0i72qkABxiJvCTRcUfkqFzbaVYd1+gOA+q43co5z8DGDkk+6wADF/7wxktjL4cyiYzOAEcyWUCmC6hKhyJkNTAJKtuSR1Ji5VoCyZRVGDngmh6NYroKWJ2ug2ZDgT00OMxXGPFknQenLI3DyENjs2LTQCs1XdgJ0TZAWH7f4UfNlqpxbsN2CmQOQGyZwh10AySDtN0gBuf8niST95gqTaMWLLIF9n1LPfXZ30R4mwaZFbKy45TJub4YBizn9lJDF08WgPiQaEXyRgDxYK8/0h2xoNQJLs3fVi3HJOP+s2EAfVVGC1DEAGLAPgLQr1S/QcAQ2E8mJDJSgO5iqP6oa61/y+cZROaak9/EApkBbBUOOTD37TMhv8kCr/uBqt1GQqwdPwZBh9cdY521NFthbCoY8qz/Syu90iqGRbR3AWwtu8DA0kq4DsCvDo6fme3tVrwPg68TBfPC4AnbjHFUpakf+CtXmoLAgJ8FnQxtaI66WsSk/BGRjTvOa2/zmf1g5y3fO856XwuU1NC3Jh070op/U2MoaNDX/PJr0ihMP6bdSejSYHnWnJw/qn5K6M6iedauXoVRg4LqjQoWzBsRpWCkISU7enDsSoN0GYEdNN1GAE3ysbFag+47qQNMfoSBH7QNAy0LFSHZefs3t/lUBRbzzqsTrisZ5bxjCEikCqW1FPheCCMYEmhzGc3KNhTdd4t8yJqW0y3HQptmznkR6HK/DIwgoQARqQhh9ME28kBcBBAZSgIFiyj7KSdBBgK+amgjyXMrp0h5Br1CcpZpTFWJPlELT6WZxxjMme9s/IXBKBniEAOh488jiXoKKQakk4rFPlogvoXYU6ToMDvzgtRj6dqRsBJzKjkYoxOx/q74cisEpOCMf/9+nGgrQAEp2SvJBfrrHe77nOcBnHxG4HOPRD10ifQfQf14WX/TXfPKRTZdWeSQSfbG0MhJBDsDxf4XjMSRyNn1DY9/BM/KXN5B3dwYAbZiiIm6jg/vnIethEHP3EryWaMy3ApxSFjeCGoizTmRSAukxFJRkfV1TTKthMQUoAvxhDqNTAKVDfkfCXgwzFncXeIQxhnvng+2xbN9hAFHIgVGkdcsgdosCh8ggh4hCh8Rgh4WCh8Cgh4LCh1PgKydAN67iAm/XOoSHZW1nBqliM4g3ErxiiPIhK2S4fIm4B4JoAoQoLPJRLFVyf593iSzwf9BCAqf0eoFXEy3zFmx3Ef/X8iDasi1PchP+8C3hshPlQS7mojn1oC5twWTuEhPrIi8tQy+Jly+W2IEt8H8D4yp6Q4BiUw4OoyA7ExnqwDA3eB0PE2K7IRgU0yZmZjSiNoPAyIILADIkMH4pwkt3xzrz94ZYpoKqwin5UoD3MICUVDSs4TMDGDQ+ODRZoo9wQxZI0jmQGDfW4TT6UYDQBzmVhHVjF49cA4A284xQsw734IIIcxRlMyoaCTFq842f4TbiKDeXd5DxcTfkWCzXsTd3BJFzKJGEoyrL9g+oiJHu8BaohITp8Diso5ND4i3hJS4EgznkMJB9dpLtUg+hUx5bWDoAcDq8tIiFBJN36HX/QECVfuCHewKIKqCVfcCVdOKVkSCWOkKWkGCWAIKWj6CWw8GWjuCWeCF0RleXdnmXs2ByMKRzPrdzNtWXgBkAQIdzh2SVhIlDhwkIxZWYZbCYjClZj5lBhhmZLsCX4fOXAzSYlCk4MRWY5dNAm7kskzlRo9ltjjkopRlrp/k6qQlqqxkEr3mYsflpoekvrdk7t9lhswlrtclbuSk8v+lduwlovYkClolAndkJmskDOoeZmbCcNEeX1qOXjyJyu0CdNddbG9VRwSlR2hlo3BmZ31lLI8WY44krWIltiXmeg5Ke7maeZIRoizFIiNiemEaf01aV4klGkTRJV0Oe7zUb/zKSn4zSnQxVX6E0SqVUk5TnaeiJaejwAPlZbuVxTgZaUH1yS87mXo7noPZJArjWAAqQn2BCE3Uhlx/VJ+OUa+kQTRJGSNtJRrgGETpBjQ4GHCiKUSpaT85mAj36ah8aoIQxEJsBJqx0ohcqTzsqAuPWYzAKnjJKjbKxGRT6o++5nu5JbLDpnjnqnVnqoa/DpUkKTuwZphA1pspUplt6pvsZUkEKRmhKS9JZPdgJKtapC3Uac8fpnJoAnTrQnMnZp8VJb3HaZIWaWMNZbIM6P4eaqNnZqIc6WI66WpEqV9qWDtxWQosKA/CWDvKmqZvqAvmWDvsGqqHKAgKXDgRnqv+nugIJt3BcMKkpB3ESF6uVKlcYp3G22qov8HE5xasugHIbBKy9A3O/SqwrMHPDiqxrIKvMiiu3+qyESpjH6Zmh4KekSZhzipcrBVXOKmhf6lveGq0wBJcIpag4Z65pNK7aGq7DRZzp6q7Ixa7xGnb0enNwyUryBxLfsYFASqnt2gTo4E0K4GcDBq/4KjPhJYNq4mCQxqBM5msocIPEomQFirA2Zw2jVkz5tV8p5mBtGAONsxn6Wh7+qp7vQ64rZA20pmDx1187FmHTRGHWYWJLcUy24QDDxmwHi64Jy2cgNhIj5mpWygJAhgAyMkn4tWwTAqYp22EwFpUyZh1vprH/N/YWMjK0Tvpj6xBQ7NFnVoayotlhRwY6UlZlDecFhvStdCRlVAZncSavzHCv3sVl/4ZnefYFa6uy0FNmroa36vqfPltgbnZmTJZm9oqx3mVnhhu2bHlPPRoT29GzoMK3IsSWYKIVCaBLvQGK//q09YoajuawFiZpkVa4vVazJ2ARVlEA5wgX57a3AfsUTTstpkYWqAZ3/2B4CKAtQ3iloPuzupdgtiZuCmIdu3YCEqsCkTRqG+u0Yxu6ogazy9Zs3gQmMgBkumcAJHsjEdC0nxu9wotjtkYQ4uYk5GZuXLtORuEUaxi2wGsDlzoAmRqdevRvABdUnToAn2q/KYC//1GgRqM6AKXqv3obVKk6AKtqwGrrVK8qvV2AR7QKwVyAR7marnfKrbyQpyI7AIF1c9VqrTLFA8IqrWewWCaMBsqawizcwi78wjCcAyEswjT8Q/OGQDWcw59puerDtpDpmjzMJ0EMPT4sWEDcCEXcR0ksRUO8PEtsBAyYrabJQZgDT5lIkzdAJWjLAlFsRU1sPC3kJCmTiT+gxaSSe1KsmhdkLYIhLaOjIu7yHVKRILWnSU5yFB6BgGMhLwuweguQEE15kcoBI9GoFNkCvtHzxcGjQl9zeNQRJPJRNx8oMd8XfpAhGQVYE0Oyf5D8x+VweC8INoQsfgKDjZekyLyDQv8seiJbfBvAVzoXg4BTZh3epxblgBl4khDsl8nS+BEKuABgGWeoXDsoRGXqmDJ4IsnzcUsxKCGmaMubfCC5/Mk0hoyaLCl404kOOa1TfGL+hTKjsxzJzJRryDdZGCVOog726A4x0ceeA8j5cY5Cocej/JTa7I7crMZIPMyu88TLqs+M4M/0x8+Kq5s6dYhsINBveND3nANaCXxXSGjw4sU3zNAhGwTs9wIrQxmuVpgVXQPGuAA0Ixb1QNJMaHpMQjOpQ2sCVSpicRTZok9Y2IO4+dEzUDKWhwCDgSDlcRokGCFWI4JgcxCSQoKuIbVWkce/ezwEnTVXxZCYlzD+cBT/6jUd16EdlkIz0sR5wIfNV30R8HGFkVjT3XzTLRnVrEPHCKLJJwLUEGIwmkONRX0iYY3GFF3WMyCVIv3WNkkk6yAl6DwUKm0lyJEWDODSTVjX64DFHo3XiqDQRwTZKdTUMCPZWWDZ5UrZAOvYl6XZSefZ4uuagarDpP0JoBlrMxyYfFra2NrCmB3DwAnbTCzbFkTb/2zbk43bPZDaDDTa5dPazIrDpe0Jpw3br81RoH2gY3rcBcbchmrbzl1jyY2hyz3dSlrd0I3dtB3d0Q1c3G3dK1Stqy1aQrBy420JwA1y29qtg5LBuMDBMaemWiOmmynfj0LflGnfioXfbapR/9MVnvktr+gE4P19ZoFEnw/5pg7mDpuknwEOXuXgn8kYMyUwG5qUaRf74HyWoPa0oOgFvfdd4awEfgAFS1qKpbakZBu6Sxc94NckTO1UTBvYpTpKTyCBvNI0YeEb4iQgEyC4SArATRZa3zaOSydgpS5e4TORDjH+TiA+u3xWT03KFAYbvzwuYhIhFCBh4k9OwWxqpuX5mPoNKvwt5gL+32UOn25K4WGu5v6t4Ota3+69wf8957YA3ykn3r6NCek9A+a95+RNrN+d3awKw4O+3dot24cew/Nbv4gJ2/vbv48ewwNcwJMOwwm8wJcOww982eBNSxPs6bR9waJO277qQv+2XcKovt3GuuqyvcKurtuxLutI9en5beviievLw9s53OexLeZ2rsF56VTdLadyCwR4VOyeFLihuNlurgXJrutgfOzYQOzSvsjU7gPRXuBZsO1m3gSShhxjaLDe/uxKgGhlAQEhkQDZBCXljuKiqxTjVV4P++GpGxo2+70HQEpxQrFia5sFvrFLq18O9rEdGgMPYAAKI2pN++6yKTMtu2ChQb0kluNxsrw+OhWAwTffS03Wzu2ttrQiFrMltr69V0znqPBEWLn8FrVxMWNQYrUWhrXKxmNU3m4ntg4UCn8Tv+O+yW9lm2Q+crjM7uDO3m1uCzl4VvQZfvSxZrdetvT/2d4DDg9qftu4FFfBH19wqLvFcav1g9ttjGsPRD/1LQC5EiG5ClH1Xn4EmbscnDsR98f247uwpDtpC0ppNIvvq9sfrisb6yB4//7z3067PV5qRu5e2EsDaVEv7eS7Ps+oBR7xyoZryGujJYDxKNC8wjYhdJ+xaJRsD8azVrr467u93Tuknv9Tjf7sb1G+s3G+Dbbz55YCQGYcOh1jF7H2PxXp5l7hJ/taP1Xpv9/jwU9bP5XpxZ9lQdXp8A7tQRXqz9/tQUXq048FeHTqshnswh4LeN4Cqn6YvF7Dvn5JrU7rVQDr6L/+7N/+jTD+wx3/8j//N/UI6939+J//+i/s/98PAoA4kqV5oqm6sm0ZCK4807V947m+y0LAA4NCE2xoPCKTyqVv6XySitAptWrVNa/anXTr/YKd2TB51S2j0+rVeK0+UxkDwoowd7cig8EBn2z7kcGtIAwoiNgNJNjI0anYOSY1AhQosiQMFKw8DCDM2EUgdhrslXpWFS7MAAaCDaoU3insLdZMPt5BVdbuLAwwzEBkipCqAtxapa7+tJa9phQWKBAU7CY07CmoyiEUMMiR/h4PNFR6XmerQo7vOcZWLmDTYfeNJP5ye0PG/ibEamMqgC1BNQD3tI04UMoAuzu+DEAkgW2BwkMikIkISEoBhIADHczqBOBAOD7+0v95zHTgHkMXrJpteYaiUCIGu1IlUFAggZw93+6QejCp0gGcOhNAsgNsoh1PqR4Ka0Ci6Yiev9btApBKmAJMpQhqskduqjilACb62tNShINOyDACCAigbQOvexQy1OOAlIMRWw3JpaqsBzOYrmLISFUIwq6sxW5NSjWJ1AHHAxbsuzyOAU2tmmcNFhH6FlZLlUopGiaiYLyFZIEpk8PA16kS1WZBqJprhFy8cg2i/tVWLcHgcml7NuaysGEvMk+Evnk5507Ic3LymczH6M6k4ph+15zIotjapO9Uyl2ob0bVlDRVeoD3NfCll5Gb0DNWd6T2mpr+Np8JfK3H2zDIFUj/WHOHzRCdIugMYMA2uchxWl/aHQChhMDR0VMBdKBTQDFxVdKfKD6dR0dNJ+2xk3sFJULKWvVd1CId+JXAyQDs1WhiQJXU9dtcIc1x2gChsJjJcSJVFqGCCzqH2BJwAYFdbmBBiYOQaLyUJRTPBUFlDnYVwJ5ZXtawZRldorkEmG3CGSebcR7xJp13LjgnnkG8QpkMOAaSVQrriGUiCwKugagQeu7JQ598rJAVoCT4ScYuYhIqiqErKGpCeqtBSh0K99Rmg6LYsCfPSNg4mZZIJjDaqA6P1pOCpK+2Iuiou3FIQ6cl6HGjkx6iMNs4m7qgKF0k7kSQAbwQoEqCJMQq/ysOj8bSF0l7NAABP7NFKCMvnh0gRzm4EhPhHqqQkgpIe5xyDzBWddiJNyHuUhq8vRYKXDv+GqLKAbNUwpADp4UlAicMdbZawijoAYxY6QDQ7r8DZ+IkCdUgJZIdIUmcrnIjVGutDbRiedTClFjii1Sq+pUdepCOQBljmpRkR147UiWKfQtYxdnMHfc3ywOZcmgWbmJJNcsBvmWSmwlGFzRC1XatlUitZEkVFCeaON1psEElV/EAD4xEyqYlm0wDrSzP51VxiyCHUSHlAkVzun3s4uc9PoUWGz65+JnvHVZdhnRmqC3QGnHDzKcfusDNEorVD5MAoYmOO0lZQL1pPP8CJ7NYpNex/MLKXNt8SkkpH6MDoLKTn9bN690Yun4A7H4q2jONE90yEctE2yFVKorPAcrGZ8/H8coZfTqCMHugfTkKlZTpKfOdmzSM86GPEJIjLpu9NQpsr+7Co9n0sS05udVUe3+35701KZUo0Eel7/4rLzsfng4AEJiFAQxHgATcrxjIUxFqVqKWVj3QAAqxkQmwQR7EGcpI7vGXjMq3JHXN6ERS85cC2CMmAKAvfSyw0xMqpcIXpvCFKWChE1wow9XF8IZEaJ0Oe3iFHPpQBDQMIhGBAMQgDrGISsTBEX2YxCVCcRlRlEEAKCCAK2Ixi1rcIhe76MUvgjGMYhz/IxnLaMYzojGNY6SA6qaYAgkEII5ynCMd62jHO+Ixj3rcIx/7WMcJTMCPghwkIQtpyDtKwI2KdFQbF+nIRwIhjpCcJCVn1chKYjKTJ5CkJjvpyShc8pOibA4cDylIQJpSkIkcJSuFEIBApjKWspRjIFtpS0buiZO33OXJQpklXfIymOrzJZSAKcxjzpCYCzImMpsJylwq05m8ZGabqClNZFrTS9m8ZjC3WcxocrOV3lwmOMO5yFLqEZV8XOUX0HlHdeKRneZ0YxXVuEU2hqGeasTnPBX5xBQ0MZI8pEFA+5nLgTKxnEr4J8kUatD0MfQEBeUCQp/0UChGNHX5rOhy/y4axYyWYKKz4mgLROpRNA3CABIjQFc6yqAcAQYAEZDK+Rx6UlkNQiEHYMzI2GDTOg10dKGYKUB/elM8vYIABkCAJx4QkguVYmsmvVZQd3Q2oj4Aezya6lGb84yjUKIvC9CEZjT6UhJwAgINUABRAXiwWnC1qzB5BgGkMr1SQIClRxpXXGswiLROsFsDkNpgRdBXuQaCrjTNnqd4hEKjDuGvhdWDVABIDbhCFrEorWhdFRaSrpzmWdTKLOtMkFYBjiWrmdgqaTVbTJIStLWOgq1PXatDkI52ozk4rG3fQFuLRmm3su1tM3DbUN0mlLgvNK5hhztS4SpXhfq0Jxb5+f+F6aLRutE1mTvxCE89ynML3f0jLOO5XYw6N5/pPa+1xunV9bK3Ue41zHzji0T4Oge/9qVTfYur3/2iCQOo8UCcBFwKAgM4ihxATQfitOBSNDjBUKwAaj4QJwqXwsISXuIGUJOBOHW4FB/e8BIvsAcM3MnEA0AxiZeogT1w4E4vHkCMW6xEC+yhAnfC8QB0bGMl7mEDeAryj5U4gQvs6chFVmIANJBLJy+ZiBmwwJ6mHOUrYznLWt4yl7vsZSeMd5Zi9iM7wzzmM9sxvF8mghWp62Y3Wxe7b57zGv8bX+Z6YQx4tgJv2btnLej5t27o83n//MPCGHoKhN5uoqsQaDT/LTq6jabCo70UaeVOWtGIFjQSnLpahYVDBESi6XHXPENOJ8HT2YNAOOoynGyYFQCZZgEAOZEAYVhO1I7NralRMOsW1FoRDGAIYxyLgFyXWtatO9i/YvGshakEQpgj0h5GmLlcFABopBa1Wqz92F77eqDMvoOzEwDtAmSIVdMOjrfb44hsg8QBBKnVaUO6aYmETKmLMAABOIG2BkTA1jlIBDzOFaERIrBU3wb3DiuYb9Hy299nCbglcEDwy7A6AgUolUolem/RkaIBB5DckTghggiEokImonZhVaBTBDjCAMjuLK8ZHoWghnzkqKH4yVOeiZWzm1PbkVgDJPZWj4/g/xXH1rfoBtDzhLS8BcKongANIBWmq/QBQeK3vW3+Ao4uXbQKc7pMc62Qdqdg6tKzulYYgkBg5ARZlRYBq/LnmT04wORl19GRgnG2ucCrFrGoC6u5Na6FRxlVdJ9DcHYziLr3gR95JzvK+Y5sFqh9OAhYROHJsQiWHj7Zv/5DG6nhkwMo/iyMDw6yDLossNTChsqW08ezBAj8RIAAr+fY3lzLMd/JfvRMqD2UAKEzBtTq97iS/VHH9vfe35z2SUd1GgABoUyowvlUZ/5NR2eI3H1d+kKkPpcuSYBCSMX75CmfbcUH/ujDae5XiFEfOu9q1Kwf8RdhwCLaYjn314zeIP9WIlhb8JGfEdAfqO0Bt3FLrAnfCeiUQTDEsAkQY4nG5d2eVeQaAb7fhj0gCkSgUqEWspVQUU0fCbgPAkCb3Y1HH9zD1rAc2vlC+yhCvM1b03nbpRFXToWDCqoLC7IPwMBg0JnADI6EsG1b7HSbA7aOCI5d5CFAZfQBZygE1dnAOyhCxm0cpYRMsnnd7JWAEwIAJ0ChFB5DFD7fDWDhNYQWwi0VE5KAt0TI5CFCCeEfSKBADNaBJiAA0RndTsTaFw6CHBoAHRqEHZZCCeVf+BDhoPBhzM1cEiJeUimA3smcGYpAFdaA2ikMACGA23Vc3CHdF47foFQi2V0iukGdFbrSACeOoWVBHANoXQIgkKHI3z1M3hLeQyi8oAyonX44gv19XksFotcNAi7ynQHATynwYlT54t8BY8x4njDCIQro3aDZmZ/B1jVi4wlaI9l1IymCYQpw4xrIX55kY6EdYPURHzqK4zhCWjs2hw721gciwTnOYzoy2jqWnzfanj5KWpvR2UCSUZwJJEEiJBdpl9eZGZo5JB2V2UNKZB2p2Tta5EViZEZq5EZyZEd65EeCZEiK5EiSZEma5EmiZEqq5EqyZEu65EvCZEzK5EzSZE3yUggAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Algorithm for distinguishing ventricular tachycardia (VT) from supraventricular tachycardia (SVT).",
"    <div class=\"footnotes\">",
"     sens: sensitivity; spec: specificity.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_3_24638=[""].join("\n");
var outline_f24_3_24638=null;
var title_f24_3_24639="Retinal vasculitis sarcoid";
var content_f24_3_24639=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retinal vasculitis in sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vascular occlusion and hemorrhage from a patient with ocular sarcoidosis. Ophthalmologists would describe this lesion as indicative of retinal vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James T Rosenbaum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_3_24639=[""].join("\n");
var outline_f24_3_24639=null;
